# AGRO & INDUSTRIAL BIOTECHNOLOGY

P.K. Chakraborty
Dr. Vikas Kumar
Dr. Alpana Joshi

# Agro & Industrial Biotechnology

# Agro & Industrial Biotechnology

P.K. Chakraborty
Dr. Vikas Kumar
Dr. Alpana Joshi

BLACK PRINTS
NEW DELHI

# Agro & Industrial Biotechnology

*P.K. Chakraborty, Dr. Vikas Kumar & Dr. Alpana Joshi*

*This edition published by* BLACK PRINTS INDIA INC.,
*Murari Lal Street, Ansari Road, Daryaganj, New Delhi-110002*

ALL RIGHTS RESERVED
*This publication may not be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers.*

Edition: 2022

ISBN: 978-93-82036-19-7

BLACK PRINTS
Excellence in Academic Publishing

**Editorial Office**: 116-A, South Anarkali, Delhi-110051.
Ph.: 011-22415687

**Sales & Marketing**: 4378/4-B, Murari Lal Street, Ansari Road, Daryaganj, New Delhi-110002.
Ph.: +91-11-23281685, 41043100 Fax: +91-11-23270680

**Production**: A 2/21, Site-IV, Sahibabad Industrial Area
Ghaziabad, U.P. (NCR)
e-mail: blackprintsindia@gmail.com

# CONTENTS

# CHAPTER 1

# EMERGENCE AND IMPACT OF WHITE BIOTECHNOLOGY: PIONEERING SUSTAINABLE CHEMISTRY AND INDUSTRIAL INNOVATION

Dr. Vikas Kumar, Assistant Professor, Department of Agriculture & Environmental Sciences,
Shobhit University, Gangoh, Uttar Pradesh, India,
Email Id- vikas.panwar@shobhituniversity.ac.in

Dr. Alpana Joshi, Associate Professor, Department of SAES,
Shobhit Deemed University, Meerut, Uttar Pradesh, India,
Email Id-alpna.joshi@shobhituniversity.ac.in

**ABSTRACT:**

In the area of biotechnology, industrial biotechnology, sometimes known as "white biotechnology," has emerged as a separate discipline from red biotechnology which focuses on medicinal applications and green biotechnology which focuses on genetically modified crops. White biotechnology makes use of biocatalysts and fermentation technologies as well as advancements in molecular genetics, enzyme engineering, and metabolic engineering to create chemicals, materials, and energy using biological processes. This essay examines the astonishing development and widespread acceptance of white biotechnology, including the ecologically friendly and sustainable features of its use. White biotechnology, which is positioned as a cornerstone of green chemistry, makes it possible to transform renewable resources into a wide range of chemical products, including fine and bulk chemicals, medicines, biofuels, and more. The report focuses on the switch from utilizing limited fossil fuels as starting materials to renewable agricultural crops to stress the ecological benefits of industrial biotechnology. This research highlights the revolutionary effects of the technology on numerous chemical industry sectors by examining the major performance advantages provided by industrial biotechnology, such as enhanced efficiency, decreased energy consumption, and reduced chemical waste. In addition, the study explores the market trends, social changes, and technical developments that are fueling the growth of industrial biotechnology and showcasing its potential to transform agriculture and support sustainable development.

**KEYWORDS:**

Agriculture, Biotechnology, Microorganisms, Sustainable Chemistry.

## INTRODUCTION

Red biotechnology, which is targeted at the medical industry, and green biotechnology, which concentrates on genetically modified crops, have lately been clearly distinguished from industrial or white biotechnology. Biological systems are used in industrial biotechnology to produce chemicals, minerals, and energy. With advances in molecular genetics, directed evolution, enzyme engineering, and metabolic engineering of microorganisms and cells, this technology is primarily based on biocatalysis the use of enzymes to catalyze chemical reactions and fermentation technology the directed use of microorganisms. The term "white biotechnology," which was first put forth by the EU's decision-making bodies, is now gaining popularity across the globe. It refers to industrial biotechnology, with "white" also denoting the advantageous environmental effects associated with its use. The so-called "green chemistry" field, in which renewable resources like sugars or vegetable oils are transformed into a variety of chemical products like fine and bulk chemicals, pharmaceuticals, biocolorants, solvents, bioplastics, vitamins, food additives, as well as biofuels like bioethanol and biodiesel, has been greatly aided by this new biotechnology [1], [2].

Industrial or "white" biotechnology applications provide important ecological benefits. The desired starting materials are renewable agricultural crops rather than depleting fossil fuels like crude oil and natural gas. As a result, this technology reduces greenhouse gas emissions while also assisting the agriculture industry, which supplies the raw materials for this industry. In addition, industrial biotechnology frequently demonstrates significant performance advantages over conventional chemical technology, including an increase in reaction rate, improved product purity, increased conversion efficiency, reduced energy consumption, and a sizable decrease in chemical waste generation. In recent years, industrial biotechnology has become more prevalent throughout all areas of the chemical industry, especially in fine chemicals but also in bulk chemicals like polymers and fuels. The chemical industry's adoption of biotechnological manufacturing methods was expected to be 5% in 2003 and would rise to 10% by the year 2010.

Given the improved efficiencies attained by biotechnology manufacturing techniques, the rules of the market economy are now primarily driving this progress. A number of societal and technological developments are anticipated to reinforce this trend in the near future, including the depletion of crude oil reserves, the increased demand for energy and raw materials from a populating world, the need for sustainable and efficient chemical production systems, and adjustments to agricultural policy. The economically significant chemical and agro-industries are immediately interested in the robust growth of industrial biotechnology. Biorefineries, which are completely new chemical processes, may be developed from the cooperation of these two businesses. Future global agriculture may benefit significantly from industrial biotechnology. Furthermore, given the obvious connection between industrial biotechnology and the sustainable growth of our society, efforts to raise public awareness of industrial biotechnology are required. As an added bonus, this is likely to improve consumers' perceptions of biotechnology as a whole [3], [4].

**Green or Sustainable Chemistry**

The chemical industry is a major producer, but it is also a significant consumer of fossil fuels and a significant producer of trash. This industry creates a wide variety of substances that may broadly be categorized into the following groups: fuels, plastics, pharmaceuticals, bulk chemicals, and fine chemicals. The development of sustainable chemical processes that protect the environment, enhance our quality of life, and are also competitive in the market presents significant problems for researchers, chemists, and chemical engineers. This involves creating innovative industrial methods that utilize fewer harmful or potentially harmful compounds, consume less energy, produce less waste, and start with as many renewable raw materials as feasible.

The creation of a clean chemical technology with lowest waste production, maximum productivity, and competitiveness is the ultimate aim. It will start with renewable raw materials and energy. Sustainable chemistry is based on a variety of technologies, including improved catalysts, novel separation techniques like membrane processes, recycling and re-use technology, and last but not least, the use of industrial biotechnology. Because biotechnology is inherently suited for sustainable chemistry, it is having a growing influence on the chemical industry. Industrial biotechnology can exploit renewable raw resources with astonishing ease, but traditional petrochemical processes find it somewhat challenging to use them. The sustainability of this technology is ensured by low energy and waste creation, the use of safe, nontoxic, and renewable raw materials, and high efficiency. Industrial biotechnological processes are progressively making their way into the chemical industry, and this has had a very good impact on both industrial competitiveness and sustainability [5], [6].

It is crucial to emphasize that there are other technologies at play in the fight for sustainability than industrial biotechnology. The chemistry that is most environmentally friendly involves the interaction of many technologies. In reality, it is often the case that an appropriate blend of industrial biotechnology and traditional chemical technology yields the finest results. So-called combi-syntheses, which combine a variety of chemical and biotechnological stages, seem to be the foundation of new processes more and more often. This "green chemistry" is becoming more eco-efficient because to the incorporation of cutting-edge separation techniques like membrane technology and supercritical solvents.

**Multidisciplinary Technology of Industrial Biotechnology**

The development of practical processes and products based on microbial, animal, or plant cells, their organelles, or enzymes as biocatalysts involves the integration of disciplines such as biochemistry, bio-informatics, molecular genetics, and process technology. Particularly microorganisms have drawn a lot of interest as a biotechnological tool and are used in so-called fermentation processes. Although there are many helpful bacteria, yeasts, and fungi in nature, they seldom find the ideal circumstances for development and the production of products. To more effectively manage and influence the microbial cells' metabolism throughout these fermentation processes, the biotechnologist may make artificial (in vitro) changes to both the DNA and the environment of the microbial cells in a fermenter or bioreactor. Many microorganisms are extremely effective and, in many cases, indispensable workhorses in the various fields of industrial biotechnology due to their high synthetic versatility, simplicity in using renewable raw materials, high rate of microbial reactions, rapid growth, and relatively easy genetic material modification [5], [7].

Healthcare, the food industry, and fine chemistry are just a few of the industries that have long used industrial biotechnology. In a world where sustainable growth is the watchword, this technology is now permeating more and more fields including bulk chemical and energy supply., According to the McKinsey report, industrial biotechnology's market share will significantly rise by 2010 in all industries, but notably in the manufacturing of fine chemicals. For fine chemicals, the penetration level in 2010 is predicted to be between 30% and 60%, while for polymers and bulk chemicals, it will be between 6% and 12%. The penetration of biotechnology into the whole chemical industry was expected to be 5% in 2003, climbed to 10% in 2010, and will continue to grow rapidly after that. The cost of crude oil and agricultural raw materials, technical advancements, and the political will to support and structure this new technology will all have an impact on how quickly this technology is adopted.

## DISCUSSION

Renewable resources have long been used as raw materials for technological (non-food) uses. Such materials have been used since the dawn of civilization. To fulfill their fundamental requirements, humans have traditionally used raw resources derived from plants and animals, such as natural fibres for clothes, wood for heating, animal fat for lighting, natural dyes for textiles and artwork, etc. The utilization of renewable resources also served as the foundation for many of the early industrial activity. This persisted up until the industrial revolution, when a fundamental shift was brought about by the development of petrochemistry in the twentieth century and the rise of carbochemistry in the nineteenth which was based on coal, aromatics, and synthesis gas. The extraordinarily cheap costs for petrochemical resources had a significant impact on the usage of renewable raw materials. Petrochemical resources served as the foundation for the period's rapidly expanding chemical industry. Today, the chemical industry relies heavily on petrochemical materials, and fossil fuels like coal, oil, and natural

gas provide the majority of the energy we require. Currently, the basis for 95.8% of all organic chemicals generated in Europe (including fuel) is a fossil fuel.

However, a sizable number of significant sectors still rely on renewable raw resources today. The oleo-chemical industry meets our daily hygienic needs for soap and detergents based on vegetable oils, the building industry still uses a lot of wood and other natural fibres as construction material, and the textile industry uses natural fibres (cotton, wool, flax, etc.) for half of its fibre needs. Additionally, there is no practical alternative to the utilization of renewable raw materials in a number of significant applications provided by petrochemistry. For instance, the majority of antibiotics are still produced by fermentation methods that begin with natural sugars, and around half of our medications continue to be derived from live organisms [8], [9]. The 1973–1979 oil crisis, during which OPEC increased oil prices from $2 to $30 a barrel (1 barrel = 159 l), sparked a resurgence in interest in renewable energy. Due to this problem, there was a significant increase in worry about our growing reliance on fossil fuels and their finite supply. Politically, this worry was mostly focused on the energy issue, leading to several research on the creation of alternate energy sources. The findings of these studies demonstrated that renewable raw materials were not (yet) cost-competitive, and when the price of oil fell once again and the economy resumed its normal course, the excitement for renewable raw materials swiftly vanished.

New inspirations were given in the 1990s by conversations about sustainable development, the greenhouse effect, and the growth of green political parties. Another major motivator was the issues with food surpluses in the European Union. Due to the significant expenses associated with these food surpluses, the EU made significant changes to the CAP. The EU created the "set-aside" land concept for this reason in 1992. To prevent overproduction, incentives were paid to farmers for not planting anything on certain portions of their land. Then, opportunities to utilise this land for non-food purposes were developed inside the European CAP. As a result, farmers might profit more from this land. Better biodegradable intermediates and final end products become necessary due to growing awareness of industrial waste and its consequences on the environment. In contrast to persistent goods that do not or only after an intolerably long time disappear from the environment or from the food chain, these biodegradable materials may naturally break down unpleasant components that are absorbed back into the natural cycle. Due to their inherent biodegradability, renewable resources were commonly used to make numerous items that were focused on biodegradability. Examples of such applications include chemical compounds like lubricating lubricants for tree saws and agricultural gear, detergents, etc. that virtually inevitably end up in the environment. Alkylpolyglucosides, a kind of green detergent that is generated completely from renewable resources (glucose and fatty acid alcohols), have already attained a significant market share.

Crude oil supplies throughout the planet will run out eventually. Regarding fossil fuel reserves, we are now confronted with the paradoxical scenario where, despite crude oil (petroleum) being used at a greater rate than ever before, the "proven oil reserves" have, as a result of new oil discoveries, stayed at about the same level for 30 years. However, the locations of these "proven oil reserves" are becoming harder to get to. As a result, the cost of obtaining the crude oil is rising, which is reflected in rising oil prices. Contrastingly, as a direct result of increasing agricultural yields, agricultural raw materials like wheat and maize are becoming more affordable. This tendency will probably continue for a while, in part because of the successes of "green" biotechnology. The short-term consequences of market imbalances and politics may temporarily stymie this long-term trend, but for a rising number

of applications, the economic balance is shifting in favour of using renewable resources, especially in the market for (cheap) bulk chemicals.

**Resources that are Renewable for the Chemical Industry**

Biomass, the total of all the components that make up the living world, is the foundation for renewable raw resources. Its primary source of energy is photosynthesis, which is driven by plant growth and production. Animal production may also play a role in this process, which produces a variety of biomass that is readily accessible. The estimated 170 billion tons of biomass produced annually on our globe are made up of around 75% carbohydrates (sugars), 20% lignins, and 5% of other compounds including oils and fats, proteins, terpenes, alkaloids, etc. 6 billion tons, or 3.5%, of this biomass output are now utilised for human purposes. These are used as follows.

**Materials from Renewable Resources for the Chemical Industry**

1. Approx. 3.7 billion tons (62%) for use as human food, maybe after first raising animals;
2. Approx. 2 billion tons of wood (33%) for papermaking, building, and energy purposes;
3. Further, 300 million tons (5%) of technical (non-food) raw materials (clothing, detergents, chemicals, etc.) to suit human requirements.

The remaining biomass output is either lost when biomass is collected for people (particularly by burning), is utilized in natural ecosystems (as food for wild animals), or is lost as a consequence of natural mineralizatio6n processes. Almost majority of the renewable raw resources covered here come from forests and agriculture. Due to the poor conversion efficiencies of plants to animals (between 10 and 25 percent), the animal breeding industry and fisheries both make contributions (mostly in the form of animal fat), but they are obviously less significant in terms of volume. This readily available biomass may be industrially transformed into sustainable raw materials or energy carriers using a variety of different processes. Due to the fact that the same firm may produce both renewable raw materials for technical use and food ingredients, this economic activity is often related to or connected to the food industry. For instance, glucose and sugar are generated for use in human meals and are the primary starting ingredients for commercial fermentation operations. The most significant sources of renewable raw materials at the moment are the following industrial sectors:

1. The sugar and starch industry generates sugar, glucose, starch, and molasses from plant-based raw materials such sugar beet, sugar cane, wheat, maize, potatoes, sweet cassava, rice, and so forth.
2. The oil and fat processing industry creates a variety of oleo-chemical intermediates from plant-based raw materials such rapeseed, soybeans, palm oil, coconuts, and animal fats, including triglycerides, fatty acids, fatty alcohols, and glycerol.
3. The cellulose and paper business, which primarily uses the wood-processing industry to generate cellulose, paper, and lignins.
4. These sectors break down basic plant resources into individual components such sugar, starch, cellulose, glucose, proteins, oils, and lignins. Utilizing two technical foundations
5. Fractionation technology: this divides agricultural raw materials into their distinct components mainly using physical and chemical separation techniques.

6. Enzymatic technology: this makes adjustments to the way agricultural raw materials are transformed. In actuality, mostly hydrolytic enzymes, such as amylases, which hydrolyze starch to glucose, are utilized.

Despite the fact that these technologies are obviously extremely distinct from one another, how they interact is very important for success. For instance, the employment of hydrolytic enzymes has a significant impact on fractionation technology. The resulting pure basic components oils, starch, sugar, and cellulose are subsequently transformed via physical, chemical, and biological processes into a very wide variety of goods. For instance, cellulose and starch are chemically altered to produce derivatives that are used in several aspects of our everyday life. To create detergents and emulsifiers, sugars like sucrose and glucose are chemically joined to oleo-chemicals.

The fermentation technique must be specifically discussed in relation to industrial biotechnological processes. With the aid of microorganisms (bacteria, yeasts, micro-algae, and fungus), such as sugars and oils, basic raw materials may be transformed into a virtually infinite number of products. The raw material, such as sugar, can be transformed into completely different products by simply using another production organism. These products can range from those that have a chemical structure that is very similar to the raw material (such as gluconic acid from glucose) to those that have almost nothing in common with the starting material (such as antibiotics, enzymes, etc.). This whole series of several process stages suggests the utilization of a wide range of technologies, often in the same factory or industrial complex. Similar to petrochemical crude oil refineries, they are increasingly referred to as "biorefineries."

**Fermentation Processes in Industrial Biotechnology**

A vast range of bulk and fine chemicals, including alcohol, lactic acid, citric acid, vitamins, amino acids, solvents, antibiotics, biopolymers, biopesticides, industrial enzymes, biocolorants, biosurfactants, alkaloids, steroids, etc., are produced using industrial biotechnology. The primary technique used in this case is industrial fermentation, which involves the cultivation of bacteria, yeasts, and fungi that effectively transform carbohydrates into valuable compounds. For several of these items, it is the exclusive technique of industrial manufacturing, and others are produced in very large amounts. From cheap bulk goods to highly costly fine chemicals, the price range is wide.

Recombinant DNA technology has made it possible to specifically alter these microbes' genetic makeup. On the one hand, it is possible to alter or even totally alter the metabolism of microorganisms (referred to as "metabolic engineering"). On the other hand, industrial microorganisms may be genetically modified to express genes from higher species (plants and animals) or other microorganisms (yeast, bacteria, viruses, and algae). As a result, new direct gene products or novel metabolic pathways may be developed to generate chemicals using industrial fermentation processes with a high level of efficiency. chemical products with great efficiency and yield. The fact that these genetically altered bacteria operate under carefully monitored circumstances in a fermenter or bioreactor, strictly confined, and isolated from the outside environment, is a significant benefit. They are unable to exit the facility, preventing environmental issues and worries about the discharge of genetically modified creatures into the environment [10].

**Enzyme Technology and Enzymatic Processes**

Proteins that are catalytically active and that have undergone billions of years of evolution are known as enzymes. They serve as very effective catalysts that control the chemistry of life

without the need for the high pressures, intense temperatures, or corrosive conditions that are often necessary in chemical synthesis processes. Enzymes are the biological world's machinery, and businesses are using more and more of their extraordinary capabilities. Biocatalysis is the name of this technological field.

## CONCLUSION

Due to its capacity to unlock the potential of biological systems for environmentally friendly production methods, industrial biotechnology, sometimes known as "white biotechnology," has emerged as a significant force transforming the chemical industry. White biotechnology focuses on the conversion of renewable resources into a variety of useful goods, whereas red biotechnology transforms medicine and green biotechnology modifies agriculture. By lowering greenhouse gas emissions, improving resource usage, and minimizing the production of chemical waste, this paradigm shift provides significant environmental benefits in addition to economic ones. This essay examines the significant contributions, difficulties, and potential of white biotechnology on sustainable chemistry. A significant step towards sustainability has been made with the rise of white biotechnology, which ushers in a new age of efficient and clean chemical synthesis. Industrial biotechnology presents a viable answer as the globe struggles with the depletion of fossil fuel supplies, rising demand for raw materials, and the need of minimizing environmental impact. Synergy across fields, from biochemistry to molecular genetics, makes it possible to design novel, specialized processes that take use of microbes' capacity to manufacture a wide range of valuable molecules. White biotechnology is positioned as a cornerstone of green chemistry, transforming industries and accelerating the shift to a more sustainable future due to the convergence of economic viability, environmental stewardship, and social growth. There are several obstacles on this revolutionary path, including as technical complexity, regulatory issues, and public awareness. White biotechnology, on the other hand, is positioned to play a crucial role in transforming the chemical landscape and promoting the well-being of both people and the planet with continuous cooperation, creativity, and a shared commitment to sustainable development.

## REFERENCES:

[1] B. Yuan en Q. Xiang, “Environmental regulation, industrial innovation and green development of Chinese manufacturing: Based on an extended CDM model”, *J. Clean. Prod.*, 2018, doi: 10.1016/j.jclepro.2017.12.034.

[2] C. J. Chen, B. W. Lin, J. Y. Lin, en Y. C. Hsiao, “Technological diversity, knowledge flow and capacity, and industrial innovation”, *Technol. Anal. Strateg. Manag.*, 2018, doi: 10.1080/09537325.2018.1472759.

[3] M. H. Lee *et al.*, “How to respond to the Fourth Industrial Revolution, or the second information technology revolution? Dynamic new combinations between technology, market, and society through open innovation”, *J. Open Innov. Technol. Mark. Complex.*, 2018, doi: 10.3390/joitmc4030021.

[4] P. A. Zawislak, E. M. Fracasso, en J. Tello-Gamarra, “Technological intensity and innovation capability in industrial firms”, *Innov. Manag. Rev.*, 2018, doi: 10.1108/INMR-04-2018-012.

[5] X. Lin, B. Liu, J. Han, en X. Chen, "Industrial upgrading based on global innovation chains: A case study of Huawei technologies Co., Ltd. Shenzhen", *Int. J. Innov. Stud.*, 2018, doi: 10.1016/j.ijis.2018.08.001.

[6] K. Schwab, "The Fourth Industrial Revolution (Industry 4.0) A Social Innovation Perspective", *Tạp Chí Nghiên Cứu Dân Tộc*, 2018, Doi: 10.25073/0866-773x/97.

[7] R. Li en R. Ramanathan, "Impacts of industrial heterogeneity and technical innovation on the relationship between environmental performance and financial performance", *Sustain.*, 2018, doi: 10.3390/su10051653.

[8] P. Lu en H. Jiao, "Research on green innovation model of industrial cluster development in chemical industry parks", *Chem. Eng. Trans.*, 2018, doi: 10.3303/CET1866241.

[9] Y. Han en G. Chen, "The relationship between knowledge sharing capability and innovation performance within industrial clusters: Evidence from China", *J. Chinese Econ. Foreign Trade Stud.*, 2018, doi: 10.1108/JCEFTS-06-2017-0018.

[10] X. Li en L. Liu, "Ecological innovation decision behavior of enterprises in the strategic emerging industrial clusters based on cognitive neuroscience", *NeuroQuantology*, 2018, doi: 10.14704/nq.2018.16.6.1589.

# CHAPTER 2

# SHAPING THE FUTURE: INDUSTRIAL BIOTECHNOLOGY AND SUSTAINABLE CHEMISTRY FOR A CHANGING SOCIETY

Dr. Vikas Kumar, Assistant Professor, Department of Agriculture & Environmental Sciences,
Shobhit University, Gangoh, Uttar Pradesh, India,
Email Id- vikas.panwar@shobhituniversity.ac.in

Dr. Alpana Joshi, Associate Professor, Department of SAES,
Shobhit Deemed University, Meerut, Uttar Pradesh, India,
Email Id-alpna.joshi@shobhituniversity.ac.in

**ABSTRACT:**

The transformative role of industrial biotechnology and sustainable chemistry in addressing the evolving challenges of our changing society. This paper delves into the convergence of technological advancements and ecological imperatives, highlighting the symbiotic relationship between economic progress and environmental stewardship. By introducing biotechnological processes into chemical syntheses, significant ecological benefits such as reduced waste generation, energy efficiency, and minimized use of hazardous intermediates emerge. However, economic incentives remain the driving force for technology adoption, with ecological advantages serving as a valuable secondary outcome. The paper also anticipates forthcoming societal and technological changes, including shifts in primary raw material supply, growing demand for resources due to population growth, emphasis on production efficiency, and changing consumer perceptions. Emphasizing the potential of industrial biotechnology to contribute to a sustainable bio-based society, the paper underscores the urgency of transitioning from fossil-based systems to renewable resource utilization. Ultimately, the synthesis of industrial biotechnology and sustainable chemistry presents a promising pathway towards harmonizing economic progress with environmental preservation.

**KEYWORDS:**

Industrial Biotechnology, Ecological, Environment, Society.

## INTRODUCTION

The importance of technology in determining our future grows as the globe struggles to meet ever-changing difficulties brought on by social expectations, resource depletion, and environmental degradation. The intersection of industrial biotechnology and sustainable chemistry is examined in "Shaping the Future: Industrial Biotechnology and Sustainable Chemistry for a Changing Society" as possible engines of revolutionary transformation. The core of this issue is the comparison between technological development with ecological responsibility. The study explores the practical advantages of incorporating microbiological methods into chemical synthesis, emphasizing their potential to advance both the economy and environmental preservation. Additionally, it explores the intricate interactions between social changes and technical advancements, imagining a world in which industrial biotechnology becomes a key force for good.

When biotechnological process steps are included into chemical synthesis, there are often considerable ecological benefits, such as significantly reduced waste generation, lower energy needs, less need for solvents, removal of hazardous intermediate products, etc. The move in technology is often not motivated by these ecological benefits, however. The ecological benefits are a welcome byproduct of such a decision and, by themselves, are insufficient to persuade decision-makers to adopt a new technology (with associated failure risk). Instead, it is almost always the technological process improvements and accompanying

cost reduction that drive such a decision. Industrial biotechnology often combines economic and ecological advances. The higher production efficiency and lower cost of such biotechnological procedures almost always have a significant negative influence on the environment and typically improves competitiveness [1], [2].

**Anticipated changes in technology and society**

In the next years, a number of social and technological innovations are anticipated that might significantly alter the status quo. The technical foundation of our civilization will have to shift drastically if we are to overcome these changes, even though they are likely to occur gradually and may cause some serious "shock waves." Our energy demands are now mostly satisfied by fossil fuels like coal, petroleum, and natural gas, and the majority of organic chemical compounds are based on petrochemical resources. This is mostly a result of the historically very cheap costs for petrochemical resources. The global crude oil reserves, nevertheless, are not limitless. An expanding global population's rising demand for crude oil is currently being met by a stagnant supply rate. New oil discoveries have caused the known oil reserves to roughly stay at the same level for 30 years, but these reserves are now more spread out in locations that are challenging to access. As a result, the cost of producing crude oil is rising, which is reflected in rising oil prices. Contrarily, as a direct result of increasing agricultural yields, locally produced agricultural raw materials like wheat and maize are continuously becoming less expensive, thereby shifting the economic scales in favour of the utilization of renewable resources. This pattern will probably continue for a while [3], [4].

Fossil fuels are now two to three times more costly per unit of energy than similar renewable resources like maize. Even agricultural waste items like straw are 10 times less expensive than gasoline. Due to their low cost, self-sufficiency, possibility for sustainable development, and ability to preserve natural resources, renewable resources have a great deal of promise as a supply of raw materials for both our chemical requirements and our energy needs (biofuels). Industrial biotechnology is the important technology in this regard, but the technologies for the effective conversion of these renewable resources into usable goods remain a significant restriction. Conventional chemical processes often have significant challenges utilizing renewable raw materials, although they have great technical maturity and efficiency when using fossil resources. Contrarily, industrial biotechnology processes can manage these renewable resources with incredible ease since microorganisms easily transform basic materials like, for example, carbohydrates into a range of valuable products. In order to make the transition from our current civilization, which is dependent on fossil fuels, to a sustainable bio-based society in the future, industrial biotechnology must be created.

## DISCUSSION

A Growing Population's Increasing Demand for Raw Materials and Energy Currently, 20% of the world's population uses around 80% of all the raw resources and energy that are accessible. The remaining 80% of the world's population will, of course, make every effort to raise their level of life, necessitating a significant increase in the need for raw resources and energy. Not to mention, the world's population is continuing to increase at an alarming pace. An unpleasant result of the idiosyncrasies of population growth dynamics is that the often touted and incorrectly understood claim of "reduced population growth" will only be realized in a few generations at the earliest. The population of the globe is now increasing more quickly than ever. Given that these two populous nations are projected to have a short-term improvement in their living standards, it is especially important to take their dynamics into account. All of these consequences will eventually cause the demand for raw materials and

energy to rise sharply. It is doubtful that the available raw resources will be distributed fairly; as a result, more raw materials will ultimately be consumed worldwide. This will accelerate the rate of depletion of the remaining fossil fuel reserves and other raw materials and increase awareness of renewable raw materials and energy sources [5], [6].

An increase in efficiency requirements for chemical production systems. Strong incentives are provided by the regulations governing the market economy to maintainably raise the effectiveness of all production processes. Large-scale waste-producing manufacturing systems were nonetheless profitable in the past, either because the garbage could be disposed of in the environment or because the expense of cleanup was pushed to society. Today, such methods are doomed due to the "polluter pays" idea. Waste is expensive to dispose of and signifies a yield loss with all of the additional expenditures that come with it. As a result, all chemical processes nowadays must function with a high level of efficiency. Particularly effective and focused, biocatalytic processes result in minimal waste, raw material use, and energy consumption. Industrial biotechnology's entry into the chemical sector is virtually generally driven by conventional economic principles like cost reduction, higher productivity, etc. Furthermore, the need for effective chemical processes will rise due to the likelihood that the previously mentioned variables would undoubtedly lead to future price increases for raw materials and energy. Industrial biotechnology's further penetration into the chemical sector and its beneficial interaction with traditional chemical technology will undoubtedly be greatly influenced.

**Growing Demand for Production Systems Sustainability**

The development of clean, sustainable manufacturing methods that respect the environment, enhance our quality of life, and are also competitive in the market is a significant challenge for the whole globe. This comprises the creation of novel manufacturing techniques that, in a preferred scenario, start with renewable raw materials, use the least amount of energy, and generate the least amount of trash. Particularly well suited to play a significant part in this effort to achieve sustainability is industrial biotechnology. In general, bioprocesses generate less waste, and utilizing an enzyme sometimes results in a total cessation of the use of hazardous and poisonous chemicals. Industrial biotechnology often causes a significant decrease in the environmental impact of industrial production. Regarding the utilization of raw materials and energy policy, the majority of industrialized countries are required to adhere to a number of fundamental standards. Numerous nations have made efforts in accordance with the Kyoto Protocol. The fact that CO2 emission permits are negotiable is already established, and the first fines for exceeding the standards will shortly go into force. It is anticipated that this will lead to a fundamental shift in how people view the usage of raw resources and energy consumption. It is obvious that this development will be advantageous for CO2-neutral, renewable raw resources like biomass.

**Consumer Perceptions and Behaviour Changing**

Consumer need for product information is on the rise in the majority of modern cultures, and this desire extends beyond questions of quality and cost. The production methods used to create today's goods organic farming, animal welfare, etc. and what happens to them after use (waste, degradability, etc.) are likewise becoming more and more important to customers. Even if they occur far away and strictly speaking do not burden or directly hurt customers, production processes that harm the environment, cause animal suffering, are based on unfair trade or exploitation such as child labour, etc. are increasingly being rejected by consumers. Customers are searching for products and services that may be purchased and utilized in a

way that is both socially and economically acceptable and that does not provide any moral or emotional quandaries.

This explains the opposition to genetically modified crops among Europeans. Ironically, the same people who reject genetically modified crops often eat items manufactured via fermentation methods, including fermented milk products or Quorn, a mycoprotein derived from fungus, without complaint and even with delight. Natural substitutes are in demand since consumers have a highly poor image of chemical products in food (preservatives, colourants, and antioxidants). Therefore, it is reasonable to anticipate that industrial biotechnology-derived goods will gradually replace these "chemical" ones. There is a chance that industrial biotechnology will be seen as interacting with nature. The use of biomass in place of petroleum and biological processes in place of more traditional synthesis is usually well received. Therefore, bio-processes have an advantage over conventional procedures in terms of public acceptability in addition to being cost-competitive and offering ecological benefits. Additionally, industrial biotechnology and related procedures are mostly carried out in enclosed production systems, and the microorganisms used are either harmless or incapable of surviving in the natural world.

Enzymes have become more important for biocatalytic processes in a range of industrial sectors. Usually, microbial enzymes from the fermentation techniques indicated above are used. The number of natural enzymes that may be employed is substantially increased by metagenomics, and new techniques for enzyme engineering, such as directed evolution, enable the development of unique, customized enzymes. These developments might significantly improve this technology or perhaps widen its usage to include whole new applications. Conventional applications of enzymes include the substantial use of glucose, one of the most major renewable raw materials, which is generated in the starch sector, another area where they are heavily used. An essential enzyme is -amylase, which hydrolyzes starch at 105 °C and is very thermostable. The ability of these thermostable enzymes to occur at high temperatures considerably accelerates bioreactions. Glucose isomerase is an important enzyme in this area. This enzyme converts glucose to fructose. It retains its catalytic activity when used industrially for up to two years in immobilized form. More than 15 million tons of glucose and fructose syrups are generated yearly worldwide with the help of this enzyme.

The detergent business is a significant additional use for enzymes. In this case, protein and lipid stains on clothing are removed using proteases and lipases. The market for animal feed is another significant one. For instance, phytase from the fungus Aspergillus niger is used to release phosphate from phytic acid in animal feed. This lessens the demand for additional phosphates while also having a positive impact on the environment. To considerably improve food conversion, other enzymes are applied, which has positive ecological benefits. In the chemical industry, enzymes are utilized as catalysts in a number of processes. In this case, the enzymatic reaction's specificity is essential. Comparing the specificity to conventional chemical catalysts, it is often extremely high. Chiral properties, in addition to possessing a high degree of reaction specificity, have promoted the application of biocatalysts in the chemical industry. making use of enzymes (discovered in

It is fast becoming accessible for particularly specific organochemical processes in free or immobilized form. The majority of them are one-step reactions with very high levels of specificity, efficiency, and reaction rate. These procedures, often referred to as "bioconversions" or "biotransfor- mations," are frequently carried out at standard pressures and temperatures, avoiding the requirement for hazardous intermediate products and the creation of hazardous waste. Although enzymes are also active in "conventional" chemical solvents like methanol, acetone, chlorinated solvents, etc., most reactions take place in

"green" solvents like water, ethanol, or supercritical CO2, which is why this scientific topic is sometimes referred to as "biocatalysis." At this point, it should also be stressed that practically all of the enzymes used in industrial biotechnology and biocatalysis are produced from bacteria via fermentation. Industrial enzymes represent a $2 billion market in industrial biotechnology [7], [8].

**The Agricultural System Has Changed**

Under pressure from consumers, governments, and international forces that want to loosen import restrictions, it is obvious that the agriculture industry will need to adapt regularly to new requirements and issues. The growth of the European Union with several new member states from Eastern Europe will put a lot more strain on the system, especially in Europe. Agriculture that is more focused on high-quality agricultural goods and less on (mass) production

1. Agriculture with more environmental sensitivity;
2. Reduction or elimination of agricultural production-related subsidies;
3. Lowered import tariffs on a variety of agricultural goods to enable emerging nations to sell their goods in europe.
4. More variety in agricultural systems, including new agricultural crops and production techniques like organic farming;
5. Encouragement of the growth of agricultural crops for reasons other than food.

It is obvious that using agricultural raw materials as a renewable raw material for fuel and the chemical sector satisfies the various demands. As a result, these innovations are enthusiastically embraced, especially by the agricultural community, which has realized the significance of industrial biotechnology. A wide variety of chemical compounds may be synthesized through industrial biotechnology, which often makes use of helpful microbes and their enzymes. The current influx of innovative applications appears to suggest that we have merely scratched the surface. Jackson Foster, a microbiologist, said in 1964: "Never underestimate the power of the microbe," and he has so far been proved correct. Some bottlenecks still exist for the time being. It goes without saying that switching from a "hydro-carbon economy" to a "carbohydrate economy" won't be simple or inexpensive. Before investments can be made, it is still crucial to understand the complete production costs and return of biomass production and usage for the various applications, in addition to persuading the petrochemical industry. Economic viability may often be significantly impacted by the possibilities for valorizing waste biomass and by-products from other bio-processes. With applications in fine and bulk chemistry, polymer synthesis, the pharmaceutical business, and the energy sector, this technology has already made significant inroads into the traditional food and healthcare industries. These procedures and goods have a significant benefit from the standpoint of sustainable development since they are typically based on renewable raw materials and have significant ecological advantages. This green chemistry and its bio-products need greater consideration from science, business, and policymakers alike. Successful innovation in a biotechnological product or process is never entirely determined by science and technology, but also by other aspects including public acceptability, the environment for innovation, and government support via a consistent R&D strategy [9], [10].

## CONCLUSION

The intersection of industrial biotechnology and sustainable chemistry provides a light of hope for a changing society in the face of tremendous socioeconomic and environmental issues. The analysis of the ecological benefits of using biotechnological techniques in the research emphasizes the possibility of fostering a more amicable connection between

economic development and environmental wellbeing. The pressing need for more effective, environmentally conscious manufacturing processes is becoming more and more obvious as global supply networks, population dynamics, and consumer behaviours change. With its expertise in using sustainable resources and streamlining processes, the industrial biotechnology sector emerges as a potent weapon in the transition to a sustainable bio-based society. Humanity can create a future that not only satisfies its wants but also protects the earth for future generations by embracing this paradigm shift and taking advantage of the synergy between technology and sustainability.

**REFERENCES:**

[1] G. Q. Chen en X. R. Jiang, "Next generation industrial biotechnology based on extremophilic bacteria", *Current Opinion in Biotechnology*. 2018. doi: 10.1016/j.copbio.2017.11.016.

[2] J. Dupont-Inglis en A. Borg, "Destination bioeconomy – The path towards a smarter, more sustainable future", *New Biotechnology*. 2018. doi: 10.1016/j.nbt.2017.05.010.

[3] M. M. Babar *et al.*, "Omics approaches in industrial biotechnology and bioprocess engineering", in *Omics Technologies and Bio-engineering: Volume 2: Towards Improving Quality of Life*, 2018. doi: 10.1016/B978-0-12-815870-8.00014-0.

[4] J. Hemmerich, S. Noack, W. Wiechert, en M. Oldiges, "Microbioreactor Systems for Accelerated Bioprocess Development", *Biotechnology Journal*. 2018. doi: 10.1002/biot.201700141.

[5] A. Pellis, S. Cantone, C. Ebert, en L. Gardossi, "Evolving biocatalysis to meet bioeconomy challenges and opportunities", *New Biotechnology*. 2018. doi: 10.1016/j.nbt.2017.07.005.

[6] L. Zamani *et al.*, "High Cell Density Perfusion Culture has a Maintained Exoproteome and Metabolome", *Biotechnol. J.*, 2018, doi: 10.1002/biot.201800036.

[7] I. Ghaffar *et al.*, "Microbial production and industrial applications of keratinases: an overview", *International Microbiology*. 2018. doi: 10.1007/s10123-018-0022-1.

[8] J. Lian, M. HamediRad, en H. Zhao, "Advancing Metabolic Engineering of Saccharomyces cerevisiae Using the CRISPR/Cas System", *Biotechnology Journal*. 2018. doi: 10.1002/biot.201700601.

[9] J. É. R. L. Morlighem *et al.*, "The holo-transcriptome of the zoantharian protopalythoa variabilis (cnidaria: Anthozoa): A plentiful source of enzymes for potential application in green chemistry, industrial and pharmaceutical biotechnology", *Mar. Drugs*, 2018, doi: 10.3390/md16060207.

[10] P. Mengal *et al.*, "Bio-based Industries Joint Undertaking: The catalyst for sustainable bio-based economic growth in Europe", *New Biotechnology*. 2018. doi: 10.1016/j.nbt.2017.06.002.

# CHAPTER 3

# UNVEILING THE JOURNEY: A CHRONICLE OF THE HISTORY OF INDUSTRIAL BIOTECHNOLOGY

Dr. Vikas Kumar, Assistant Professor, Department of Agriculture & Environmental Sciences,
Shobhit University, Gangoh, Uttar Pradesh, India,
Email Id- vikas.panwar@shobhituniversity.ac.in

Dr. Alpana Joshi, Associate Professor, Department of SAES,
Shobhit Deemed University, Meerut, Uttar Pradesh, India,
Email Id-alpna.joshi@shobhituniversity.ac.in

**ABSTRACT:**

The development of industrial biotechnology is a fascinating narrative of technical innovation, scientific discovery, and human inventiveness. This thorough review explores the development of industrial biotechnology, tracing its roots from prehistoric beginnings to modern advances. The interaction of biology, chemistry, and engineering has produced ground-breaking innovations that have transformed industries, influenced economies, and promoted sustainable behaviours. This account addresses the sociological and ethical factors that have influenced the development of industrial biotechnology in addition to highlighting significant turning points. This article gives insights into the dynamic tapestry of development that characterizes the history of this multidisciplinary discipline via an examination of defining events, trailblazing individuals, and paradigm changes.

**KEYWORDS:**

Economies, Industrial Biotechnology, Microorganisms, Penicillin.

## INTRODUCTION

Industrial biotechnology has a long history dating back to antiquity. Microorganisms were used for human wants and desires long before they were "discovered," for example, to preserve milk, fruits, and vegetables, as well as to improve the standard of living by creating drinks, cheeses, bread, pickled foods, and vinegar. Yeasts have been used since prehistoric times. Beer was first produced in Sumeria and Babylonia as early as 7000 BC using the earliest fermentation technique known to man the conversion of sugar to alcohol by yeasts. By 4000 BC, the Egyptians had learned that brewer's yeast could produce carbon dioxide that could leaven bread. It is also known that ancient peoples produced cheese using moulds and germs. In the Book of Genesis, it is said that Noah drank a little too much wine. Wine is another ancient byproduct of fermentation and was produced in Assyria about 3500 BC. In the area of human health, vinegar has a long history of application, the Assyrians used it to treat chronic middle ear diseases; Hippocrates treated patients with it in 400 BC; and, according to the New Testament, vinegar was offered to Jesus on the cross.

Microorganisms have been used in food for a very long time. Ancient Rome had about 250 bakeries producing leavened bread around 100 BC. In Asia, Kluyveromyces species were used to ferment milk to lactic acid for the production of yogurt as well as kefyr and koumiss. At least as early as AD 700, moulds were being used to saccharify rice as part of the koji process. In many regions of the globe by the fourteenth century AD, the practice of distilling alcoholic spirits from fermented grain, which is assumed to have originated in China or the Middle East, was widespread. The Orleans method, a surface technique used to make vinegar, was developed in Orleans, France, around the end of the fourteenth century [1], [2].

The majority of scientists at the time believed that microorganisms developed spontaneously from inanimate objects. Supporters had previously said that maggots were spontaneously

generated from decomposing flesh, but this notion was refuted by Italian physician, Francesco Redi, resulting in a 100-year argument over spontaneous generation, fittingly dubbed the "War of the Infusions." The notion of spontaneous generation, which had been proposed initially by Aristotle and others, had at this point been disproved with regard to higher forms of life, therefore its proponents focused their arguments on bacteria. It did seem that the idea explained how a clear broth may become hazy when it grew a significant number of "spontaneously generated microorganisms" over time.

Others, on the other hand, thought that microbes only emerged from pre-existing ones, and that since they were always present in the air, they would develop in organic infusions once they had access to these rich liquids. In 1850, Casimir Davaine discovered rod-shaped objects in the blood of anthrax-infected sheep and was able to infect healthy sheep with the disease by injecting such blood. The idea of spontaneous creation was finally disproved and the origin of current microbial life was shown to be previous life during the course of the next 25 years by Pasteur of France and John Tyndall of Britain. Pasteur's research on chirality as a chemist gave rise to his body of work. Pasteur had discovered two optical varieties of amyl alcohol in the 1850s, namely D and L, but he was unable to distinguish between the two. In 1857, he came to the conclusion that fermentation was a live process carried out by yeast after starting to investigate living bacteria that were engaged in the process.

The distillers of Lille contacted Pasteur to determine the cause of the fermentation vats' soured contents. He saw under his microscope that the fermentation broth included bacteria as well as yeast cells, and he was previously aware that bacteria were capable of producing lactic acid. One of Pasteur's biggest achievements was to show that each form of fermentation was mediated by a particular bacterium. This insight led to his suggestion that such souring might be avoided by a gentle heat treatment, which eventually became known as "pasteurization." Furthermore, he demonstrated the presence of living forms that were solely anaerobic in research that was conducted to find out why French beer was inferior than German beer. Interest in the mechanics behind these fermentations led to Pasteur's subsequent discoveries, which not only helped to establish microbiology as a separate field of study but also paved the way for the creation of vaccines and conceptions of hygiene that completely changed how medicine was practiced.

The second part of the nineteenth century was defined by the fight against illness when Pasteur and Koch established the germ theory of disease, and microbiologists' attention was focused on areas of microbiology related to medicine and sanitation. The fact that the human body has its own defences against harmful germs as a consequence of this was discovered. Among others, Pasteur and Koch discovered that when a bacterium invades the body, proteins (also known as antibodies) are produced in the circulation that may specifically neutralize the invader. Immunology as a field of study was therefore established. Pasteur was able to make a person immune to the sickness by injecting either dead or attenuated versions of the bacte- rium that causes the illness. The majority of the early microbiology research was focused on the creation of these vaccinations. The eighteenth century also saw the discovery of how microbes communicate with one another. Mouldy bread, pork, and cheese have been used in traditional medicine to treat wounds for thousands of years. The antagonistic effects of one bacterium on another were later directly seen by Tyndall, Pasteur, and a British doctor named William Roberts in the 1870s. With his signature foresight, Pasteur hypothesized that the phenomena may have some medicinal use. Various microbial formulations were tested as medications over the following 50 years, but they were either ineffective or too poisonous for living animals. The turning point in the history of microbiology was when Alexander Fleming discovered penicillin in 1927.

## DISCUSSION

When Eduard Buchner discovered that yeast extracts devoid of complete cells could turn sugar into ethanol, the science of biochemistry was founded. As a result, Pasteur's theories were changed, and it was realized that fermentation could occur even in the absence of live cells. Yeast was utilized in World War I to convert carbohydrates into glycerol because it was necessary for the production of armaments. This advancement prompted Neuberg to conduct a thorough investigation into the mechanisms behind these reactions and those that turn carbohydrates into ethanol after the war. This was followed by research conducted by Dutch scientists at Delft on the kinetics of enzyme-catalyzed reactions and oxidation/reduction processes.

Chaim Weizmann at the University of Manchester exploited the butyric acid bacteria that had been used for generations to ret flax and hemp to produce acetone and butanol during World War I. The first non-food fermentation established for mass production was his use of Clostridium, but it also brought with it issues of virus and microbial contamination that needed to be resolved. Although this fermentation's usage declined since it could not produce solvents as well as chemical approaches, it did serve as a learning experience for the creation of large-scale fungal culture for the synthesis of citric acid. Soon after the First World War, an aerobic procedure using Aspergillus niger was developed. The emergence of penicillin and streptomycin as commercial products not too long after their discovery signalled the beginning of the antibiotic era [3], [4].

### The Story of Penicillin

The accidental discovery of penicillin by Alexander Fleming in England in 1929 marked the start of the golden age of antibiotics. He discovered that Penicillium notatum had infected several of his plates containing Staphylococcus aureus, and he was startled to find that none of the bacterial colonies could develop near the mould. Fleming came to the conclusion that the mould was generating some kind of inhibitory substance. Additionally, he noticed that mould filtrates killed staphylococci and had no harmful effects on animals. He gave the drug the name penicillin. The study was abandoned because the activity was highly unsteady and Fleming had little support from his other scientists on the value of this substance.

The significance of Fleming's discovery lay in the fact that it created penicillin, the first effective chemotherapeutic agent made by a bacterium, ushering in the era of wonder medications. Penicilin was not developed into an effective medicine without difficulty, however. It remained a laboratorial curiosity for ten years, and an unstable one at that. Many British scientists tried to isolate penicillin in the 1930s, but they were unsuccessful due to the substance's volatility. Through this work, a stable version of penicillin was successfully created, and its exceptional antibacterial efficacy and lack of toxicity in animals were shown. Unfortunately, the strain of P. notatum that is now in use produces penicillin at such a sluggish rate that it required more than a year to gather enough samples for a clinical test on humans.

However, when the clinical trials were successful, large-scale manufacture became necessary, which prompted Florey and his colleague to go to the United States in the summer of 1941 to look for help. They convinced numerous American pharmaceutical firms, including Merck, Squibb, and Pfizer, as well as the Northern Regional Research Laboratory (NRRL) of the US Department of Agriculture (USDA) in Peoria, Illinois, to develop the commercial production of penicillin. For a while, Heatley stayed at the NRRL to collaborate with Moyer and Coghill. Thus started a historic period of collaboration between academic institutions in the UK and the United States, as well as industry labs, that lasted the whole War.

As a consequence, both on and off the battlefield, thousands of lives were saved. One of the most significant contributions of contemporary science and technology was the discovery and development of beta-lactam antibiotics. Following years of continuous advancement after Fleming's unintentional discovery of the mould that produced penicillin, the beta-lactam class of chemicals is now one of the most effective instances of natural product use and chemotherapy. An era of rapid advancement in microbial genetics started in the 1940s. These early genetic studies concentrated heavily on the production of mutants and the study of their properties, although Fleming's original strain produced only traces of penicillin, "brute force" genetic manipulation made tremendous strides in production ability and led to a whole new technology known as "strain improvement." The simplicity of the mutation approach and the ease with which "permanent" properties of microorganisms might be altered through mutation greatly appealed to microbiologists. The staff at the USDA in Peoria, the Carnegie Institution, Stanford University, and the University of Wisconsin formed a collaborative "strain-selection" program. Penicillin was first created in surface culture, but it was discovered that the titers were quite low. The preferred approach quickly emerged as submerged culture. The production of penicillin was multiplied 100 times in a matter of years by the use of strain enhancement and medium modifications, such as the addition of maize steep liquor.

The future of penicillins was questioned throughout the 1950s when resistant forms of Staphylococcus aureus appeared in hospital populations. By choosing penicillinase-producing strains, the staphylococcal population was developing penicillin resistance, and it was obvious that new medications were required to treat these resistant strains. The penicillins that have been discussed up to this point were solvent-soluble and quite effective against Gram-positive bacteria, but considerably less effective against Gram-negative ones. Thankfully, two events brought about a resurgence of interest in penicillins and related antibiotics. One was Koichi Kato's 1959 Japanese discovery of the buildup of the "penicillin nucleus" in P. chrysogenum broths without the addition of side-chain precursors. The "penicillin nucleus" identified by Kato, 6-aminopenicillanic acid (6-APA), was found in the isolated substance. 6-APA was utilized to create "semi-synthetic" penicillins, which are natural antibiotics that have undergone chemical modification to provide them beneficial features including resistance to penicillinase and acid as well as broad-spectrum antibacterial action.

The second breakthrough was the identification of penicillin N, a hydrophilic form of penicillin that has similar action against both types of microbes. Two different teams of workers independently found this chemical. In 1948, Brotzu reported his research on the isolation of an antibiotic-producing culture of the fungus Cephalosporium acremonium (later reclassified as Acremonium chrysogenum) from sewage in an unidentified Sardinian journal. When he was unable to isolate the antibiotic substance, he sent the culture to Florey at Oxford, where P. notatum had been at a comparable stage of development some 10 years previously. Workers at the Michigan Department of Health in the United States were researching this antibiotic complex's components while British researchers were doing the same. Gram-positive and Gram-negative bacteria were caused by the carboxyl group in the side-chain, it was revealed that a species of Tilachlidium generated a novel antibiotic they dubbed "synnematin."

**The Introduction of Cephalosporins**

Penicillin G's enormous success in the fight against illness not only earned Fleming, Florey, and Chain the Nobel Prize, but it also sparked a new field of antibiotic research and a whole new antibiotic business. The discovery of penicillin paved the path for the creation of several

additional antibiotics, and it continues to be the most potent and one of the least hazardous of these substances. Approximately 100 antibiotics are now being used to treat diseases in people, animals, and plants.

**Waksman's reign**

The findings of Selman A. Waksman, a soil microbiologist at Rutgers University, closely followed the discovery of penicillin, which marked the start of the antibiotic era, in the 1940s He and his pupils, particularly H. Many novel antibiotics, including actinomycin D, neomycin, and the most well-known of these new "wonder drugs," streptomycin, were successfully discovered by Boyd Woodruff, Albert Schatz, and Hubert Lechevalier from the filamentous bacteria, the actinomycetes. Streptomycin was used to treat bacterial meningitis after Waksman, Schatz, and Bugie's historic discovery of it as a byproduct of Streptomyces griseus in 1944. It was also used to treat TB caused by Mycobacterium tuberculosis and Gram-negative bacteria.

In 1952, Waksman received the Nobel Prize in recognition of his significant contributions to medicine. This aminoglycoside, the first actinomycete antibiotic to be commercially successful, helped establish actinomycete bacteria as the most prolific makers of antibiotics. Additionally, streptomycin offered a useful tool for researching cell function. After some time when it was believed to work by changing permeability, its principal effect interference with protein synthesis was discovered. Its interaction with ribosomes revealed a lot about their structure and function since it not only prevented them from doing their job but also led to errors in the genetic code and was necessary for ribosome function in streptomycin-dependent mutants [5], [6].

**Strain Reduction**

The discipline of biochemical engineering was established as a result of collaboration on the creation of industrial processes between Rutgers University, Princeton University, Columbia University, and Merck & Co., Inc. Waksman was able to create the renowned Institute of Microbiology thanks to the manufacturer, Merck, transferring royalties on streptomycin to Rutgers University. There have been shown to be around 15,000 secondary metabolites produced by microbes, 12 000 of which are antibiotics. They included huge macrolide rings, cyclic peptides with "unnatural" and non-protein amino acids, odd sugars and nucleosides, polyenes, and -lactam rings, among other uncommon chemical structures. Most were ineffective for humans because they were either too poisonous or inactive in higher organisms, but several may have saved lives. In the United States, the average life expectancy rose from 47 years in 1900 to 74 for men and 80 for women in 2000 thanks in large part to the use of antibiotics, which were essentially the only medications used for chemotherapy against harmful bacteria.

For whatever reason, the actinomycetes were very prolific producers of antibiotics. These filamentous prokaryotes provided over 70% of all antibiotics, and 75% of them were produced by the single species Streptomyces. The fact that distinct Streptomyces hygroscopicus strains generated over 180 different secondary metabolites is extremely astounding. Unicellular bacteria produced 10% of the antibiotics, while fungus produced 20% of the antibiotics. The rate of discovery of new bioactive compounds from microorganisms was astounding: from 200–300 per year in the late 1970s to 500 per year in the 1990s. Synthetic antimicrobials like quinolones and fluoroquinolones were available alongside natural product antibiotics in the pharmaceutical industry. Even these synthetics may be traced back to quinine, a natural substance. Nalidixic acid, the first quinolone, was based on quinine. However, the commercialization of antibiotics slowed down in the 1980s, and in the

following decades, only three antibiotics daptomycin, caspofungin acetate, and the synthetic oxazolidinone were marketed.

**Strain Reduction**

The experiments mentioned above, in which cultures that generate penicillin were mutagenized and tested for better producers, paved the path for the widespread use of genetics to increase production capacity. Genetic modification techniques like mutagenesis and screening were replaced starting in the 1950s by mutagenesis, selection, and screening, which used a variety of selective techniques to reduce the number of strains that needed to be tested for increased productivity. Then, it was discovered that mutations may make new derivatives, some of which were superior to the original molecule. Although Kelner first found this in 1949, the more potent compounds were not separated and identified. Demethyltetracycline and doxorubicin, however, were only subsequently identified through mutation of the cultures that produced tetracycline and daunomycin, respectively. In this procedure, analogues of the moiety whose biosynthesis was inhibited were given to a mutant whose secondary metabolism was prevented. The mutant known as a "idiotroph" created a novel secondary metabolite if it was successful. Many fresh secondary metabolites were discovered by means of mutational biosynthesis. The most well-known of them was the commercial antihelmintic drug doramectin, which was produced by a mutation of the avermectin producer Streptomyces avermitilis.

Prior to 1975, genetic recombination for strain enhancement was mostly disregarded in industry, largely because of the low frequency of recombination, which may be as low as 106. However, actinomycetes dramatically altered the situation by using polyethyleneglycol-mediated protoplast fusion. The use of genetic recombination was hastened by Okanishi's research on protoplast production, fusion, and regeneration. Since then, there has been a rise in interest in using genetic recombination to produce significant microbial products. Genetic engineering-based targeted deletions and duplications. Genetic recombination by protoplast fusion and plasmid transformation. The elegant work on Streptomyces coelicolor by David Hopwood, Keith Chater, Mervyn Bibb, and their colleagues at the John Innes Institute in Norwich, England sometimes referred to as the "temple of Streptomyces genetics revealed much about genetics and regulation in the actinomycetes. In addition to an A-factor-like molecule and the antibiotics actinorhodin, undecylprodigiosin, methylenomycin A, and "calcium-dependent antibiotic" or CDA, their favourite bacterium produced at least five more secondary metabolites [7], [8].

The genes encoding the majority of antibiotic biosynthesis pathways were found to be grouped into operons via the work of geneticists in academia and business throughout the globe in the 1970s and 1980s. This made it easier to transfer complete processes from one organism to another. It was discovered that these gene clusters also included regulatory and resistance genes. "Combinatorial biosynthesis" was created in 1985. A pathway from one streptomycete that produces the isochromanequinone antibiotic actinorhodin into strains that produce granaticin, dihydrogranaticin, and mederomycin was cloned as a result of an international effort from the United Kingdom, Japan, and the United States. Mederrhodin A and Dihydrodrograna natirhodin, two novel hybrid antibiotics, were discovered as a consequence. Recombinant DNA (rDNA) technology made the approach of combinatorial biosynthesis highly popular for the development of novel hybrid pharmaceuticals. The genes of a particular pathway in its natural host were rearranged to produce new antibiotics.

Recent advancements in strain development have made extensive use of new genetic techniques, including (i) metabolic engineering, which quantifies and controls metabolic

fluxes, as well as inverse metabolic engineering, transcript expression analyses, such as association analysis and massive parallele signature sequencing, (ii) directed evolution, (iii) molecular breeding, which includes DNA shuffling and whole genome shuffling, and (iv) cooperative mating. These initiatives are assisting in the identification of novel genetic targets that may be exploited in the creation of new products, as well as the isolation of enhanced strains.

**Combating Resistant Microbes with Semi-Synthetic Antibiotics**

Although many believed in the late 1970s that the age of bacterial disease product discovery was coming to a close, the fight against resistant microorganisms persisted and saw some unexpected advances. The creation of semi-synthetic erythromycins was a significant success. These comprised the antibiotics telithromycin, clarithromycin, roxithromycin, and azithromycin. The first two demonstrated better bioavailability and acid stability than erythromycin A, but they had no effect on resistant bacteria. On the other hand, macrolide-resistant bacteria were affected by azithromycin and telithromycin. Each of the aforementioned semi-synthetic erythromycins listed above was a potent treatment for upper respiratory tract infections and may be used orally or parenterally. For community-acquired respiratory infections, telithromycin was very important since it was bacteriostatic, effective orally, and. Its poor capacity to both cause cross-resistance and select for resistance mutations was particularly intriguing. Additionally, it did not cause MLSB resistance, which is a drawback of other macrolides.

The glycopeptides vancomycin and teicoplanin were essentially the only naturally occurring antibiotics active against multidrug-resistant Gram-positive bacteria for more than 35 years. The rise in multidrug resistance reduced their usage. New semi-synthetic antibiotics, like Synercid, came to the rescue. Quinupristin and dalfopristin, two narrow-spectrum streptogramins that synergistically outperformed each other (by a factor of 100) and were produced by the same strain of Streptomyces pristinaespiralis, served as the basis for Synercid. A polyunsaturated macrolactone (Group A) with a unique oxazole ring and a dienylamide fragment and a cyclic hexadepsipeptide (Group B) with a 3-hydroxypicolinoyl exocyclic fragment made up the pair. The Synercid components were both water-soluble, in contrast to the naturally occurring streptogramins, which had limited water solubility and could not be administered intravenously.

**The essential metabolites**

The genuine start of what may be referred to as the "golden age of industrial microbiology" came with the invention of penicillin fermentation in the 1940s. Louis Pasteur's research demonstrated the significance of non-pathogenic bacteria' role in the production of alcohol in wine and beer. As a consequence of this insight, fermentation has been used to produce a significant number of important primary microbial metabolites. Primary metabolism entails a connected set of catabolic, amphibolic, and anabolic events that are controlled by enzymes. These reactions produce energy and biosynthetic intermediates while transforming biosynthetic precursors into vital macromolecules including DNA, RNA, proteins, lipids, and polysaccharides. It is well balanced, and intermediates seldom ever build up. The fermentation industry was able to produce too many primary metabolites by deregulating primary metabolism. The most significant major metabolic components in terms of commerce were amino acids, vitamins, flavour nucleotides, organic acids, and alcohols. Due to feedback control, glutamic acid overproduction is often not anticipated to happen. PEP carboxylase, citrate synthase, and NADP-glutamate dehydrogenase are all suppressed by glutamate, while the latter enzyme is also inhibited by it. However, glutamate was blasted out

of the cell by lessening the efficiency of the barrier to outward passage, enabling its production to continue unhindered. The glutamate pathway was released from feedback regulation by excretion until abnormally high levels accumulated [9], [10]. By using different treatments, such as restricting the amount of biotin in Corynebacterium glutamicum, glutamate excretion was purposefully affected. All glutamate overproducers were naturally occurring biotin auxotrophs. Acetyl-CoA carboxylase, which is necessary for the production of fatty acids, uses biotin as a cofactor. Shiio and colleagues hypothesized (i) that growth of the glutamate-overproducing bacterium in the presence of non-limiting levels of biotin resulted in a cell membrane permeability barrier restricting the outward passage of intracellular amino acids out of the cell and (ii) that inhibition of cell wall biosynthesis by penicillin altered the ph of the glutamate-overproducing bacterium.

Despite the data shown above, some researchers rejected the leaky plasma membrane theory in favour of an efflux mechanism that was glutamate-specific and controlled by the cell's energy level. Fatty acid synthases' activity was linked to the effects of biotin on intermediate metabolism, which explained how it worked. Other arguments against the permeability theory linked glutamate overproduction to a decline in ketoglutarate dehydrogenase activity brought on by a biotin deficiency, the addition of penicillin, or the presence of surfactants. The permeability modification theory, however, was confirmed in 2001. It has been shown that the numerous treatments that lead to glutamate overproduction enhance the permeability of the mycolic acid layer of the cell wall.

A unique cell envelope made of mycolic acids that surrounds the whole cell as a structured layer and is hypothesized to be involved in solute penetration distinguishes glutamate-overproducing bacteria from other types. The cytoplasmic membrane is the first lipid layer, and the second was created by the non-covalently bound mycolic acid derivatives and mycolic acids esterified with arabi- nogalactan. The concept of "permeability of the cell wall," which was first used in the very first study on L-glutamate production more than forty years ago, "now takes on a new meaning," according to these authors. Nampoothiri et al. provided evidence that overexpression or inactiv- ity of genes involved in lipid synthesis changed glutamate efflux dramatically, altered the chemical and physical properties of the cytoplasmic membrane, and that this was required to achieve efflux of L-glu. Burko- vski and Kraemer also said that "there is no doubt that stimulation of glutamate excretion in C. elegans is necessary to enable L-glutamate efflux, adding that altering the phosphoplipid content alone is sufficient to enable L-glutamate efflux. The integrity of cell walls and/or membranes is connected to glutamicum either directly or indirectly.

**Since the vast majority of grains eaten worldwide lacked L-lysine**

This necessary amino acid developed become a significant industrial product. In an organism like Escherichia coli, the lysine biosynthesis route is strictly regulated by three aspartate kinases, each of which is controlled by a different end-product (lysine, threonine, or methionine). The original enzymes were also inhibited by their respective end products at each branch point. However, there is just one aspartate kinase in lysine fermentation organisms (such as mutants of C. glutamicum and its relatives), and it is controlled by coordinated feedback inhibition from threonine and lysine. A glutamate-producing wild-type Corynebacterium was genetically altered to produce excess lysine, which prevented it from growing without the addition of methionine and threonine to the medium.

E. Plasmids containing operons for the biosynthesis of amino acids were used to create coli strains. Corynebacterium, Brevibacterium, and Serratia all underwent plasmid transformation so that rDNA technology could be employed to enhance these commercial amino acid-

producing bacteria. The idea of metabolic engineering, or the targeted enhancement of product creation or cellular features by the modification of certain biochemical processes or the introduction of new ones using rDNA technology, proved particularly helpful. Its core was combining analytical techniques for flux quantification and flux control with molecular biology approaches to put the recommended genetic modification into practice. The entire flux through a metabolic route depends on several processes, not just one rate-limiting reaction, according to metabolic control analysis. research on the metabolic flux of C wild-type. Glutamicum and four upgraded lysine-producing mutants demonstrated that compared to the glucose flux, yield rose in the series from 1.2 to 24.9%. The relative flux through isocitrate dehydrogenase was found to have decreased from 83 to 60%, the pentose phosphate pathway had increased, the anaplerotic net flux had almost doubled, and the NADPH demand had increased from 109 to 172%.

## CONCLUSION

Industrial biotechnology, a synthesis of biological mechanisms and technical aptitude, has left its mark on the history of human development. The fascinating journey of "Unveiling the Journey: A Chronicle of the History of Industrial Biotechnology" sets out to learn more about the genesis, advancements, and revolutions that have shaped this ground-breaking field. This story attempts to show how industrial biotechnology has developed from humble beginnings into a worldwide powerhouse by tracing its origins to ancient fermentation processes and the emergence of genetic knowledge. Important individuals, ground-breaking discoveries, and social processes all played crucial roles in determining the course of this subject as the complex interaction between science and industry came into focus. The story aims to shed light on both the ethical issues that have followed the march of development as well as the major technical achievements. The development of industrial biotechnology is evidence of humanity's ongoing drive for progress and sustainability. The journey has been astounding, starting from primitive times when microbial fermentation led the way for nutrition and cultural mainstays to the contemporary day when gene editing and synthetic biology hold the keys to specialized goods and precision treatment. This discipline has reached incredible heights because to the synergy of biological knowledge, technical prowess, and creative energy. It has sparked revolutions across several sectors and provided answers to pressing global issues. Industrial biotechnology's story includes both scientific and ethical reflection, necessitating careful manoeuvring as we use its power. Lessons learned from this chronicle suggest avenues for additional investigation, ethical concerns, and responsible management of our common biosphere as we stand at the nexus of history and the future.

## REFERENCES:

[1] A. Costessi *et al.*, “Novel sequencing technologies to support industrial biotechnology”, *FEMS Microbiology Letters*. 2018. doi: 10.1093/femsle/fny103.

[2] G. Q. Chen en X. R. Jiang, “Next generation industrial biotechnology based on extremophilic bacteria”, *Current Opinion in Biotechnology*. 2018. doi: 10.1016/j.copbio.2017.11.016.

[3] T. Stadler en J. M. Chauvet, “New innovative ecosystems in France to develop the Bioeconomy”, *New Biotechnology*. 2018. doi: 10.1016/j.nbt.2017.07.009.

[4] C. Ling *et al.*, “Engineering NADH/NAD + ratio in Halomonas bluephagenesis for

enhanced production of polyhydroxyalkanoates (PHA)", *Metab. Eng.*, 2018, doi: 10.1016/j.ymben.2018.09.007.

[5] A. Pellis, S. Cantone, C. Ebert, en L. Gardossi, "Evolving biocatalysis to meet bioeconomy challenges and opportunities", *New Biotechnology*. 2018. doi: 10.1016/j.nbt.2017.07.005.

[6] L. Zamani *et al.*, "High Cell Density Perfusion Culture has a Maintained Exoproteome and Metabolome", *Biotechnol. J.*, 2018, doi: 10.1002/biot.201800036.

[7] M. Larroude, T. Rossignol, J. M. Nicaud, en R. Ledesma-Amaro, "Synthetic biology tools for engineering Yarrowia lipolytica", *Biotechnology Advances*. 2018. doi: 10.1016/j.biotechadv.2018.10.004.

[8] M. C. S. Barcelos, F. B. Lupki, G. A. Campolina, D. L. Nelson, en G. Molina, "The colors of biotechnology: General overview and developments of white, green and blue areas", *FEMS Microbiol. Lett.*, 2018, doi: 10.1093/femsle/fny239.

[9] R. Hatti-Kaul, L. Chen, T. Dishisha, en H. El Enshasy, "Lactic acid bacteria: From starter cultures to producers of chemicals", *FEMS Microbiology Letters*. 2018. doi: 10.1093/femsle/fny213.

[10] I. Ghaffar *et al.*, "Microbial production and industrial applications of keratinases: an overview", *International Microbiology*. 2018. doi: 10.1007/s10123-018-0022-1.

# CHAPTER 4

# THE BIOPHARMACEUTICAL REVOLUTION: FROM GENETIC MILESTONES TO INDUSTRIAL BREAKTHROUGHS

Dr. Vikas Kumar, Assistant Professor, Department of Agriculture & Environmental Sciences,
Shobhit University, Gangoh, Uttar Pradesh, India,
Email Id- vikas.panwar@shobhituniversity.ac.in

Dr. Alpana Joshi, Associate Professor, Department of SAES,
Shobhit Deemed University, Meerut, Uttar Pradesh, India,
Email Id-alpna.joshi@shobhituniversity.ac.in

**ABSTRACT:**

The Biopharmaceutical Revolution stands as a testament to the extraordinary convergence of genetics, molecular biology, and industrial innovation. This paper traces the evolution of biopharmaceuticals, beginning with the foundational genetic milestones that laid the groundwork for modern biotechnology. From Gregor Mendel's insights into inheritance to Avery, McCloud, and McCarty's discovery of DNA's role as the genetic material, the genetic journey unfolded over decades. The monumental finding of the DNA double helix by Watson and Crick in 1953 ignited a cascade of events that led to the birth of modern biotechnology. The year 1966 marked a pivotal moment with the deciphering of the genetic code, followed by the breakthroughs in gene isolation and synthesis. The true revolution, however, occurred in 1972–1973, with the inception of recombinant DNA technology. This breakthrough shattered species barriers, laying the foundation for the biopharmaceutical industry's growth and success. Visionaries like the founders of Cetus Corporation and Genentech propelled biotechnology into a realm of possibilities that would transform patient care and redefine industrial microbiology. The Biopharmaceutical Revolution stands as a testament to humanity's capacity to harness biology for unprecedented advancements. This narrative recount the journey from genetic discoveries to industrial breakthroughs, highlighting the relentless pursuit of scientific curiosity and technological excellence that continues to drive this ongoing revolution.

**KEYWORDS:**

Biopharmaceutical, Biotechnology, Genetics, Industrial Microbiology, Molecular Biology.

## INTRODUCTION

The discoveries of Gregor Mendel on the character inheritance in peas in the middle of the nineteenth century are among the major turning points in genetics. Avery, McCloud, and McCarty at the Rockefeller Institute made the significant discovery in 1944 that DNA was the genetic material. Lederberg and Tatum exposed sex to microorganisms two years later. Watson and Crick's 1953 discovery of the double-stranded structure of DNA served as the impetus for the biotechnology revolution. The extraordinary developments in the fields of molecular biology and molecular genetics are mostly attributable to the use of microbes and their antibiotics as fundamental research tools [1], [2]. The genetic code was cracked by Nirenberg, Matthei, Leder, Khorana, and Ochoa in 1966, which was a crucial year. In 1969, Shapiro and Beck extracted a gene, and in 1970, Khorana chemically manufactured a gene. Genetic recombination was previously thought to only happen between members of the same species or closely related species. Protoplast fusion was limited to animals that were genetically related, even in the lab. All living things have restriction endonucleases, which identified foreign DNA and eliminated it to prevent "illegitimate recombination."

Then, in 1972-1973, Berg, Cohen, and Boyer at Stanford University and the University of California, San Francisco, developed recombinant DNA, which sparked the creation of contemporary biotechnology. These researchers learned how to split DNA molecules using restriction enzymes, combine DNA molecules from several animals with DNA ligase, and introduce rDNA into E via a vehicle such as a plasmid or phage. coli. They therefore defied nature and overcame barriers between species to carry out recombination. This increased the potential of biotechnology and sparked the growth of the global and American biopharmaceutical industries.

The groundbreaking application of fundamental biological findings, which got under way in 1971, didn't happen in a bubble; it primarily relied on the robust structure of the fermentation sector. Peter Farley, a doctor, Ronald Cape, a scientist, Donald Glaser, a Nobel Prize-winning physicist, and others had the idea to commercialize rDNA technology at the time, and the Cetus Corporation was established in Berkeley, California, in 1971 as a result. One of the most thrilling journeys in industrial biotechnology history started in this manner. These Cetus founders' vision inspired the creation of a significant biotechnology industry that now serves patients worldwide and has transformed the field of industrial microbiology. Herbert Boyer and Robert Swanson founded the second biotechnology business in 1976 in South San Francisco, across the water from Cetus. A human gene was expressed in bacteria during the same year, and yeast DNA was duplicated and expressed. Genentech created tissue plasminogen activator (tPA) and human insulin by 1978. Additionally, in 1978, Cambridge, Massachusetts-based Biogen was established and bacterial DNA was successfully introduced into yeast chromosomes. Yeast protoplasts were altered in 1979 by a hybrid E. the plasmid coli/yeast. Amgen was established in southern California in 1980, the same year that the US Supreme Court issued a landmark decision allowing for the patentability of biological things. This was based on Ananda Chakrabarty's work [3], [4].

Numerous businesses have been founded since then, such as Immunex, Centocor, and MedImmune. Many of them made investments in contemporary biotechnology in the belief that genetics will provide goods that were previously unimaginable; in fact, this goal was greatly realized. This sparked a surge in investment activity in new businesses, many of which were focused on genetically-based innovation. In a variety of markets, including downstream processing and microbiological engineering, more recent businesses have emerged.

## DISCUSSION

The product that started the biopharmaceutical business will always be remembered as human insulin. Human insulin was created by Genentech in 1979 and put into commercial production by Eli Lilly in 1982. It was the first recombinant protein to be manufactured and subsequently authorized by the FDA. In the past, the procedure entailed removing pancreatic tissue from deceased pigs and calves, and the resulting substance was not exactly like human insulin. Additionally, the animal products included allergen-triggering contaminants. All of these issues were resolved thanks to recombinant human insulin.

### Erythropoietin Procrit, Epogen

Erythropoietin (EPO) is a bone marrow factor used to treat chronic renal failure in individuals receiving kidney dialysis and for chemotherapy patients. By promoting the production and differentiation of red blood cells, it helps to treat certain anemias. Clinical studies for the product began in 1985, and it was authorized in 1989. It is also helpful for anemia brought on by chemotherapy for cancer and azidothymidine (AZT) for AIDS. Patients who choose to utilize their own stored blood over that of others may also get EPO.

**Activator of Tissue Plasminogen (Activase, Alteplase)**

The drug tissue plasminogen activator (tPA) is used to break blood clots in human coronary arteries and to treat acute myocardial infarction, deep vein thrombosis, pulmonary embolism, and stroke with rapidity. It was released to the public in late 1987. In 1996, tPA use was expanded to include stroke patients.

**Interleukins**

Interleukin 2 (IL-2, proleukin) was licensed in 1992 after demonstrating effectiveness against renal cell carcinoma. Due to its capacity to promote platelet production, recombinant IL-11 (Neumega) was given FDA approval in the early months of 1998 for the treatment of cancer chemotherapy-related thrombocytopenia (low platelet count). To make up for their lack of the blood-clotting protein Factor VIII, patients with hemophelia have traditionally received blood coagulant products made from human plasma, but 60% of these patients contracted HIV, hepatitis, or other diseases whose viruses contaminate such products. Recombinant Factor VIII for treatment in hemophelia underwent clinical testing in 1989. The product received FDA approval in 1993.

**Factors That Stimulate Colonies**

Bone marrow variables for renal disease and chemotherapy patients are colostrumating factors. In 1991, granulocyte colony-stimulating factor (G-CSF; Neupogen, Filgrastim, Leukine) was licensed to treat neutropenia brought on by chemotherapy. Also licensed in 1991 was granulocyte macrophage colony-stimulating factor (GM-CSF), which promotes the development of white blood cells in autologous bone marrow transplants.

**Pulmozyme DNase from humans**

In 1994, the FDA authorized human DNase for the treatment of cystic fibrosis (CF). It was the first brand-new treatment for CF, a condition that affects 30 000 individuals in the US, in thirty years. In clinical studies, DNase has also shown effectiveness in treating chronic bronchitis, a condition that affects 2 million individuals in the US. Gaucher's disease is a hereditary illness for which glucocerebrosidase was authorized in 1994. Patients missing this enzyme are unable to stop fat buildup in bones and other organs.

**Molecular antibodies**

Georges Kolter and Cesar Milstein made the discovery of monoclonal antiobodies (mAbs) in the UK in 1975. They combined a white cell that makes antibodies with a mouse skin cancer cell called a "myeloma". A hybrid cell (or "hybridoma") was created as a consequence, and it generated a completely unique antibody. In 1984, the two immunologists shared the Nobel Prize. Polyclonal antibodies (pAbs) were used in the past, although they had a wide range of specificities and affinities. Unlike mAbs, which were made by individual immune system cells, they had been created by the animal's whole immune system.

To produce mAb, mice were vaccinated with a single antigen, allowed to mount an immune response, their spleens were excised, cells were collected, and mouse lymphoma cell line (immortal malignant) cells were fused with the retrieved cells. The hybridoma cells that secreted the appropriate antibodies were then isolated by cloning and screening the fused "hybridoma" cells. The mAbs were "humanized" via genetic engineering methods since the human body could respond unfavourably to mouse sequences. The mice were genetically altered such that the relevant mouse genes, which were deleted, were replaced with human genes that encode human heavy chains and human kappa light chains. Human immune cells

might possibly produce monoclonals. They served as a "magic bullet" for delivering a medication or radioisotope to a specific target by binding to or inhibiting the binding of a target protein.

After 2000, mAbs emerged as the therapeutic protein class with the greatest rate of growth, with a market value of US$6.8 billion in 2006. ReoPro, which was authorized in 1994 to suppress platelet aggregation (blood clotting), was the first effective therapeutic mAb. It effectively avoided angioplasty consequences including mortality, heart attack, and the need for further angioplasty. It was followed by four additional monoclonals in 1998: (i) infliximab (Remicade), which inhibited tumour necrosis factor (TNF) and was approved for the treatment of Crohn's disease and rheumatoid arthritis; (ii) basiliximab (Simulect), which was used to prevent acute organ rejection in patients receiving renal transplants along with ciclosporin and corticosteroids; and (iii) tras The respiratory syncytial virus (RSV), which may cause significant lower respiratory tract sickness in young kids, was prevented by using this first-ever monoclonal antibody (mAb) against an infectious disease. 2003 saw the approval of adalimumab (Humira) for rheumatoid arthritis. Retuximab (Rituxan), used to treat non-Hodgkin's lymphoma, is another extremely significant monoclonal.

**Further Biopharmaceuticals**

Etanercept (Enbrel), a drug licensed in 1998 for the treatment of rheumatoid arthritis, works by interacting with and inhibiting TNF, a protein involved in inflammation, and imatinib (Gleevec, Glivec), a drug effective in the treatment of chronic myelogenous leukemia (CML). A chromosomal translocation between chromosomes 9 and 22 results in the aberrant protein Brc-Ab1, which promotes unchecked white blood cell proliferation and leukemia in CML. Imatinib is effective against gastrointestinal stromal tumours (GIST). Coli was the source of the inclusion bodies made of heterologous proteins. The recombinant proteins in this state were inert, aggregated, and insoluble and often included atypical free cysteines as well as non-native intra- and intermolecular disulfide linkages. These bodies had to be separated from the cell by homogenization, washing, and centrifugation in order to create active protein. The protein had to be unfolded by denaturants such guanidine HCl, urea, and sodium dodecyl sulphate before being solubilized and treated with reducing agents to break the disulfide bonds. Refolding was then accomplished by removing the denaturant and reducing agent. The renaturation methods included (i) Protein-S-sulfonate and protein-S-glutathione mixed disulfides, (ii) glutathione reoxidation, and (iii) air oxidation. By joining their genes to the E, heterologous recombinant proteins were also produced at high amounts in physiologically active soluble form. thioredoxin gene of coli. Many human proteins were synthesized as fusions in E at a rate of 5-20% of all proteins. cytoplasm of coli. Some fusions managed to retain the great thermal stability of thioredoxin as well as its capacity to release under osmotic shock or freeze/thaw conditions [5], [6].

Another effective way to stop inclusion bodies containing heterologous proteins from forming in E. Coli must reduce its growing temperature from 37 to 30 °C. goods produced in E. Human growth hormone and insulin are present in E. coli. Nearly 80% of the polypeptides that eukaryotes excrete are glycosylated. Specific to species, tissues, and cell types, glycosylation occurs. Regrettably, E. Proteins are not glycosylated in coli. In rare circumstances, a typically glycosylated protein may be produced by bacteria and is functional without the carbohydrate moiety. This was shown to be true of -interferon. Recombinant yeast, mould, insect, or mammalian cells may often produce proteins where glycosylation is required for stability or appropriate folding (e.g. erythropoeitin).

**Yeasts**

As a cloning host, yeasts have several benefits over bacteria. (i) When appropriate signal sequences are joined to the structural genes, they may secrete heterologous proteins into the extracellular broth. They perform the glycosylation of proteins (ii). On the other hand, S. Because higher eukaryotic proteins feature sialylated O-linked chains instead of mannose-only oligosaccharides, cerevisiae is often unsuitable for mammalian proteins. Additionally, S. Overglycosylation of N-linked sites by cerevisiae results in decreased activity and receptor binding, which impairs immunity.

**Animal Cells**

Insect cells in culture provide excellent hosts for the synthesis of recombinant proteins. Over 200 proteins encoded by genes from viruses, bacteria, fungi, plants, and mammals have been produced via recombinant insect cell cultures. The baculovirus that only affected invertebrates and not plants or vertebrates has been used to make expression vectors, ensuring safety. The nuclear polyhedrosis virus (Autographa californica), which has circular double-stranded DNA, is inherently harmful for lepidopteran cells and can be cultivated readily in vitro, is the most often utilized baculovirus. The protein polyhedrin, which is often produced at very high levels and is not required for viral replication, is encoded by a gene in the virus. The viral polyhedrin promoter exerted strong control over the gene that would be cloned, resulting in the production of the required amount of proteins with many posttranslational modifications found in higher eukaryotes, such as phosphorylation, glycosylation, correct signal peptide cleavage, proteolytic processing, palmitylation, and myristylation. In suspension culture, the fall armyworm (Spodoptera frugiperda) serves as the typical host. An alternative is to employ a larval culture, which is substantially less expensive than cell culture. Recombinant protein 600 mg/l has been created via larval systems.

**Biological Cells**

The early 1980s saw the introduction of mammalian cell culture, namely immortalized Chinese hamster ovary (CHO) cells, which were required for the manufacture of EPO and tPA. Prior advancements in microbial fermentation technology aided in the creation of mammalian cell culture. Because the proteins were created in mammalian cell cultures in a correctly folded and glycosylated state, there was no need to renature them. N50 murine myeloma cells, baby hamster kidney cells, green monkey kidney cells, and human embryonic kidney cells have all been used by mammalian cells to produce recombinant proteins. Human growth hormone, GM-CSF, G-CSF, EPO, and Pulmozyme were among the recombinant pharmaceuticals produced most often using mammalian cell culture. Processes using CHO cells were created and produced 3-5 g/l of recombinant protein.

**Gene-Modified Animals**

Recombinant peptide synthesis techniques have been established using transgenic animals. A 3 g/l concentration of tPA was found in the milk of transgenic goats. Cows produce 30 litres of milk every day, with 35 gram of protein per litre; thus, the total protein daily production is 1 kilogram. Antithrombin III and human growth hormone have production titers of 2 g/l in mouse milk, 4 g/l in sheep milk, 5 g/l in sheep milk, 8 g/l in rabbit milk, 14 g/l in goat milk, 35 g/l in sheep milk, and 40 g/l in sheep milk, respectively. All of these genes are human-derived. The protein is often just as active as the original protein. The tPA generated by transgenic goats has a different glycosylation than that produced in cell culture and a longer half-life than native tPA. The amount of time required to gauge protein output levels in transgenic mice is one of its drawbacks. In mice, this takes 3.5 months, in pigs 15 months, in sheep 28 months, and in cows 32 months [7], [8].

**Gene-Modified Plants**

A variety of useful compounds, including as glucuronidase (GUS), avidin, laccase, and trypsin, might be produced by transgenic plants. Enkephalin and a neuropeptide have both been made from oilseed rape plants. Phytase from A. niger and hirudin from Hirudo medicinalis are two examples of recombinant proteins that may be generated in transgenic plants at quantities as high as 14% of the total tobacco-soluble protein and 1% of the weight of canola seeds, respectively. Targeting, compartmentalization, adequate glycosylation, and natural storage stability are all potential benefits.

**Enzymes**

When Buchner discovered in 1897 that cell-free yeast extracts could produce ethanol from sugar, he named the glycolytic enzyme complex "zymase," which means "the enzyme of yeast itself." Enzymes became valuable in manufacturing because of their quick and effective action at low concentrations under mild pH values and temperatures, their high degree of substrate specificity (which reduced side-product f, and their high degree of substrate specificity (which increased the amount of f that was converted into ethanol) Extracellular enzyme production by certain microbial strains reached very high levels. Commercial strains of Bacillus licheniformis generated 20 g/l of protease, compared to 5 g/l produced by wild bacteria. Aspergillus strains with high yields generated 20 g/l of glucoamylase. The following are some additional benefits of using microbial cells as sources of enzymes: (i) enzyme fermentations were relatively inexpensive on a large scale due to short fermentation cycles and inexpensive media; (ii) screening procedures were straightforward and thousands of cultures could be examined in a reasonably short period of time; and (iii) different species produced somewhat different enzymes catalyzing the same reaction, allowing one flexibility with regard to operating conditions in the reaction.

Microbial enzymes were utilized more often in the 1980s and 1990s for applications that had previously relied on plant and animal enzymes. These shifts included the partial replacement of (i) amylases of malted barley and wheat in the beer, baking, and textile industries by amylases from Bacillus and Aspergillus; (ii) plant and animal proteases by Aspergillus protease for chill-proofing beer and tenderizing meat; (iii) pancreatic proteases by Aspergillus and Bacillus proteases for leather bating and in detergent preparations; and (iv) calf stomach rennet (chymosin) by Mucor rennins for cheese manufacture. Manufacturers of cheese were later interested in mammalian chymosin cloning, and experiments on cheese created with the recombinant enzyme demonstrated economic success. The price of recombinant chy- mosin, which was authorized in the US, was half that of native calf chymosin. The following were significant industrial enzymes: (i) nitrile hydrolase for hydration of acrylonitrile to acrylamide; (ii) penicillin acylase for production of semi-synthetic penicillins; (iii) peroxidase for manufacture of phenolic resins (which could replace synthetic phenol-formaldehydes). The discovery of glucose isomerase allowed the corn wet milling industry to take 30% of the sweetener market from the sugar industry in the 1970s. Glucose isomerase was used along with -amylase and glucoamylase to convert starch to mixtures of glucose and fructose known as "high fructose corn syrup." High fructose corn syrup is manufactured at a rate of 30 billion pounds annually in the United States alone [9], [10].

Numerous enzymes have had their characteristics changed genetically. Over the years, changes in pH optimum, thermostability, feedback inhibition, carbon source inhibition, substrate specificity, Vmax, Km, and Ki have been brought about by "brute force" mutagenesis and random screening of microorganisms. The more logical protein engineering strategies have taken use of this knowledge. Numerous other enzymes have undergone

comparable alterations as a result of single changes in amino acid sequences. For instance, the heat tolerance of a protease from Bacillus stearothermophilus was raised from 86 °C to 100 °C, making it resistant to boiling! By use of site-directed mutagenesis, the enzyme was created. It was only necessary to modify eight amino acids. The 340-fold improvement in temperature stability at 100 °C did not result in a reduction in activity at lower temperatures. The active site of the enzyme was remote from all eight mutations. Directed evolution, also known as applied molecular evolution or directed molecular evolution, is a great way to improve enzymes. DNA shuf- fling is one type of directed evolution that has significantly improved catalytic activity, modified specificity, and improved stability of enzymes.

**Bioconversions**

The synthesis of acrylamide, used as a flocculant, a component of synthetic fibres, a soil conditioner, and a recovery agent in the petroleum business, was the first instance of the utilization of a biological process to compete with a chemical process in the petrochemical industry. There were issues with the chemical reaction that included hydrating acrylonitrile with copper salt catalysis. The chemical process was opposed by a bioconversion involving Pseudomonas chlororaphis B23 or Rhodococcus rhodochrous J1, in which nitrile hydratase was activated by methacrylamide and catalyzed the hydration. The cells were used several times, the conversion yield was above 99.99%, and the process was done at 10 °C. After 10 hours, the titer was 656 g/l. Bioconversions are now commonly employed in the production of chemicals. The need for single-isomer intermediates has also made them crucial to the fine chemical sector.

**Vaccines**

Genes encoding for the surface antigens of viruses, bacteria, and parasites have been cloned and expressed to provide protein antigens for vaccines. Hepatitis B viral surface antigen, which was created in yeast, was the first subunit vaccine to hit the market. The USDA authorized the first recombinant live veterinary vaccination in 1994. In order to create a vaccination that is effective against both Newcastle disease and the fowlpox virus, Syntro Corp.'s VectorVax FP-N vaccine uses a fowlpox viral vector that had two of its disease-causing genes removed.

**Microbiology of Systems**

"Systems microbiology" is a word and a scientific field that describes a method to understanding the functions and operations carried out by microbial cells that takes into account genome-scale and cell-wide data. The amazing progress in (i) genomics and other "omic" methods (such as proteomics and metabolomics) as well as high-throughput technologies for measuring several classes of important intracellular chemicals allowed for a more comprehensive understanding of the microbial cell. Genomic research has produced a vast array of new targets that are being used to screen natural products in the search for novel active secondary metabolites of economic significance. Less than 50% of the 30 000–35 000 genes in the human genome have a putative function. Over 100,000 proteins might be produced by these genes. Between 600 and 10,000 proteins are thought to function as relevant targets.

## CONCLUSION

The story of the Biopharmaceutical Revolution illuminates the incredible odyssey from genetic milestones to industrial triumphs. From the foundational insights of genetics and the profound discovery of DNA's double helix structure, to the ingenious application of

recombinant DNA technology and the establishment of biotechnology giants, the journey has been one of relentless innovation. The development of pivotal biopharmaceutical products, the diversification of expression systems, and the advent of enzyme engineering and bioconversions underscore the industry's profound impact on healthcare and sustainable manufacturing. As we stand on the precipice of tomorrow, the Biopharmaceutical Revolution continues to march forward. Driven by the insatiable quest for understanding, the marvels of genetics, and the promise of biotechnology, the path ahead holds the potential to reshape medical treatments, industrial processes, and our understanding of life itself. This ongoing revolution exemplifies the potent synergy between scientific curiosity, genetic insights, and industrial prowess, ushering in an era of unprecedented possibilities for the betterment of humanity.

**REFERENCES:**

[1] K. Mullane, M. J. Curtis, en M. Williams, “Biomedical Research in the 21st Century: Multiple Challenges in Resolving Reproducibility Issues”, in *Research in the Biomedical Sciences: Transparent and Reproducible*, 2018. doi: 10.1016/B978-0-12-804725-5.00006-9.

[2] M. M. Babar *et al.*, “Omics approaches in industrial biotechnology and bioprocess engineering”, in *Omics Technologies and Bio-engineering: Volume 2: Towards Improving Quality of Life*, 2018. doi: 10.1016/B978-0-12-815870-8.00014-0.

[3] M. Kesik-Brodacka, “Progress in biopharmaceutical development”, *Biotechnology and Applied Biochemistry*. 2018. doi: 10.1002/bab.1617.

[4] F. Emami, A. Vatanara, E. J. Park, en D. H. Na, “Drying technologies for the stability and bioavailability of biopharmaceuticals”, *Pharmaceutics*. 2018. doi: 10.3390/pharmaceutics10030131.

[5] M. T. Jones *et al.*, “Considerations for the Use of Polysorbates in Biopharmaceuticals”, *Pharm. Res.*, 2018, doi: 10.1007/s11095-018-2430-5.

[6] R. Naseri *et al.*, “Anthocyanins in the Management of Metabolic Syndrome: A Pharmacological and Biopharmaceutical Review”, *Frontiers in Pharmacology*. 2018. doi: 10.3389/fphar.2018.01310.

[7] M. Zidar, D. Kuzman, en M. Ravnik, “Characterisation of protein aggregation with the Smoluchowski coagulation approach for use in biopharmaceuticals”, *Soft Matter*, 2018, doi: 10.1039/c8sm00919h.

[8] J. E. Schiel en A. Turner, “The NISTmAb Reference Material 8671 lifecycle management and quality plan”, *Anal. Bioanal. Chem.*, 2018, doi: 10.1007/s00216-017-0844-2.

[9] J. A. A. Reijers, M. J. C. Dane, A. J. van Zonneveld, J. Burggraaf, en M. Moerland, “Potential Influence of Endothelial Adsorption on the Delayed Time to Maximum Concentration of Biopharmaceuticals”, *Eur. J. Drug Metab. Pharmacokinet.*, 2018, doi: 10.1007/s13318-017-0430-1.

[10] M. Vanderlaan, J. Zhu-Shimoni, S. Lin, F. Gunawan, T. Waerner, en K. E. Van Cott, “Experience with host cell protein impurities in biopharmaceuticals”, *Biotechnology Progress*. 2018. doi: 10.1002/btpr.2640.

# CHAPTER 5

# INDUSTRIAL SYSTEMS BIOLOGY: REVOLUTIONIZING BIOTECHNOLOGICAL PROCESSES FOR SUSTAINABLE CHEMICAL PRODUCTION

Dr. Vikas Kumar, Assistant Professor, Department of Agriculture & Environmental Sciences,
Shobhit University, Gangoh, Uttar Pradesh, India,
Email Id- vikas.panwar@shobhituniversity.ac.in

Dr. Alpana Joshi, Associate Professor, Department of SAES,
Shobhit Deemed University, Meerut, Uttar Pradesh, India,
Email Id-alpna.joshi@shobhituniversity.ac.in

**ABSTRACT:**

The chemical industry is undergoing a profound transformation driven by the demand for sustainable processes in fuel, chemical, and material production, prompted by both economic and environmental pressures. To address these challenges, biotechnological processes utilizing renewable plant materials as feedstock are gaining traction as alternatives to traditional petroleum-based methods. These processes tap into the diverse metabolic capabilities of microorganisms, offering a platform for designing efficient chemical conversion processes. However, the need to enhance microorganism performance, particularly in terms of yields and productivities, is paramount for economic viability. Metabolic engineering emerges as a pivotal technology, enabling the optimization of microorganisms' metabolic landscapes to facilitate efficient conversion. The integration of systems biology techniques, encompassing omics data analysis and advanced mathematical modeling, is becoming increasingly crucial for identifying optimal metabolic engineering strategies. This paper delves into the historical evolution of these techniques and their application in industrial biotechnology, culminating in the concept of "industrial systems biology.

**KEYWORDS:**

Biotechnology, Industrial Systems, Metabolic Engineering, Microorganisms.

## INTRODUCTION

The evolving landscape of industrial biotechnology traces back to the emergence of genetic engineering in the early 1980s. Initially associated with healthcare and medical biotech, industrial biotechnology now stands as a well-defined field encompassing microbial fermentation and biocatalysis for converting organic feedstocks derived from biomass into chemicals, materials, and energy. With the global shift towards sustainable alternatives, industrial biotechnology's importance has grown, and it is projected to account for a substantial share of chemical production sales. The transition is driven by factors like process economics, biotech process development, environmental concerns, and the pursuit of sustainability and self-sufficiency. Notably, metabolic engineering has proven transformative by reshaping microbial metabolism to enhance desired product yields and titers. The convergence of metabolic engineering and systems biology has led to the emergence of "industrial systems biology," revolutionizing bioprocess development and enabling the creation of a diverse portfolio of bio-based products.

Due to both financial and environmental restrictions, the chemical industry is now going through a major transition that is being pushed by the need for more sustainable procedures for the production of fuels, chemicals, and materials. In order to replace conventional chemical processes based on petroleum feedstocks, the industry is investigating the use of biotechnological methods where the feedstock is renewable plant resources. Different

microorganisms may be used in biotechnological processes, and the wide variety of metabolic reactions in particular provides a wealth of information for designing chemical conversion processes that result in the effective synthesis of desired goods. However, it is frequently discovered that microorganisms that produce a desired product, either naturally or as a result of being engineered through the insertion of heterologous pathways, have low yields and productivities, and it is necessary to improve the performance of the microorganism in order to establish an economically viable process [1], [2].

The enabling technology in this case is metabolic engineering. Through metabolic engineering, the microorganism's metabolic environment is modified to ensure an efficient conversion of the source material, often glucose, to the desired product. This process often includes involves the deregulation of current regulatory structures functioning in the cell. It may entail the introduction of novel enzyme activities or the deletion of existing enzyme activities. The industry is increasingly considering the use of systems biology technologies in order to quickly discover the best metabolic engineering method. This incorporates both cutting-edge mathematical modelling techniques like genome-scale metabolic modelling and "x-ome" technologies like transcriptome, proteome, metabolome, and fluxome analysis. Here, we examine the development of these many methods across time and discuss how industrial biotechnology uses them to produce what we refer to as industrial systems biology.

## DISCUSSION

Early in the 1980s, when genetic engineering started looking for uses outside of medicine and medical biotechnology with the help of recombinant DNA technology, the phrase "industrial biotechnology" first became frequently used in the literature. Industrial biotechnology is now a well-defined field that has a substantial academic, governmental, and industry presence. Industrial biotechnology is defined informally as the bioconversion of organic feedstocks taken from biomass or their derivatives into chemicals, materials, and/or energy, either by microbial fermentation or biocatalysis. Biomass is created when plants fix carbon via photosynthetic processes to create organic polymers that may then be broken down chemically or enzymatically to yield carbohydrate, protein, and lipid monomers. Industrial biotechnology, often known as "white biotechnology" in Europe, strives to provide environmentally benign, cost-competitive, and self-sufficient substitutes for current or newly planned petrochemical processes.

With conventional petrochemical processing under scrutiny due to rising raw material prices, environmental restrictions, and declining self-sufficiency, processes that use industrial biotechnology have lately attracted significant worldwide interest. Industrial biotechnology has grown at an unheard-of rate, with bio-based manufacturing methods accounting for 5% of the overall sales volume of chemical manufacture. According to numerous projections, the overall share will reach 20% by 2010, accounting for US$310 billion of an anticipated US$1600 billion in sales. In the markets for basic chemicals and commodities (2-15%), specialty or added-value chemicals (2-20%), and polymers (1-15%), industrial biotechnology will continue to account for significant sales volume percentages. The fine chemical industry, where industrial biotechnology platforms allow sophisticated chemistry that is now generated through complicated synthetic or combinatorial pathways, is expected to have the largest percentage increase (16–60%), but Industrial biotechnology is also opening up new product opportunities, notably for novel medicinal agents like polyketides and speciality chemicals that had not yet been identified, including the various polyunsaturated fatty acids and biopolymers generated by microalgae.

In each of these cases, naturally isolated host organisms that were suitable for producing the target chemical were used. Random mutagenesis, followed by screening, selection, and classic bioprocess development, were also utilized in controlled environments to improve production yields, titers, productivities, and resilience. This method has been proven to be commercially successful despite offering little to no mechanistic understanding of which specific genetic perturbations result in improved strains so that they can be further exploited. One example is the more than 1000-fold increase in penicillin titer by P. chrysogenum. Several important factors, which can be grouped into four broader factors that are important to consider in connection with the development of a new bio-based process, may be responsible for the significant increases in fundamental research and development, as well as the commercialization at industrial scales of biotechnological processes.

1. Process economics
2. Development of biotechnology processes
3. Effect on the environment
4. Self-sufficiency and sustainability.

In order to apply industrial biotechnology to processes that were previously exclusive to the petrochemical sector or to produce new chemicals, each of these broad elements involves a number of quantifiable and identifiable drivers. With crude oil prices rising by 41.2% between January 2007 and 2008, industrial biotechnology has recently attracted a lot of attention as a way to create petrochemical alternative processes that are affordable, commercially viable, sustainable, self-sufficient, and environmentally friendly. Additionally, the well-head price of natural gas, a major feedstock for the manufacturing of commodities and high-value chemicals, increased by 175.4% between 1997 and 2007. In determining commercial feasibility, process economics must be compared to petrochemical counterparts or other benchmarking procedures, with special attention given to long-term operational expenses.

The costs, resources, and development efforts associated with biotechnology are then taken into account, with the first study concentrating on establishing pilot-plant size proof-of-concept. The last two factors to be critically evaluated are sustainability and self-sufficiency, and environmental impact. This review will in particular highlight the impact metabolic engineering and systems biology have had on upstream process development, referring to a game-changing paradigm referred to as "industrial systems biology." Sustainability and self-sufficiency entail attention to public opinion and the socio-political environment in addition to process-specific factors like feedstock availability or the potential for future development via biorefinery integration. Without a doubt, even in the present economic context, the recent investment of time and money into biotechnology processes would not have been conceivable without the significant government policy measures, along with wide societal. Comparing the industrial biotechnology process to its petrochemical counterpart [3], [4].

1. The cost of biomass feedstock in relation to yield, titer, and productivity
2. Continued or rising market demand
3. Commercialization of biotechnology may be achievable
4. Why Lowering long-term operational expenses is essential for commodities

**Factory for microbial cells**

is taken into account when evaluating an environmental effect, especially in light of recent scientific confirmation of a shift in the world's climate brought on by a rise in greenhouse gas emissions. The decision of whether to go further with the development of a biotechnology method is justifiable or not will ultimately depend on carefully weighing these four major

areas. The influence these factors may have on process development may not be immediately apparent to the majority of research and development scientists or engineers, but it is crucial to keep them in mind while developing strategies for the creation of a microbial cell factory. Such analysis often identifies the restrictions, restrictions, targets, and possible metabolic engineering solutions, as well as which systems biology methodologies should be used for proof-of-concept experiments.

This review aims to offer a historical perspective on the development of industrial biotechnology processes with a focus on the rapid adoption of systems biology and metabolic engineering technologies that were initially developed by academic research groups under the influence of the human health and medical biotechnology sectors. For inspiration, specific mature, recently released, and in-development examples of goods that have benefited from this innovative operating method, namely systems biology, will be showcased. under this article, we define a new term, industrial systems biology, based on such instances and de novo processes now under proof-of-concept, noting that techniques developed in the quickly expanding field of systems biology, often used in metabolic engineering, are common in two forms. Companies are reorganizing or creating new process development teams with skills and experience in industrial systems biology, or they are outsourcing process development to small, newly established companies that specialize in industrial systems biology [5], [6].

A dynamic interplay between several fields and methodologies is industrial systems biology. The platform technology used at its core is built on a production host for which a genome sequence is available, and annotations are then completed using existing literature reviews, database searches, comparative genomics, and experimental data, where available. A standard skeleton syntax structure of defining a gene, the gene product (for example, a metabolic enzyme), the metabolites serving as reactants and products (including any cofactors and intermediates), and the resulting stoichiometry is frequently applied. The annotations may vary in the types of functional genomics data assigned to specific fields. Then, additional fields may be defined for this genome annotation, such as levels of protein translation, isotope-based flux measurements, intracellular or extracellular metabolite concentrations, or transcriptome levels that have been established by experimentation. The application of this framework, known as a genome-scale metabolic network reconstruction, for stoichiometric or kinetic modelling is thus possible. Flux balance analysis (FBA) is often used since kinetics parameters like the forward and reverse reaction rates under physiologically relevant circumstances have not been empirically measured for a significant portion of the network. Such modelling enables the accomplishment of two crucial tasks for metabolic engineers.

The process starts by building an organized library of microbial metabolism that can be examined, questioned, and further improved via visual displays. Second, it offers a framework for predictive simulations, subject to predetermined limitations, which helps to focus the strategies for metabolic engineering that are taken into consideration. These strategies are often based on knowledge of traditional biochemical pathways or on new ones that emerged as a consequence of simulation results. Genetic engineering is carried out on the production host to produce a modified strain when a high probability of success (HPOS) metabolic engineering method has been identified. This technique often calls for gene overexpression, deletion, or rebuilding of non-native pathways. After being first defined, the modified strain may proceed through directed evolution or other non-targeted methods to produce an enhanced phenotype. Physiological characteristics of the resultant modified strain, including maximal specific growth rate, substrate consumption rates, product yields and titers, by-product generation, and morphology, are next assessed under carefully controlled fermentation conditions [7], [8].

**The Industrial Biotechnology Market**

Additionally, functional genomics characterization is finished, which often requires measurements of the transcriptome, proteome, metabolome, and fluxome. The examination of the resultant modified strain and the identification of prospects for a second round of metabolic engineering subsequently necessitate the use of bioinformatics together with data integration. Additionally, the investigation should result in an updated model with better predictive capability, which might provide interesting methods for future phenotypic improvement. Despite the fact that this method is often referred to as the metabolic engineering cycle, we complement it in this paper using integrative strategies and systems biology data sets. This is collectively referred to as industrial systems biology when used to create industrial biotechnology products. The sections that follow will provide a short review of industrial systems biology and (i) the market drivers for industrial biotechnology. The emphasis of the next sections will be on investigating industrial systems biology from the viewpoint of modelling microbial metabolism and, in particular, on offering case studies of various products that have greatly benefited from advancements in systems biology and metabolic engineering.

**The Industrial Biotechnology Market**

Quantitative modelling is often used to predict process economics and incorporates significant operational and capital expenses as well as process value, which is determined by the product's expected market price, demand growth rate, market share, and any potential competitive advantages. Before addressing the development of biotechnology processes, sustainability, or environmental effect, it is logical to assume that process economics must be favourable for commercialization. Given that many of the factors taken into account, such as the availability of raw materials and the possibility for process integration into a biorefinery, are likely to be addressed in the context of process economics, sustainability and self-sufficiency are possibly less clearly defined. a distinct category just because of the recent attention it has gotten against the backdrop of significantly rising feedstock and gasoline costs.

When factors like national security are involved, self-sufficiency and sustainability may even take precedence over process economics. It may seem strange to talk about market factors in a chapter about how metabolic engineering and systems biology have helped to understand microbial metabolism and make it possible to exploit it, but this is one of the things that sets industrial biotechnology apart from many other fields. Which metabolic engineering approach may be adopted will significantly influence market drivers, and a good knowledge of their effect will drive research and development. For an industrial biotechnology process, choosing the right feedstock, such as glucose, xylose, or glycerol, or complex feedstocks like lignocellulose, will have a significant impact on the metabolic engineering strategy chosen and, as a result, the systems biology tools that will be applied. A recent analysis of the effect that biofuels, and more specifically, bioethanol, have had on the field of industrial biotechnology, offers a more specific illustration. It gives context and establishes a clear connection between market forces, later industrial systems biology milestones, and their influence on process development.

**Systemic Industrial Biology**

Systems biology is the quantitative gathering, analysis, and integration of whole genome size data sets that enables the construction of mathematical models that are physiologically relevant and often predictive. Process development has benefited from the scientific advances in systems biology, notably in the fields of transcriptomics, proteomics, metabolomics, and

fluxomics, since genome sequences have been easily accessible for production organisms. These modern advancements include a systems biology toolbox that may be used to produce metabolic intermediates, which often act as desired precursors in the petrochemical industry. The examples that will be covered here will mostly centre on upstream process development, with special emphasis on the metabolic engineering approach used and how functional genomics data and analysis gave definite benefits. The examples provided will use a variety of fermentation organisms, with Saccharomyces cerevisiae as the primary emphasis [9], [10].

A discipline that includes both inverse and forward metabolic engineering. The gene-targeted, logical, and quantitative method of rerouting metabolic fluxes to increase the yield, titer, productivity, and/or resilience connected with a particular metabolite in a biological system is known as metabolic engineering. the use of experimental or numerical techniques created as a consequence of separate or combined x-ome analysis for the development of bioprocesses. Improvements in strain or expression system titer, yield, productivity, or process robustness and efficiency are all included in bioprocess development. The linear sequence from modelling to target gene identification to strain building and characterization is represented by this targeted metabolic engineering. This approach includes precise and hypothesis-driven genetic modifications based on predictive metabolic modelling, ranging from simple stoichiometric balancing of biochemical pathways to more complex kinetic models. Systems biology methods are used to analyze a host strain created by random or directed mutagenesis and/or evolution to identify the genetic perturbation(s) that result in the desired phenotype. A generic phrase used to describe the gathering and analysis of any global data set in order to explore any sort of informational route that may be traced back to the genome of a cell. The whole cell genetic sequence, ideally annotated, is necessary for X-ome analysis and data collecting. also seen as being equivalent to functional genomics.

The traditional method of strain formation has been random mutagenesis of a production host, mostly using chemical and radiation mutagens, followed by screening and selection in controlled settings for a desired phenotype. Despite the enormous success of this system, it has mostly been end-product focused and has little mechanistic knowledge. It is now possible to identify high-probability targeted genetic strategies to increase yield, titer, productivity, and/or robustness thanks to the exponential increase in genome sequences of current and potential production hosts and tools from bioinformatics that enable integration and inter-rogation of x-omic data sets . Additionally, inverse metabolic engineering is now a possibility, where previously successful production systems may be x-omically characterized to identify critical metabolic pathways and control points for subsequent rounds of focused metabolic engineering. Systems level models and simulations are expediting the development of bio-based processes in both forward and inverse metabolic engineering. This results in a shorter time to commercialization with a much lower resource investment.

Industrial biotechnologists are now thinking about broad portfolios of petrochemical commodities, added-value, high added-value, and speciality chemicals that may be produced using biotechnology rather than a single product. In 1999, it was proposed that lignocellulosic raw materials transformed to a variety of bio-commodities via integrated unit processes may provide comparable performance to current petrochemical refineries. This was the first time the word "biorefinery" was used. It will need two key driving factors for the biorefinery platform model to transition from an academic notion to an industrial reality. The significant financial investment, advantageous legislative policy, and consumer-driven demand must first continue to be supported and justified by the economic and sociopolitical environment.

Second, the systems biology developments and tools for metabolic engineering must be effectively implemented in industrial settings. The economic viability of biorefineries has

been shown by a number of instances, such as bioethanol; nonetheless, the variety of product streams that will be needed will continue to call for more advanced native and non-native multigene metabolic engineering techniques. Only by sophisticated probing and integration of microbial metabolic space utilizing systems biology methods may these strategies be accomplished.

## CONCLUSION

The synergy of metabolic engineering and systems biology has catalyzed a paradigm shift in industrial biotechnology, facilitating the creation of sustainable bioprocesses for chemical production. As the chemical industry grapples with economic and environmental challenges, the incorporation of renewable feedstocks and efficient microorganism engineering becomes imperative. Industrial systems biology emerges as the key enabler, offering a comprehensive toolbox to model, analyze, and optimize microbial metabolism. This integrated approach accelerates process development, from target gene identification to strain construction and characterization. The success of recent endeavors, such as bioethanol production, underscores the viability of biorefineries and highlights the necessity for sophisticated metabolic engineering strategies. Industrial systems biology represents a pivotal milestone, shaping the future of sustainable chemical production and revolutionizing biotechnological processes.

## REFERENCES:

[1] M. M. Matson en S. Atsumi, “Photomixotrophic chemical production in cyanobacteria”, *Current Opinion in Biotechnology*. 2018. doi: 10.1016/j.copbio.2017.11.008.

[2] C. J. Knoot, J. Ungerer, P. P. Wangikar, en H. B. Pakrasi, “Cyanobacteria: Promising biocatalysts for sustainable chemical production”, *Journal of Biological Chemistry*. 2018. doi: 10.1074/jbc.R117.815886.

[3] C. Palmer, F. Saadi, en E. W. McFarland, “Technoeconomics of Commodity Chemical Production Using Sunlight”, *ACS Sustain. Chem. Eng.*, 2018, doi: 10.1021/acssuschemeng.8b00830.

[4] B. Alonso-Fariñas, A. Gallego-Schmid, P. Haro, en A. Azapagic, “Environmental assessment of thermo-chemical processes for bio-ethylene production in comparison with bio-chemical and fossil-based ethylene”, *J. Clean. Prod.*, 2018, doi: 10.1016/j.jclepro.2018.08.147.

[5] D. Shepelin, A. S. L. Hansen, R. Lennen, H. Luo, en M. J. Herrgård, “Selecting the best: Evolutionary engineering of chemical production in microbes”, *Genes*. 2018. doi: 10.3390/genes9050249.

[6] B. Ye, Y. Lu, H. Luo, G. Liu, en R. Zhang, “Tetramethyl ammonium hydroxide production using the microbial electrolysis desalination and chemical-production cell with long anode”, *Bioresour. Technol.*, 2018, doi: 10.1016/j.biortech.2017.12.049.

[7] F. J. Lozano en R. Lozano, “Assessing the potential sustainability benefits of agricultural residues: Biomass conversion to syngas for energy generation or to chemicals production”, *J. Clean. Prod.*, 2018, doi: 10.1016/j.jclepro.2017.01.037.

[8] M. R. Park, H. S. Kim, S. K. Kim, en G. T. Jeong, "Thermo-chemical conversion for production of levulinic and formic acids from glucosamine", *Fuel Process. Technol.*, 2018, doi: 10.1016/j.fuproc.2017.12.016.

[9] L. Xu *et al.*, "Recent Advances in Nanowire-Biosystem Interfaces: From Chemical Conversion, Energy Production to Electrophysiology", *Chem.* 2018. doi: 10.1016/j.chempr.2018.04.004.

[10] S. Cloete *et al.*, "Economic assessment of chemical looping oxygen production and chemical looping combustion in integrated gasification combined cycles", *Int. J. Greenh. Gas Control*, 2018, doi: 10.1016/j.ijggc.2018.09.008.

# CHAPTER 6

# EXPLORING THE EVOLUTION OF METABOLIC ENGINEERING AND SYSTEMS BIOLOGY IN INDUSTRIAL BIOTECHNOLOGY

Dr. Vikas Kumar, Assistant Professor, Department of Agriculture & Environmental Sciences,
Shobhit University, Gangoh, Uttar Pradesh, India,
Email Id- vikas.panwar@shobhituniversity.ac.in

Dr. Alpana Joshi, Associate Professor, Department of SAES,
Shobhit Deemed University, Meerut, Uttar Pradesh, India,
Email Id-alpna.joshi@shobhituniversity.ac.in

**ABSTRACT:**

The creation and refinement of microbial cell factories for various bioproducts has advanced significantly in the realm of industrial biotechnology. Traditional strain creation, which includes deliberate evolution and random mutation, has proven essential for improving microbial performance. The history of microbial metabolism research is outlined in this study, including its beginnings in the early 20th century. The development of the ground-breaking Biochemical Pathways wall chart, which provided a visual depiction of metabolism and encouraged hypothesis-driven metabolic engineering techniques, is particularly highlighted. The ensuing gap between the use of biological data in industrial settings and its application was filled by genome sequencing and functional genomics. Targeted genetic alterations were made possible by the development of metabolic engineering, and predictive simulations were made possible by the development of genome-scale metabolic models. We now have a more complete grasp of metabolic regulation thanks to the development of quantitative flux balance analysis and metabolic control analysis. The progression from early metabolic research to the integration of systems biology and metabolic engineering is highlighted in this article, shedding light on their vital contributions to the development of industrial biotechnology.

**KEYWORDS:**

Biochemical, Industrial Biotechnology, Mutagenesis, Metabolic Models, Metabolic Engineering.

## INTRODUCTION

There have been in-depth analyses of how random mutagenesis and directed evolution may be used to improve or construct new microscopic cell factories that can produce a variety of industrial biotechnology goods. What is frequently referred to as "classical strain development" depends on the ability to induce and promote genetic diversity in a desired production host organism that can be selectively screened, isolated, cultured, and preserved based on phenotypic criteria, all under control-led laboratory conditions. Genetic recombination, radiation, UV light exposure, intercalating agents, and mutagenic chemicals may all be used to create more diverse populations of people. The resultant changed strains may then be further physiologically characterized, but the precise genetic changes that result in the better phenotype remain unknown, precluding the application of any mechanistic insight to further rounds of strain improvement [1], [2].

Microbial metabolism and its bearing on the cancer problem" in science. Microbial metabolism has been characterized and built up a scientific body of knowledge for nearly a century. Similar to how recombinant DNA technology was first developed at Stanford University and the University of California, San Francisco in the early 1970s, the first uses of microbial metabolism were in the fields of medicine and human health. Another publication from 1932, which was released five months before Kluyver et al. and attracted far less notice

at the time, provided one of the first examples of the function that microbial metabolism will serve in industrial biotechnology. The title of this work by Pulley and Greaves was "An application of the autocatalytic growth curve to microbial metabolism," and it was published in the Journal of Bacteriology.

In bacterial cultures, it moves very slowly at first, then progressively quickly, and subsequently extraordinarily slowly. If the initial inoculum into new medium is extremely little, this will be most obvious. We have discovered that the pace of accumulation of microbial metabolic products is also variable; it starts slowly, picks up speed, then slows down once again. This is the first obvious instance of how mathematical models were used to fit existing microbial metabolic data and, as a result, produce a prediction link between the buildup of metabolic products, such as nitrates and carbon dioxide, and time, controlled by a reaction rate constant. Since the 1930s, when carbon dioxide formation in S was studied using traditional reaction rate expressions to describe autocatalyzed reaction chemistry, microbial metabolism has been intensively studied. cerevisiae. In order to calculate the reaction rate constant using this method, metabolite concentration profiles as functions of time were necessary.

However, semi-quantitatively studied the link between metabolite intake and production rates in relation to growth rate. This was a data-fitting method with no emphasis on prediction capability. The elucidation of glycolysis, the citric acid cycle, and fatty acid oxidation made significant progress during the next 20 years. Growth kinetics the study of the interaction between growth rate, substrate utilization, and product creation rate was also further explored. This strategy used traditional mass balance with a focus on kinetic parameter resolution. Beginning in the 1960s, the method of characterizing metabolism via mass balance and the determination of kinetic parameters was greatly broadened to cover the bulk of metabolic space. The release of Biochemical Pathways, which offered the first graphic portrayal of the main components of metabolism, was a significant turning point. Over 1000 enzyme-catalyzed reactions are shown in the newly released 4th edition of Biochemical Pathways with detailed annotation, including stoichiometry, chemical structure, route connectivity, compartmen- talization, and where feasible, control. The first generation of metabolic engineering methods were able to be developed using logical, hypothesis-driven procedures thanks to the reconstructed microbial network, which was especially given in a single, graphical form [3], [4].

Although Jacques Monod is frequently given credit for the modern mathematical characterization of growth kinetics, known as "Monod growth kinetics," which includes a kinetic relationship for biomass formation as a function of substrate concentration and affinity and evolved from his seminal work on enzyme kinetics using -galactosidase in Escherichia coli, as summarized in a series of publications culminating in a 1953 publication in Nature, it was Pulle who first proposed the theory. Although the roots of contemporary microbial metabolism may still be located in the literature, the tiny collection of instances given here only serves to put the early industrial biotechnology processes in perspective and context. A significant advancement in the field of metabolism literature occurred before recombinant DNA technology was invented, but it is sometimes overlooked in deliberations about metabolic engineering and systems biology techniques today. This integration of biological data, which included stoichiometric relationships, most significantly, it offered one of the first comprehensive visual representations of the rebuilt metabolic network, allowing for the realization of connection between metabolites, pathways, and compartments. The development of intuitive, hypothesis-driven metabolic engineering strategies based on directing carbon flux in specific ways or rerouting other metabolic fluxes in desired

directions was made possible by a systematic visual depiction of the metabolic network. This metabolic map was often displayed on the walls of all significant university and commercial research facilities for industrial biotechnology and gave metabolic engineers a thorough overview of the environment in which they were working. The relationship between genes, gene products (such functioning enzymes), and the metabolic pathways on which they operate was, of course, a crucial piece of knowledge that was absent. The Biochemical Pathways wall chart has also mainly been viewed as a synopsis of all metabolic processes in the several diverse creatures investigated, despite evolving to contain organism-specific data. Once again, comparative genomics together with bioinformatics initiatives to build organism-centered databases would finally give the necessary specificity [5], [6].

## DISCUSSION

With an emphasis on seminal articles, many studies have offered historical perspectives on the development of the interdisciplinary field of systems biology and its influence on metabolic engineering or more generally industrial biotechnology. Examining the patent literature is a supplement technique that is more focused on identifying which milestones were essential for the commercialization of industrial biotechnology. The patent literature not only lists the relevant scientific or technical accomplishments, but also makes an argument for their industrial significance. The list of inventions that follow which is by no means exhaustive offers a chronological context for some of the significant developments in the fields of recombinant DNA technology and industrial biotechnology that led to the creation of the first significant added-value product made through extensive forward metabolic engineering.

### Models of Reconstructed Metabolic Networks

A total of 96 genomes were released during this time, of which 34 were deemed to be relevant to biotechnology and/or the environment. The number of organisms that have been sequenced specifically as a result of industrial biotechnology operations, where specific products like citric acid, bioethanol, lactic acid, and amino acids such as glutamate are mentioned, is of special interest. The number of genome sequences relevant to industrial biotechnology is growing, despite the fact that a significant portion roughly two thirds remain driven by medical biotechnology. Examining the respective US National Institutes of Health operating budgets for fiscal year 2008 reveals that they are far larger than the US Department of Energy's Division of Energy Efficiency and Renewable Energy, which has a budget of US$1.7 billion. The US Department of Energy has financed almost all of the genome sequences described as having biotechnological value, indicating that functional genomics and systems biology are seen as a crucial advantage in developing industrial biotechnology. This was most definitely not the situation less than ten years ago. full genome sequences have undoubtedly improved genetic modification targeting, and knowing the full component lists for a specific cell factory is incredibly significant knowledge.

Genome sequences for a number of commercial model organisms were available, and it was the annotation of those sequences that allowed the gap between growing knowledge-based databases such as genome sequence collections and data-driven databases such as the use of the genome sequences for annotation, model development, and deeper understanding to be closed. Functional genomics, which focuses on creating multiple experimental and theoretical techniques for determining gene function, has developed from the annotation of genome sequences into a well-defined field. The creation of genome-scale models for multiple data types, such as reconstructed metabolic network models, has been made possible by functional

genomics, which links gene products (such as enzymes) to gene functions (such as reaction stoichiometry) [7], [8].

**Models of Reconstructed Metabolic Networks**

Even while it is obvious that genome sequencing has made it easier to utilize targeted genetic modifications to create cell factories with desired phenotypes, the main advancement has been the development of metabolic engineering, the enabling science for the design and building of cell factories. Through the use of molecular biology tools, specific and targeted genetic modifications (gene deletions, overexpression, or modulation) are identified, implemented, and the fluxes are redirected to increase the production or robustness of a particular product or organism, as appropriate. The availability of a well-annotated genome, as well as the quantitative tools that allow meticulous examination and modification of the genome, is a crucial technological element in the effective implementation of metabolic engineering. The most recent creation of genome-scale metabolic models (GSMMs) is one of such tools.

The stoichiometry and kinetic reaction rates for each biochemical process in a cell under physiological circumstances would be needed to create a model of cellular metabolism that permits the prediction of concentration profiles as functions of time. This information is not yet accessible by experimental measurement or estimate. But it is conceivable to link well-known genes with well-known biochemical processes and their accompanying stoichiometry by meticulous annotation based on already-known biochemical principles, literature study, and experiments. The end result is a biochemical model that explains how each metabolite is created and depleted. This enables constraint-based simulations of the metabolic network under various settings by giving mass-balance boundary conditions. To put it another way, these models may be used to predict the linkages between genes with function in the metabolic network functioning in a cell using simple stoichiometry.

**Reconstructed Network Process at the Genome Scale**

A reliable technique has been devised for de novo model creation, given the comparatively high number of genome-scale reconstructions that are now accessible. The process of genome-scale network reconstruction has been extensively reviewed, including the initial biochemical annotation carried out, the mathematical framework used to describe metabolism, the resulting system of linear differential equations, the assumptions and constraints required for simplification, and finally numerical solution methods. It is generally acknowledged that flux balance analysis first gained popularity in the 1960s and 1970s, despite the fact that the history of quantitative flux balance analysis has early roots in many fields, particularly if one takes into account the previously mentioned isotope-labeled substrate experiments performed in the 1950s. Early efforts concentrated on specific enzyme kinetics, such as the in vitro study of yeast pyruvate kinase for the estimation of glycolytic flux under anaerobic culture conditions.

The broader framework for what is now commonly known as biochemical systems theory first emerged during the 1960s through a series of seminal publications in the Journal of Theoretical Biology, thanks to the work of Michael Savageau and other groups in the development of systems analysis of biochemical processes. Along the same lines, Kacser and Burns (1973) and Heinreich and Rappoport (1974), two separate research teams, created a mathematical framework for a quantitative analysis of how flux control is distributed in metabolic pathways, a concept now known as metabolic control analysis. It should be emphasized, however, that flux balance analysis, especially with genome-scale resolution, has advanced significantly since the late 1990s, with significant computational tools and

approaches created with the objective of gaining greater predictive potential from the pool of current models [9], [10].

**Reconstructed Metabolic Network Models**

The integration of genome sequencing and functional genomics has played a pivotal role in bridging the gap between biological knowledge and its application in industrial biotechnology. The creation of well-annotated genomes has facilitated the development of genome-scale metabolic models (GSMMs), enabling constraint-based simulations of cellular metabolism under various conditions. These models provide a framework to predict the relationships between genes and metabolic pathways, allowing for the exploration of potential genetic modifications.

**Genome-Scale Reconstructed Network Process**

The establishment of a robust methodology for de novo model construction has propelled the development of genome-scale reconstructions. Flux balance analysis (FBA) has a rich history, with roots in early enzyme kinetics studies. The broader framework of biochemical systems theory and metabolic control analysis has emerged over the years. The late 1990s witnessed the rise of FBA with genome-scale resolution, bolstered by computational tools that enhance the predictive power of metabolic models.

## CONCLUSION

Industrial biotechnology has evolved significantly, with microbial cell factories driving the production of a wide array of valuable products. The foundation of strain development lies in inducing genetic diversity through random mutagenesis and directed evolution. However, the mechanistic understanding of the genetic alterations leading to improved phenotypes has remained elusive. This paper delves into the historical progression of metabolic studies, particularly in the context of microbial metabolism, as the groundwork for subsequent advances in industrial biotechnology. Notably, it emphasizes the role of visual tools like the Biochemical Pathways wall chart in shaping hypothesis-driven metabolic engineering approaches. The evolution of metabolic engineering and systems biology has significantly impacted industrial biotechnology, revolutionizing the way microbial cell factories are developed and optimized. From the foundations laid by early metabolic studies to the integration of visual tools, genome sequencing, functional genomics, and predictive modeling, the journey has been one of continuous advancement. This journey has brought us to a point where the integration of knowledge from various disciplines empowers researchers to engineer microbes with enhanced capabilities for sustainable bioproduct production.

## REFERENCES:

[1] A. Costessi *et al.*, “Novel sequencing technologies to support industrial biotechnology”, *FEMS Microbiology Letters*. 2018. doi: 10.1093/femsle/fny103.

[2] G. Q. Chen en X. R. Jiang, “Next generation industrial biotechnology based on extremophilic bacteria”, *Current Opinion in Biotechnology*. 2018. doi: 10.1016/j.copbio.2017.11.016.

[3] J. Dupont-Inglis en A. Borg, “Destination bioeconomy – The path towards a smarter, more sustainable future”, *New Biotechnology*. 2018. doi: 10.1016/j.nbt.2017.05.010.

[4] A. Osmakova, M. Kirpichnikov, en V. Popov, “Recent biotechnology developments and trends in the Russian Federation”, *New Biotechnology*. 2018. doi: 10.1016/j.nbt.2017.06.001.

[5] C. Ling *et al.*, “Engineering NADH/NAD + ratio in Halomonas bluephagenesis for enhanced production of polyhydroxyalkanoates (PHA)”, *Metab. Eng.*, 2018, doi: 10.1016/j.ymben.2018.09.007.

[6] T. Stadler en J. M. Chauvet, “New innovative ecosystems in France to develop the Bioeconomy”, *New Biotechnology*. 2018. doi: 10.1016/j.nbt.2017.07.009.

[7] A. Pellis, S. Cantone, C. Ebert, en L. Gardossi, “Evolving biocatalysis to meet bioeconomy challenges and opportunities”, *New Biotechnology*. 2018. doi: 10.1016/j.nbt.2017.07.005.

[8] L. Zamani *et al.*, “High Cell Density Perfusion Culture has a Maintained Exoproteome and Metabolome”, *Biotechnol. J.*, 2018, doi: 10.1002/biot.201800036.

[9] J. Lian, M. HamediRad, en H. Zhao, “Advancing Metabolic Engineering of Saccharomyces cerevisiae Using the CRISPR/Cas System”, *Biotechnology Journal*. 2018. doi: 10.1002/biot.201700601.

[10] M. Larroude, T. Rossignol, J. M. Nicaud, en R. Ledesma-Amaro, “Synthetic biology tools for engineering Yarrowia lipolytica”, *Biotechnology Advances*. 2018. doi: 10.1016/j.biotechadv.2018.10.004.

# CHAPTER 7

# EXPLORING THE DIVERSITY AND DESIGN OF FERMENTATION PROCESSES: FROM MICROORGANISMS TO PRODUCTS

Dr. Vikas Kumar, Assistant Professor, Department of Agriculture & Environmental Sciences,
Shobhit University, Gangoh, Uttar Pradesh, India,
Email Id- vikas.panwar@shobhituniversity.ac.in

Dr. Alpana Joshi, Associate Professor, Department of SAES,
Shobhit Deemed University, Meerut, Uttar Pradesh, India,
Email Id-alpna.joshi@shobhituniversity.ac.in

**ABSTRACT:**

Fermentation processes represent a remarkable intersection of biology, chemistry, and engineering, harnessing the power of microorganisms to transform substrates into a wide array of valuable products. From food and beverages to pharmaceuticals and industrial compounds, fermentation has become a cornerstone of modern production. This paper delves into the intricate world of fermentation, exploring its diverse applications and the design considerations that underpin successful processes. The paper examines different types of fermentations, ranging from solid-state to submerged cultures, and discusses their significance in various industries. It also delves into the intricacies of growth and product formation, highlighting the role of microbial interactions and metabolic pathways. Moreover, the study outlines the key features of fermenters, including their construction, agitators, and aeration mechanisms. The downstream processing steps necessary for product recovery and purification are also explored. Throughout the paper, an emphasis is placed on the delicate balance between optimizing yield, purity, and operational efficiency. By unraveling the complexities of fermentation, this study contributes to a deeper understanding of this vital bioprocess.

**KEYWORDS:**

Antibiotics, Aeration, Fermentation Processes, Microorganisms.

## INTRODUCTION

In fermentation processes, microorganisms are utilized to convert a substrate into a product. In vitro conversions or bio-transformations brought about by the action of animal or plant cells are also referred to as fermentation processes. Due to the vast array of potential substrates, microorganisms, and end products, fermentation processes may be quite diverse. Examples of the many different kinds of products produced by fermentation include bread, cheese, wine, beer, coffee, industrial and medicinal enzymes, amino acids, antibiotics, soy sauce, compost, biopolymers, bioplastics, microbial oils, flavours, colourants, specialty chemicals, vaccines, therapeutic proteins, and many other items. To begin a fermentation, the appropriate microbe is injected onto a substrate. The setting in which the infected substrate is stored makes it easier for it to develop into the desired result. The raw material may either be used immediately or put through further processing to separate out certain molecular components [1], [2].

### Types of Fermentation

The bulk of commercially significant fermentations may be categorized as either solid-state or submerged cultures. The microorganisms in solid-state fermentations grow on a moist solid with little to no "free" water, even when capillary water may be present. Solid-substrate fermentations include those involving cheese, bread, coffee, and composting. Submerged fermentations may employ either a liquid substrate (such a sugar solution) or a solid substrate suspended in a sizable amount of water to make a slurry. Submerged fermentations are used

to produce a variety of products, including beer, penicillin, and recombinant insulin. Submerged and solid-state fermentations may be further divided between processes that need oxygen (aerobic) and those that can only be carried out without it (anaerobic). An example of an aerobic submerged fermentation is the process used by the fungus Penicillium chrysogenum to produce the antibiotic penicillin. Fermented meat products like pepperoni and salami are produced using anaerobic solid-state fermentations. An anaerobic fermentation that is submerged occurs when yogurt is made. If just one microbial species is required to provide the necessary biochemical change, a fermentation may be monoseptic. In monoseptic fermentations, the substrate must be sterilized to eliminate unwanted bacteria before being inoculated with the desired species. Insulin is one of several pharmaceuticals that are made utilizing monoseptic fermentations or monocultures. For many food fermentations and biological waste treatment processes, the presence of numerous microbial species, or mixed cultures, operating simultaneously and/or sequentially, is required [3], [4].

**Process of Fermentation**

Industrial fermentations may be performed continuously, in fed-batch operations, or in batches. The most frequent processes are batch and fed-batch; continuous fermentation is rather uncommon. The activated sludge technique of wastewater treatment typically involves a continual fermentation. Beer brewing and the majority of antibiotic fermentations are done in batches or feed batches. In batch processing, a batch of culture medium in the fermenter is infected with a microbial culture, or the "starter culture." The fermentation continues for a predetermined amount of time, the "batch time" or "fermentation time," and the result is harvested. Although most traditional food fermentations span 4-5 days in a batch, some of them may go on for months. In fed-batch fermentations, the infected fermentation batch receives intermittent or continuous additions of sterile culture media. With each addition of the medium, the amount of the fermenting broth grows. After the batch period, the batch is harvested. The feeding medium's make-up may change over time.

Continuous fermentations maintain an unchanging fermentation volume because sterile medium is continually delivered into the fermenter and the fermented product is continuously removed. Typically, batch cultures are used to start continuous fermentations, and feeding only happens after the microbial population has achieved a specified concentration. A small portion of the harvested culture may be recycled in certain continuous fermentations in order to constantly inoculate the sterile feed material entering the fermentation. Depending on the sort of mixing done in the fermenter, continual inoculation may or may not be required. Continuous inoculation is required for "plug flow" fermentation systems, such as lengthy tubes that do not permit back mixing. The fluid passing via a plug flow device behaves like a small batch fermenter. Therefore, real batch processes may be converted into continuous operations very readily in plug flow fermenters, particularly if pH control and aeration are not necessary. Continuous cultures are especially vulnerable to microbial contamination, however in certain circumstances, the fermentation conditions (such as a low pH, a high alcohol concentration, or a high salt content) may be chosen to favour the desired microbes rather than any possible contaminants.

The feed rate of the medium in a "well-mixed" continuous fermenter should be set so that the dilution rate, or the ratio of the volumetric feed rate to the constant culture volume, stays below the microorganism's maximum specific growth rate in the specific medium and under the specific fermentation conditions. The microbe will be flushed out of the fermenter if the dilution rate exceeds the maximum specific growth rate. A portion of the biomass in the harvest stream is concentrated and returned to the fermentation tank in certain well-mixed continuous fermentations. In the presence of biomass recycling, the dilution rate may be

raised above the point at which washout would occur. The throughput of the fermenter is increased by a high dilution rate. With the activated sludge technique, continuous well-mixed fermentation with biomass recycling is often utilized to remediate wastewater. The preculture is used to inoculate the "seed" fermenter after it has grown enough. Industrial fermenters may be rather big (150–250 m3), therefore the inoculum is built up gradually over multiple stages to 5–10% of the production fermenter's operating capacity. By reducing the batch duration in the production fermenter, this tactic enables optimum utilization of this vessel. The quantity of product produced per unit of time and fermenter space is decreased and expenses are raised by an abnormally lengthy fermentation duration (or batch time). Inoculation spores, which are created as seeds, are sometimes blown into a large fermenter with the incoming air [5], [6].

**Expansion and product creation**

In a freshly infected batch fermenter, the pattern is usually followed by microbial growth. In the beginning of the lag phase, there is not a significant rise in cell concentration. The growth history of the inoculum, the make-up of the medium, and the volume of culture used for inoculation all affect how long the lag phase lasts. The duration of the lag phase should be kept to a minimum since an overly lengthy lag phase binds up the fermenter ineffectively. Short lag phases happen when: the seed culture and production vessel's medium concentration and environmental conditions are the same (thus requiring less time for adaptation); the dilution shock is small i.e.; a large amount of inoculum is used; and the inoculum's cells are in the late exponential phase of growth. In essence, the lag phase is a time of acclimatization to a new environment. After the lag period, the cell mass grows rapidly during the exponential growth phase. The culture eventually reaches a stationary phase when nutrients are depleted and inhibitory products of metabolism accumulate. In the end, hunger results in cell death and lysis, which lowers biomass concentration.

Growth may be hampered by an extremely high substrate concentration, which may reduce water activity, for example. Additionally, certain substrates prevent the production of products, while in other circumstances, a fermentation product may prevent the development of biomass. Examples of inhibitory cells include ethanol created when yeast ferments sugar. When two or more growth-supporting substrates are present, it is sometimes possible to see several lag phases also known as diauxic growth. The cells undergo a lag phase while the preferentially used substrate is depleted, during which time the biochemical machinery required to metabolize the second substrate is produced. Growth then picks back up. The byproducts of microorganisms may be divided into primary and secondary metabolites. Products known as primary metabolites are necessary for the survival of microbial cells. The rate of biomass increase often has a direct correlation with the major metabolite synthesis. Examples of primary metabolites are amino acids and citric acid. Products known as secondary metabolites perform a variety of important tasks but are not necessary for living. The majority of antibiotics are examples of secondary metabolites. After the growth has stopped, secondary metabolites are often formed. Conditions that encourage growth and those that encourage the formation of a secondary metabolite could be quite different. For fermentations to be carried out successfully, it is crucial to comprehend the connection between biomass development and product creation.

**Lift Fermenters by Air**

These are available in internal-loop and external-loop configurations. The aerated riser and the unaerated downcomer are housed in the same shell in the internal-loop configuration. The riser and the downcomer are independent tubes that are connected at the top and bottom in

the external-loop configuration. Between the riser (upflow) and the downcomer (downflow), liquid flows. Airlift fermenters have a working aspect ratio of six or higher. These are excellent fermenters in general, with the exception of handling the most viscous broths. They do a fantastic job of transferring heat, oxygen, and solids. There is little hydrodynamic shear. In industry, the external-loop design is seldom ever employed.

**Fermenter with a Fluidized Bed**

These have a cross-section that is extended at the top, like bubble columns. The bottom of the vessel is continually pumped with fresh or recirculated liquid at a rate sufficient to fluidize the particles or keep them suspended. Fluidized beds need a separate pump. The bioreactor's particles are prevented from being washed away by the extended top portion, which reduces the local upward flow's velocity.

**Fermenter with a trickle-bed**

These are made out of a cylindrical jar filled with structural materials like wood chips, pebbles, and plastic objects. Large open areas on the support allow for the free flow of liquid and gas. The bacteria cling to the sturdy framework as they proliferate. Spraying liquid nutritional broth over the top, it drips down the bed. Air may rise up the bed against the stream of the liquid. These fermenters are used in several procedures, including the manufacturing of vinegar. They work well with liquids that have few suspended particles and a low viscosity [7], [8]. There are several characteristics that all fermenters or bioreactors for monoseptic submerged culture share. For pH, temperature, and dissolved oxygen sensors, the fermenter vessel has side apertures. It is customary to utilize retractable sensors that may be changed while they are in use. In the reactor vessel, connections for acid and alkali (for pH regulation), antifoam agents, and inoculum are situated above the broth level. Through a vertical viewing glass on the side of the vessel, the liquid level is plainly visible. The bioreactor's top has a second sight glass, and an externally attached light may be used to illuminate the inside. A jet of steam condensate may be used to internally clean the top sight glass. To determine exactly how much material is within the vessel, it may be positioned on a load cell.

## DISCUSSION

A top or bottom entering agitator may be utilized when mechanical agitation is utilised. The more popular bottom entry form enables the use of a shorter agitator shaft, often doing away with the necessity for support bearings within the vessel. Single or double mechanical seals that are steam sterilizable are installed on the agitator's shaft. Seals stop possible environmental pollutants from entering and leaking out of the fermenting vessel. Double seals are preferred; however, they need to be lubricated with sterile fluid or cooled clean steam condensate. Alternately, magnetically connected agitators may be employed to do away with the mechanical seals where torque restrictions permit. The culture receives oxygen via an air (or other gas combination) sparger, as well as sometimes carbon dioxide or ammonia for pH regulation. Foam is produced when the fermentation broth is aerated. To accommodate the foam and allow for gas disengagement, 20 to 30 percent of the fermenter's capacity must typically be kept vacant. Chemical and mechanical techniques are used to control foaming in bioreactors. At the start of fermentation, chemical antifoaming agents are often introduced with the broth. As necessary, more antifoam agent additions are applied occasionally.

Few internal components and consideration of the demands for clean-in-place and sterilization-in-place should be included in the design of the bioreactor vessel. A minimum

quantity of ports, nozzles, connectors, and other attachments should be present to meet the process's present and expected future requirements. There should be no cracks or still spots in the bioreactor where pockets of liquid or material might collect. It's crucial to pay attention to the design of even seemingly unimportant details like the gasket grooves. Channels with rounded corners that are simple to clean are desirable. Sanitary couplings should be avoided as much as possible in favour of welded connections. For sterilization, steam connections must allow for the full displacement of all air pockets in the vessel and related piping. Even the façade of a bioprocess facility should have a clean appearance with few exposed threads and smooth curves.

If there are no special needs, the jacket is constructed in accordance with the same standards as the vessel. The jacket has a chloride-free fibre-glass insulation lining that is entirely covered in a protective shroud. The jacket is shielded from overpressure by a relief valve that is either on the jacket or the pipe that is linked to it. For the great majority of applications, austenitic stainless steels are the material of choice for bioreactor construction. The bioreactor vessel is often made of stainless-steel Type 316L, whereas the jacket, insulating shroud, and other non-product contacting surfaces are made of Type 304 (or 304L), which is less expensive. Stainless steel L grades include less than 0.03% carbon, which lowers the danger of intergranular corrosion at the welds and restricts the growth of chromium carbide when welding. Items inside welds have to be cleaned and ground flush with the surface inside. Welds are difficult to notice due to excellent workmanship.

In addition to the construction materials, the surface finish should be taken into account. The finish on surfaces that come into contact with the product material and, to a lesser extent, the finish on outer surfaces, affect the ability to clean, disinfect, and sterilize the bioreactor and the surrounding processing area. The surface finish impacts the surface's durability and reactivity and may have an impact on how well animal or microbial cells attach to surfaces during the adhesion process. The mill-finished surface of stainless-steel sheet is unsuitable for use in bioreactors. At the very least, the surface should be mechanically polished. Mechanical polish is created when a material that resembles sandpaper acts as an abrasive on metal. The surface finish may be determined by the number of particles per square inch of the abrasive pad, for instance, 240 grit polish. With a higher grit number, the finish is smoother. Even a mechanically polished surface that is very smooth microscopic inspection shows a characteristic pattern of grooves and ridges that serve as sites for microbial adhesion.

Direct measurement of roughness in terms of "arithmetic mean roughness," Ra, or "root mean square roughness," provides the basis for more precise assessments of surface quality. The sharp microscopic surface projections left behind after mechanical polishing are selectively removed during electropolishing, which produces a significantly smoother finish. The metal surface area and therefore the product-metal contact area are significantly reduced by electropolishing. By reducing tiny areas of high local stress, the treatment gives stainless steel corrosion resistance and produces a passivated steel surface that is abundant with protective chromium oxide. If mechanical polishing is the only option, it should be at least 240 grits, and the polishing direction should be managed to provide a vertical grain for efficient drainage. Nitric acid wash should at least be applied to the surface. If the surface is to be electropolished, the grain direction does not seem to matter [9], [10].

**Fermentation in the Solid State**

The technological complexity of solid-state fermentation systems ranges from the very simple substrate heaps, bamboo baskets, and banana leaf wrappings to the highly automated equipment mostly utilized in Japan. Large-scale processing may make good use of certain

"less sophisticated" fermentation techniques, including fermenting cocoa beans in heaps. The continuous, highly automated soy sauce fermenting techniques, on the other hand, that have been effective in Japan are not appropriate for less industrialized regions of Asia. a few popular solid-state fermenters.

**Fermenter Tray**

These are straightforward and often used in Asia's small- and medium-scale koji enterprises. The bottom of trays is often perforated or wire mesh for better aeration. Trays may be constructed of wood, metal, or plastic. The substrate ferments in thin layers. To prevent contamination, cheese cloth may be used to cover trays. Non-sterile processing is used. Single or stacked trays may be kept in vented regions, temperature- and humidity-controlled rooms, or both. Manual inoculation and sometimes manual mixing are also used. Tray handling, filling, emptying, and washing may sometimes be automated. Despite considerable automation, tray fermenters take a lot of work and space. Tray fermenters can only be scaled up so far.

1. **Static Bed Fermenter:** This is a tray fermenter modification. It uses a single, deeper, bigger static substrate bed that is housed in an insulated chamber. Forced aeration via the substrate bed provides oxygen.
2. **Tunnel Fermenter:** This is a static bed apparatus modified. The solids bed is often rather long, although it is seldom deeper than 0.5 m. With devices for mixing, inoculation, continuous feeding, and substrate harvesting, tunnel fermenters may be highly automated.

**Rotating-disk fermentation**

The top and lower chambers of the rotating disc fermenter each have a circular perforated disc to support the substrate bed. The discs are rotated by a single central shaft. The top chamber is used to insert the inoculated substrate, which is then gradually transported to the transfer screw. The partially fermented solids are sent by the top screw via a mixer to the bottom chamber, where more fermentation takes place. By means of the lower transfer screw, fermented substrate is extracted. Air that has been humidified and heated is used to aerate both chambers. In Japan, koji is produced on a massive scale using rotary disc fermenters.

**Fermenter with a rotary drum**

The rotary drum fermenter 's cylindrical drum is supported by rollers and rotated (1–5 rpm) along the long axis. Depending on the stage of fermentation, rotation may be intermittent and the speed may change. The substrate is tumbled within the drum with the help of straight or curved baffles, increasing aeration and temperature control. The substrate may sometimes rotate from the upper intake end to the lower outflow due to the drum's inclination. Coaxial input and exhaust nozzles provide aeration.

**Fermenter in an Aerated Tank**

In cylindrical or rectangular tanks, one or more helical screw agitators are placed to stir the fermenting substrate. Sometimes, movable trolleys that are mounted on horizontal tracks above the tanks extend screws into the tanks. The paddle fermenter is a different design for a stirred tank. With the exception of the stationary drum and the periodic mixing supplied by motor-driven paddles supported on a concentric shaft, this device is identical to the rotating drum device.

**Product Recovery from Fermentation**

In order to produce the desired product in a suitably pure form from fermented crude broth, more downstream processing is required. In downstream processing, a series of procedures often yields a product with the required level of purity. This conversation is limited to the considerations that need to be made when developing any economically viable product purification and concentration scheme based on a small portion of the many processing activities that are easily available. It is critical to focus on the design of an effective downstream process since product recovery and purification often account for between 70 and 80 percent of the overall cost of production. Purifying a product beyond the point required for a particular purpose is both ineffective and expensive. Exact purity standards that are suitable for the intended use must be specified for downstream processing. The minimum number of processing steps necessary should be used to achieve the desired concentration and purity; usually, recovering industrial fermentation products calls for no more than 6-7 downstream processing steps. Utilizing the fewest number of processing steps feasible lowers operational and capital expenses. The overall yield of the process is also decreased by employing several processing steps. This is as a result of an n-step process with an overall yield of just (x/100)n and a step yield of x%. For example, a processing train with just five steps and a 90% step yield would reduce the overall recovery to about 60%. Early on in a recovery process, such as chromography, using high resolution separations lowers yield loss.

The product-containing component of the broth should be concentrated as soon as is practical during downstream processing. This reduces the size and expense of the equipment required for the subsequent processing procedures. Fermentation broths may be quite thick, which makes pumping, mixing, and filtering them difficult. Processing is greatly facilitated by reducing the viscosity of the broth, for example by digesting any undesired polymers and removing any unnecessary floating particles. Planning downstream processes is necessary to increase processing speed. Rapid processing decreases the expense associated with processing time while minimizing product loss caused by prolonged exposure to the sometimes-adverse processing conditions. Recovery and separation processes use the differences in the component elements of the mixture's physical and chemical properties to separate them. For instance, the recovery of cells via filtration from a broth uses the separation produced by the difference between the size of the cell and the fluid molecules.

To get the best overall separation outcome, the several stages used in the downstream process should normally take advantage of variations in as many physical-chemical characteristics of the mixture components as possible. When two chromatographic steps are to be used in series, ion exchange chromatography, which separates based on differences in charge on the molecules, and gel filtration, which separates based on molecular size, may be a superior combination. This chapter provided an overview of fermentation technology as used in industrial processes. Fermentations can be extremely diverse depending on the substrate, microorganism, and product. Most industrial fermentation is operated batchwise or as fed-batch operations, but other modes of operation are also used. Successful conduct of a fermentation requires attention design and pretreatment of fermentation medium, generation of inoculum and the environment conditions that are necessary for growth and product formation. In monoseptic fermentations, attention to prevention of microbial contamination is important. Although stirred tank fermenters are commonly used for submerged fermentations, many different types of fermenters are available. A suitable fermenter needs to be selected with reference to the nature of a specific fermentation, the scale of operation, and the engineering and operational issues involved.

## CONCLUSION

In the course of human history, the natural process of fermentation, which is fueled by microbes, has been crucial. It provides a revolutionary method for transforming basic materials into a dizzying diversity of goods. Fermentation has shown to be a flexible tool in a variety of sectors, from the traditional comforts of bread and beer to cutting-edge biopharmaceuticals and bioplastics. In order to shed light on the concepts that underpin fermentation processes' success, this study aims to investigate the wide range of fermentation techniques. As varied as the goods produced by fermentation processes are the methods themselves. The process of transforming substrates into useful products is one of complexity and inventiveness, starting with the simple beginnings of conventional food fermentations and ending in the advanced settings of industrial bioreactors. The delicate balancing act between yield, purity, and efficiency is achieved by the design of fermenters, the careful downstream processing, and the orchestration of growth and product production. A future where microbes drive innovation and sustainability across sectors is promised as technology develops and our knowledge of fermentation grows. We have just scratched the surface of fermentation's huge tapestry via this investigation, which is a monument to how beautifully science, nature, and human endeavor interact.

## REFERENCES:

[1] K. Kucharska, P. Rybarczyk, I. Hołowacz, R. Łukajtis, M. Glinka, en M. Kamiński, “Pretreatment of lignocellulosic materials as substrates for fermentation processes”, *Molecules*. 2018. doi: 10.3390/molecules23112937.

[2] E. Cusano, B. Simonato, en R. Consonni, “Fermentation process of apple juice investigated by NMR spectroscopy”, *LWT*, 2018, doi: 10.1016/j.lwt.2018.05.021.

[3] R. K. Srivastava, “Enhanced shelf life with improved food quality from fermentation processes”, *J. Food Technol. Preserv.*, 2018.

[4] Y. Tatsukami *et al.*, “Metabolite profiling of the fermentation process of ‘yamahai-ginjo-shikomi’ Japanese sake”, *PLoS One*, 2018, doi: 10.1371/journal.pone.0190040.

[5] T. Gervasi, V. Pellizzeri, G. Calabrese, G. Di Bella, N. Cicero, en G. Dugo, “Production of single cell protein (SCP) from food and agricultural waste by using Saccharomyces cerevisiae”, *Nat. Prod. Res.*, 2018, doi: 10.1080/14786419.2017.1332617.

[6] B. H. Tozlu en H. İbrahim Okumuş, “A new approach to automation of black tea fermentation process with electronic nose”, *Automatika*, 2018, doi: 10.1080/00051144.2018.1550164.

[7] P. Skupin en M. Metzger, “PI control for a continuous fermentation process with a delayed product inhibition”, *J. Process Control*, 2018, doi: 10.1016/j.jprocont.2018.09.011.

[8] A. Mărgean en V. Pădureanu, “The influence of ultrasound treatment on must fermentation process”, *Bull. Transilv. Univ. Brasov, Ser. II For. Wood Ind. Agric. Food Eng.*, 2018.

[9] G. R. Harvianto *et al.*, “Purification of 2,3-butanediol from fermentation broth: Process development and techno-economic analysis”, *Biotechnol. Biofuels*, 2018, doi: 10.1186/s13068-018-1013-3.

[10] E. Petre, D. Selişteanu, en M. Roman, “Nonlinear robust adaptive control strategies for a lactic fermentation process”, *J. Chem. Technol. Biotechnol.*, 2018, doi: 10.1002/jctb.5383.

# CHAPTER 8

# ADVANCEMENTS IN CUSTOM-DESIGNING ENZYMES FOR BIOCATALYTIC PROCESSES: DIRECTED EVOLUTION AND RATIONAL PROTEIN DESIGN

Dr. Vikas Kumar, Assistant Professor, Department of Agriculture & Environmental Sciences,
Shobhit University, Gangoh, Uttar Pradesh, India,
Email Id- vikas.panwar@shobhituniversity.ac.in

Dr. Alpana Joshi, Associate Professor, Department of SAES,
Shobhit Deemed University, Meerut, Uttar Pradesh, India,
Email Id-alpna.joshi@shobhituniversity.ac.in

**ABSTRACT:**

Over 300 biocatalytic methods have been used in the industrial setting to produce bulk chemicals and pharmaceuticals using enzymes as catalysts. The majority of these enzyme applications have used hydrolases, although research into enzymes from other classes, such as lyases and oxidoreductases, has advanced significantly in recent years. The search of better properties like chemo, region, and stereoselectivity, together with stability and activity under certain process conditions, has led to this transformation. Modern enzyme design methodologies combine process engineering, immobilization, and molecular biology methods to meet these goals. Among them, rational protein design and guided evolution are crucial. This chapter emphasizes the significant advances in directed evolution over the past ten years and also discusses rational protein design. The chapter examines several methodologies and provides examples from practical industry applications and relevant academic research. Despite the unreported developments in the field, directed evolution stands up as a viable approach for customizing enzymes for certain processes and promoting efficiency.

**KEYWORDS:**

Biocatalytic Processes, Enzyme, Immobilization, Stereoselectivity.

## INTRODUCTION

Over 300 processes have been applied in industry using biocatalysts, which are widely employed in the manufacture of bulk chemicals and medicines. Until date, hydrolases have been used in the majority of enzyme applications. However, given the last decade of intense study on biocatalysts from other enzyme classes (namely, lyases and oxidoreductases), where significant advances have already been achieved, this is anticipated to change soon. Independent of the reaction system and enzyme under investigation for a specific biocatalytic process, it is sometimes necessary to improve the characteristics of the enzyme because it does not satisfy the standards for a large-scale application. This usually refers to the biocatalyst's chemo region, and particularly stereoselectivity, but in order to maximize productivity, process-related factors like long-term stability at particular temperatures or pH levels and activity in the presence of high substrate concentrations must also be optimized.

The most significant technologies utilized nowadays to custom-design enzymes for specific processes are molecular biology techniques, in addition to the traditional methods like immobilization, additives, or process engineering. We use directed (molecular) evolution and rational protein design, two distinct though often complimentary approaches. This chapter focuses mostly on the significant advancements achieved in the field of directed evolution over the last ten years, but it also covers rational protein design. Examples given include industrial procedures as well as significant contributions from academic studies focusing on biocatalysts with industrial relevance. It is expected that there are a number of other enzyme-

using processes using directed evolution methods in use, since not all biocatalyst advancements produced in industry are disclosed [1], [2].

**Design Techniques for Proteins**

Rational protein design is always becoming more effective as a result of our increased knowledge of how to manipulate the characteristics of enzymes. However, the main challenges for rational protein design still remain the necessity for the protein structure or at least a sufficiently accurate homology model and a complete comprehension of the catalytic mechanism. By using molecular modelling approaches, it is possible to pinpoint certain amino acids (hot spots) that are assumed to be connected to the desired attributes from the structure. Then, at these locations, site-directed mutagenesis (SDM) is carried out, maybe utilizing Stratagene's Quik Chang SDM process. Numerous examples can be found in the literature, and rational protein design has been particularly fruitful when features like changed activity or enantioselectivity have been addressed.

**Constrained Evolution**

Protein change and selection of the fittest individuals are two processes used in directed evolution, also known as in vitro evolution or molecular evolution. This method has become a very potent and popular tool for enhancing biocatalysts in under a decade. A random mutagenesis phase is usually followed by a high-throughput screening (HTS) and/or selection stage in a directed evolution method. The selection of a known enzyme, which must be accessible in recombinant form and have an appropriate expression system on hand, and the identification of the attribute that has to be optimized are the first steps in the process. According to the methods described below, a sizable mutant library is created via random mutagenesis of the protein-coding gene. After cloning and expression, a sizable collection of enzyme variations is produced usually between 104 and 106 in number. Finally, this library is put via screening or selection procedures to find mutants with the developed desirable characteristic. The greatest hits may then act as enhanced starting points for further rounds of mutagenesis to gather advantageous mutations. Mutant analysis knowledge is often a good starting point for logical protein design strategies. The most crucial mutagenesis techniques and appropriate HTS systems are explained in the sections that follow, and then examples of how directed evolution experiments have successfully produced better biocatalysts are given [3], [4].

**Methods for Mutagenesis**

Asexual (non-recombining) evolution, in which a parent gene is subjected to random mutagenesis to produce variants with point mutations, and sexual (recombining) evolution, in which several parental genes are randomly fragmented and then recombined to produce a pool of chimeras, are the two different approaches that can be used to create mutant libraries. The following paragraphs will provide a brief overview of a few of the several ways that have been created in the previous 15 years. There are other reviews and books available for a deeper and more thorough understanding. The so-called "codon bias," which results from the defective genetic coding, is another significant issue with epPCR. This bias indicates that a particular amino acid alteration will be significantly less prevalent than others. For instance, just six different amino acid substitutions arise from a single mutation in the valine codon. As a result, in order to encode all 20 proteinogenic amino acids, all three (adjacent) codons must be changed, which is an extremely improbable occurrence when a whole protein-coding gene (i.e., 1000 bp) is put through epPCR with a 1% error rate. Sexual recombination techniques are favoured when starting with previously chosen variations or genes with enough homology since they may combine the finest qualities of both parental donors. It entails a DNase-

dependent degradation phase, followed by self-priming PCR to recombine the fragments without primers before a final PCR using primers. This technique, also known as molecular breeding or DNA family shuffling, has been improved during the last ten years. The staggered extension procedure (StEP) is an option. Short pieces of the parental genes are amplified in this process such that the ensuing short fragments may anneal on any other parental gene in following cycles.

Thus, it is possible to prevent the bias caused by DNase I digestion. The random chimeragenesis on transient templates (RACHITT), based on the ordering, trimming, and joining of randomly cleaved single-stranded parental gene fragments annealed onto a transient full-length single-stranded template, represents an advancement over the conventional DNA shuffling method. Higher recombination rates and 100% chimeric products were produced using this technique. Sequence similarity between the parental genes is undoubtedly a required restriction for the use of recombination procedures. To combine genes with high structure but low sequence similarity, such as P450 monooxygenases, methods to recombine multiple parental sequences without the necessity for significant sequence homology have been developed. Circular permutation (CP), a fundamentally novel method to develop enzymes without introducing mutations, was suggested by Lutz and colleagues. They joined the native N- and C-termini of the lipase B gene from Candida antarctica, linearized it using random digestion, and produced variants with different N- and C-termini. Unexpectedly, this did not only result in active lipase; certain variations also demonstrated better catalytic efficiency than the wild type (up to 11-fold against p-nitrophenol butyrate and 175-fold against 6,8-difluoro-4-methyl- umbelliferyl octanoate, whereas Km values were roughly the same). Kinetic studies showed that the CP of this enzyme does not affect the enantioselectivity in the resolution of various chiral secondary alcohols for the most active form [5], [6].

## DISCUSSION

A variety of methods are available to randomly modify genes, as was previously mentioned. Many software tools have been created to make the planning of directed evolution studies easier and to forecast and compare the quality of the mutant library. Many times, the ratio of transitions to transversions is used to assess a library, however Wong et al. demonstrated that this frequently fails as an estimate using the mutagenesis assistant program (MAP) (found at http://map.iu-bremen.de). The authors suggested that a suitable benchmark for library comparisons would be a chemical diversity indicator, an indicator of protein structure, and an indicator of amino acids (complemented by codon diversity coefficient).

### Directed Evolution with a Focus

Whether rational design or guided evolution is a preferable technique has been debated often, yet there is no clear answer. The complexity of proteins and our understanding of sequence-function links actually hinder rational design. Additionally, it often produces results that are not what is expected and sometimes produces quite surprise variations that may not have the required attribute. For instance, thermostability is difficult to anticipate logically, therefore guided evolution seems to be a preferable option. Recently, hybrids of rational design and directed evolution have been put forward; these hybrids have been given the names semi-rational design or rational evolution, but we prefer the term focused directed evolution. Reetz and colleagues reported the effective use of iterative saturation mutagenesis (ISM). The protein structure (or homology model) is first examined in the ISM technique to determine all the amino acid locations that contribute to a certain feature. After that, each site is (individually) treated to saturation mutagenesis, and then the libraries are checked for the

desired attribute. The best hit of each library is then utilized as a template for further rounds of saturation mutagenesis, and this process is repeated again until the desired enhanced biocatalyst is discovered.

Similar methods were used by researchers at Codexis, however unlike CASTing, their methodology is independent of 3D structure or homology models, and they were able to significantly increase catalytic activity. The link between the structure of the interacting molecule (enzyme) and the measurable attribute of interest is studied and written in an equation as a result of ProSAR, which is an extension of SAR (structure-activity relationship) for molecular protein optimization. The beneficial mutants were retained and used as parental enzymes for the subsequent round of mutations. Mutants of libraries from various mutagenesis methods were analyzed by activity and sequencing and classified as "beneficial," "potentially beneficial," "neutral," or "deleterious." Retested mutations from other groups may also act as parents. An outstanding illustration of the value of this approach is the enhancement of a halohydrin dehalogenase, which is crucial for the manufacture of a precursor to the cholesterol-lowering medication atorvastatin [7], [8].

The basis for biological selects is auxotrophy complementation or tolerance to cytotoxic substances like antibiotics. When used properly, selection is an extremely potent strategy for searching through vast libraries and finding protein mutants. Phenotypic selection, however, is only used to isolate catalysts for processes that have direct biological importance or that may be indirectly connected to a selective phenotype. Such selections may be made in solid phase or microtiter plates, in vitro or in vivo. Libraries produced by mutagenesis procedures often include 105–1010 individuals. Inactive or boring people may be removed from the library in order to screen a large portion of the sequence space.

**Display Methods**

One of the most popular methods for in vitro selection of the fittest mutants from a vast library is phage display. It involves the fusing of a gene encoding a virion coat protein with the gene of interest (in this example, each individual in a library of mutants) during the cloning process. The foreign protein appears on the surface of the formed phage. Therefore, a phage particle is used to provide a physical connection between the gene and the expression product. The displayed enzyme then interacts affinitively with a ligand that has been immobilized to catch the phages. The kind of this binder depends on the enzyme; for instance, the fusion tag might be a substrate, a suicide-substrate attached to biotin (which is then trapped on streptavidin beads), or an analogue of a transition state that has been immobilized. Through straightforward infection, the chosen phages are multiplied, amplified, and eluted.

On the surface of bacteriophages, yeast, and bacteria, protein libraries may also be seen. There are certain benefits to bacterial display over the far more common phage display. First first, phage display just requires one host for library propagation as opposed to two for bacteriophage and host in phage display. Second, the chosen variations may be amplified directly without transferring the genetic material to an additional host. Third, avidity effects could make the likelihood of affinity artifacts less likely. By combining an artificial gene with the esterase gene and the crucial autotransporter domains in E, Schultheiss et al. were able to show an esterase from Burkholderia gladioli in bacteria. coli. According to several approaches, the esterase activity was effectively directed to the outer membrane fraction.

The screening of enzyme libraries has also been extended to use flow cytometric analysis in conjunction with bacterial cell surface display. In fact, this technique now stands as the only universal method for the quantitative analysis of enzyme catalytic activity in both extremely

large populations of mutants and at the single cell level. Furthermore, the enzymes may freely access synthetic substrates thanks to their presentation on the bacterial surface. The key to quantifying catalytic activity at the single cell level turned out to be the capacity to physically connect a fluorescent reaction product with the cell that produces the relevant enzyme on its surface. There are presently several methods for displaying enzymes on the microbial cell surface, the majority of which have been created for E. coli.

**Screening**

A lot of assays can't be used in solid-phase formats. Therefore, it is necessary to cultivate and test individual clones on microtiter plates. These tests take a lot longer to complete than solid-phase tests. However, the throughput may be further boosted by using colony-picking technologies and robot automation. The ability to directly and quantitatively measure activity and even enable it to determine the kinetics makes screening much more information than a selection strategy. Additionally, screening makes it possible to directly assess an enzyme's enantioselectivity, which is often the primary aspect that has to be enhanced for commercial biocatalysis.

**Tests for Hydrolase**

Lipases and Esterases It is possible to measure the hydrolytic activity of esters using a wide range of substrates, but it is preferable to use the "true" compounds of interest as opposed to surrogates i.e., artificial substrates created to produce a strong, noticeable signal when they are converted by the enzyme. But not all activity tests can be employed in the high-throughput manner necessary for screening the sizable libraries produced by the mutagenesis methods used in directed evolution. A straightforward pH-stat experiment employing tributyrin or triolein emulsions as substrates is an example. The most popular tests to identify hydrolytic activity unquestionably include colorimetric and fluorometric assays. They involve the cleavage of an ester to produce a measurable chromophore or fluorophore. The most often used chromophores/fluorophores are coumarin, p-nitrophenol, fluorescein, or resorufin. The main drawbacks of adopting these artificial substrates are that they are often not commercially accessible and that they vary from the real substrate, which might result in false positive finds. The relatively limited solubility of most substrate in aqueous solutions and the possibility of substantial autohydrolysis at high temperatures or extreme pH levels when employing chromogenic or fluorogenic substrates are both significant drawbacks of hydrolytic activity assessments of lipases and esterases [9], [10].

There are two methods that have been discussed in the literature to get around this issue. First, the equivalent acyloxymethylethers or diacylglycerol analogues were used to replace the esters of p-nitrophenol or coumarin. Due to the ester's separation from the chromophore (or fluorophore), which prevents autohydrolysis since the alcohol moiety is now a poorer leaving group than coumarin or the p-nitrophenoxide ion, the substrate becomes significantly more stable. This methodology is also applicable to the screening and characterization of enantioselective enzymes. Depending on its specific structure, the cleaved alcohol is then either directly decarboxylated or first oxidized with periodate and then subjected to BSA-catalyzed -elimination in order to release the chromophore/fluorophore. The requirement to synthesize the specially created substrates and the fact that enzyme kinetics cannot be quantified but only end-point measurements are drawbacks. The sodium periodate used in the oxidation of the diol produced by enzymatic cleavage is back-titrated with epinephrine in the way described above. Prior to quantifying each enantiomer, a separation process is required in order to employ a racemate as substrate. When working with isotopically labelled substrates, this separation may be made based on chirality or molecular mass. Gas

chromatography and HPLC have both been modified for high-throughput application. This method allowed us to screen a mutant library of Pseudomonas aeruginosa lipase for the enantioselective esterification of 2-phenylpropanol at a rate of roughly 700 measurements per day. With one isotopically labelled chemical in an enantiomer pair in kinetic resolutions (a pseudo racemate) or in the biotransformation of a meso-compound, mass spectrometry (MS) is utilized. Using chiral selectors (such cyclodextrins) as a pseudo-stationary phase in the electrolyte, capillary electrophoresis can now analyse up to 96 samples concurrently, enabling the analysis of 7,000 samples of derivatized chiral amines every day.

**Tests for Oxidoreductases**

The majority of oxidoreductase tests measure absorbance at 340 nm in response to NAD(P)H production or depletion. Even though the concentration of the cofactor is directly related to the turnover of the substrate, caution must be used since the results might be significantly affected by background reactions occurring in unpurified cell lysates, often necessitating the purification of the relevant enzyme.

**Assays for Hydroxynitrile Lyase**

Cyanohydrins are broken down by hydroxynitrile lyases (HNL), and their activity is often gauged by how well they break down HCN from mandelonitrile. The amount of benzaldehyde generated may then be measured spectrophotometrically at wavelength 280 nm. Although this assay may be used in a high throughput setting, it only works with aromatic substrates. The conversion of benzaldehyde using an alcohol dehydrogenase and the measurement of the rising NADH content are other methods for detecting activity. Alternately, the released HCN might be found using the method Selmar et al. describe, which is based on König's reaction and can be thought of as an all-purpose screening assay that isn't limited to any particular substrate. The CN is first oxidized using chlorosuccinimide in this assay, following which it is linked to pyridine and undergoes hydrolysis to form glutaconic aldehydes.

Finally, a coloured chemical that can be seen at 580 nm is created in the König reaction using a primary amine and barbituric acid as a coupling reagent. This technique has recently been improved to monitor activity in micro-titer plates and is therefore appropriate for high-throughput systems. In theory, the test may be used to measure the activity and enantioselectivity of HNLs against any cyanohydrin substrate. Another assay's methodology is based on the Feigl-Anger technique, which produces a blue hue when HCN gas interacts with filter paper that has been impregnated with a solution of copper (II) ethylacetoacetate and tetra base. The blue-colored salt is a byproduct of tetra base's oxidation and is created when copper (II) ethylacetoacetate and hydrocyanic acid are present. The screening technique was carried out as a sandwich assembly, whereby a permeable nylon tissue served as a barrier between the Feigl-Anger test paper on top and the membrane-blotted colonies that were incubated with the substrate solution on the bottom. This arrangement only made it possible for the gaseous HCN to get to the detection paper, which is why there is a clear dark blue spot right above an HNL-producing colony.

## CONCLUSION

Enzymes have become essential instruments in the field of commercial biocatalysis, enabling the production of a wide variety of compounds and drugs. Although hydrolases have historically dominated the biocatalytic landscape, there has been a trend in recent years toward the exploration of enzymes from other classes, raising the possibility of paradigm-shifting developments. Selectivity, stability, and activity under process-specific

circumstances are all factors that must be taken into account when optimizing enzyme properties for large-scale applications. Modern methods for designing enzymes, such directed evolution and logical protein design, provide approaches to customize enzymes to fulfill these needs. The discovery of enzymes other than the typical hydrolases has contributed to the development of biocatalysis by creating new opportunities for a wide range of applications. Through repeated rounds of mutagenesis, screening, and selection, directed evolution has shown to be a powerful technique for improving enzyme performance. This strategy makes it easier to create enzymes with the appropriate properties for certain processes when combined with rational protein design. By combining these methods, biocatalysis is propelled toward better efficiency, sustainability, and customisation. The development of sophisticated enzyme design approaches will play a crucial role in determining the future of biocatalytic processes as the industry strives to harness the potential of enzymes.

**REFERENCES:**

[1] K. Kucharska, P. Rybarczyk, I. Hołowacz, R. Łukajtis, M. Glinka, en M. Kamiński, "Pretreatment of lignocellulosic materials as substrates for fermentation processes", *Molecules*. 2018. doi: 10.3390/molecules23112937.

[2] E. Cusano, B. Simonato, en R. Consonni, "Fermentation process of apple juice investigated by NMR spectroscopy", *LWT*, 2018, doi: 10.1016/j.lwt.2018.05.021.

[3] R. K. Srivastava, "Enhanced shelf life with improved food quality from fermentation processes", *J. Food Technol. Preserv.*, 2018.

[4] Y. Tatsukami *et al.*, "Metabolite profiling of the fermentation process of 'yamahai-ginjo-shikomi' Japanese sake", *PLoS One*, 2018, doi: 10.1371/journal.pone.0190040.

[5] F. C. L. Penido *et al.*, "Selection of starter cultures for the production of sour cassava starch in a pilot-scale fermentation process", *Brazilian J. Microbiol.*, 2018, doi: 10.1016/j.bjm.2018.02.001.

[6] Z. T. Tsegay, C. B. Sathyanarayana, en S. M. Lemma, "Optimization of cactus pear fruit fermentation process for wine production", *Foods*, 2018, doi: 10.3390/foods7080121.

[7] J. Li, X. Chi, Y. Zhang, en X. Wang, "Enhanced coproduction of hydrogen and butanol from rice straw by a novel two-stage fermentation process", *Int. Biodeterior. Biodegrad.*, 2018, doi: 10.1016/j.ibiod.2017.11.004.

[8] C. Guo *et al.*, "Dielectric Properties of Yogurt for Online Monitoring of Fermentation Process", *Food Bioprocess Technol.*, 2018, doi: 10.1007/s11947-018-2072-y.

[9] J. M. Da Silva *et al.*, "Study of the Fermentation Process of Different Fruit Biomasses", *Rev. Eletrônica TECCEN*, 2018, doi: 10.21727/teccen.v11i2.1331.

[10] Y. Gao, Z. Zhao, en F. Liu, "DMFA-based operation model for fermentation processes", *Comput. Chem. Eng.*, 2018, doi: 10.1016/j.compchemeng.2017.11.008.

# CHAPTER 9

# ADVANCEMENTS IN ENZYME TECHNOLOGY: PRODUCTION, ENGINEERING AND APPLICATION IN INDUSTRIAL PROCESSES

Dr. Vikas Kumar, Assistant Professor, Department of Agriculture & Environmental Sciences,
Shobhit University, Gangoh, Uttar Pradesh, India,
Email Id- vikas.panwar@shobhituniversity.ac.in

Dr. Alpana Joshi, Associate Professor, Department of SAES,
Shobhit Deemed University, Meerut, Uttar Pradesh, India,
Email Id-alpna.joshi@shobhituniversity.ac.in

**ABSTRACT:**

Enzyme technology has evolved significantly, becoming a cornerstone of modern industrial processes. Enzymes, primarily protein molecules, catalyze biochemical reactions and play a crucial role in converting substrates into products with enhanced efficiency. This paper explores the interdisciplinary field of enzyme technology, highlighting its applications in various environmentally friendly industrial sectors. Recent progress in biotechnology, particularly in genetics and protein engineering, has revolutionized the use of enzymes in industrial processes. Major research and development initiatives have led to the creation of novel enzyme products and improvements in existing processes. Enzymes' selectivity, efficiency, and resemblance to inorganic catalysts have rendered them highly attractive for industrial use. This article delves into the production methodologies, selection criteria for enzymes and production strains, and the significance of solid-state fermentation and submerged fermentation. Additionally, it discusses downstream processing challenges and the techniques employed for enzyme improvement through recombinant DNA technology and protein engineering. Overall, enzyme technology continues to shape and advance multiple industries by offering innovative solutions to complex challenges.

**KEYWORDS:**

Downstream Processing, Environmentally, Enzyme Technology, Recombinant DNA Technology.

## INTRODUCTION

Except for ribozymes, which are RNA molecules, enzymes are protein molecules that catalyze biological events. In enzymatic processes, the initial molecules, referred to as substrates, are changed into subsequent molecules, referred to as products. By creating complexes with the substrate that lower the reaction's activation energy, the enzymes quicken the process. Enzymes are appealing for industrial uses because they work similarly to the inorganic catalysts used in the chemical industry and are effective and selective in the chemistries they accelerate. In many environmentally friendly industrial areas, enzymes are often employed. Enzyme technology is a multidisciplinary field. The use of enzymes in various industrial processes has recently expanded thanks to recent developments in biotechnology, particularly in the fields of genetics and protein engineering. The core of biotechnology procedures is represented by industrial enzymes.

Along with the creation of various new products, a number of old processes have witnessed advancements thanks to a number of significant R&D projects. Enzymes are essential for almost all biological cell activities to proceed effectively. The assortment of enzymes produced in a cell influences which metabolic pathways take place in that cell since enzymes are selective for their substrates and accelerate just a few processes among numerous potential ones. Throughout human history, enzymes have been employed to make cheese and, indirectly, food using yeasts and bacteria. Although their protein nature was not established

until 1926 and their large-scale microbial synthesis only began in the 1960s, isolated enzymes were first utilized in detergents in 1914. Due to more advanced manufacturing technologies, modified enzyme characteristics, and novel uses, the industrial enzyme industry is continuously expanding [1], [2].

**Production of Enzymes**

Although certain enzymes are created via solid-state fermentation, most enzymes are commercially manufactured by microbes by submerged fermentation. In enormous biological reactors known as fermenters, microorganisms with the GRAS (generally regarded as safe) designation create the majority of industrial enzymes. Nevertheless, certain enzymes are still taken out of plant or animal cells. Commercial enzymes originating from plants include the proteolytic enzymes papain, bromelain, and ficin as well as a few more specialist enzymes such soybean lipoxygenase. Enzymes like pepsin and rennin are examples of proteinases that come from animals. For maximal productivity and the required enzymatic characteristics, the producing organism and often also the individual enzyme are genetically modified. The subsequent stages in industrial enzyme processing are determined by the level of purity needed, which is determined by the application. Industrial enzymes used in large quantities are often marketed as concentrated liquids or granulated dry goods rather than being purified. Enzymes must be thoroughly purified in order to be employed in specialized applications like DNA technology or diagnostics.

**Choosing an Appropriate Enzyme**

Specificity, reaction rate, pH and temperature optimums and stability, impact of inhibitors, and affinity to substrates are among the factors taken into consideration when choosing an industrial enzyme. Depending on the particular uses, certain enzymes with particular features are needed. For instance, enzymes employed in the paper industry shouldn't have a side-activity that breaks down cellulose since this would harm the cellulose fibres. The enzymes employed in the production of animal feed must be thermotolerant to survive in the hot extrusion process while still operating at their peak efficiency at the body temperature of the animal. Enzymes used in industrial applications often need to be cofactor-free and resistant to a variety of heavy metals.

**Choosing an Appropriate Production Strain**

The choice of an appropriate source for the manufacturing of enzymes must take into account a number of factors. Because they multiply quickly and are simple to cultivate, microorganisms are chosen over plants or animals as a source of industrial enzymes. The use of filamentous fungus for the synthesis of primary and secondary metabolites has significantly risen during the last several decades. Since the recovery and purification procedures for external enzymes are significantly simpler than those for intracellular enzymes, extracellular enzymes are often preferred over intracellular enzymes. This is because intracellular enzymes must be purified from a variety of thousands of different cell proteins and other components. Second, when the enzyme generated by the organism is employed in food processing, the production host should have GRAS-status, which denotes that it is "generally recognized as safe." Third, the organism should be able to manufacture the needed enzyme in high quantities within an acceptable length of time [3], [4] .

## DISCUSSION

New advancements in screening have made it feasible to start with the process' ideal conditions, define the requirements for the desired biocatalyst (enzyme), and then search

across the variety of the natural world for the best biocatalyst. Directed evolution or gene shuffles may also be used to push the physical limits of the proteins and the operating conditions of the available biocatalysts. A trend towards robotic handling, new technology (such as parallel capillary electrophoresis, thermistor arrays), new fluorophores and chromophores, and new approaches to screening for stereoselectivity is being driven by the development of efficient methods to create and handle diversity, which poses new challenges for screening methodologies.

Utilizing organisms of the wild kind offers a number of benefits since they often provide the combination of enzymes needed to break down a challenging substrate. However, certain wild-type organisms are difficult to scale up, and others might be dangerous. The genetically modified organism often has a wider variety of enzymes with a variety of characteristics, such as increased activity or specificity, handling safety, and a lower content of foreign proteins. The industrial strains often generate extracellular enzyme proteins at a rate of approximately 50 g/l. A small number of microbial hosts, including the fungus Aspergillus and Trichode- rma, the bacteria Streptomyces, and the fungi Streptomyces imperfecti, generate the majority of the industrial enzymes. Since yeasts are poor extracellular enzyme makers, they are seldom used in this capacity.

**Production Techniques**

The manufacturing procedure has to be designed once the organisms have been chosen. Solid-state fermentation is quickly gaining popularity across the globe for the manufacture of primary and secondary metabolites, despite the fact that submerged fermentation has historically been employed extensively for the commercial production of enzymes. Processes for solid-state fermentation may benefit from the utilization of agro-industrial wastes. Regardless of the kind of bioprocess, the optimization of a fermentation process comprises selecting the medium composition, culture method, and process parameters. Significant work and time must be invested to complete these tasks. The safety of the organism in issue must be considered before beginning any bioprocess. Are further safety measures required? What nutrients does the organism need, and what are the best/most cost-effective concentrations? What is the best way to sanitize the nutrients? Which kind of reactor mass transfer, aeration, cooling, foam control, sampling is required? How should the process be managed, and what factors need to be measured? Which kind of cultivation batch, fed-batch, or continuous is optimal for this organism? Which growth circumstances, rate of specific growth and product creation, yield, and volumetric productivity are ideal? How can the reactor's cell concentration be maximized? If the product is intracellular, how should the cell be broken down and how should the product be collected, purified, and preserved? Choosing the fermentation procedure is equally important and solely relies on the finished product and its intended use [5], [6].

**Floating Fermentation**

Submerged fermentation is the primary industrial method for producing the enzyme, and genetically modified strains are often used in this process. Submerged fermentation bioreactors are highly developed, provide online control over a number of parameters, and have no issues with mass transfer or heat removal. In fermenters that are 50 to 500 m3, industrial enzymes in enormous quantities are generated. In submerged fermentation, the liquid medium keeps the microorganisms in touch. In submerged fermentation, oxygen is a must. In submerged fermenters, microorganisms may be grown in four different ways: batch culture, fed-batch culture, perfusion batch culture, and continuous culture. The bacteria are injected in a fixed volume of media during batch culture. When using fed-batch culture, the

concentrated nutrient components are progressively incorporated into the batch culture. In perfusion batch culture, an equivalent amount of used cell-free media is removed before adding the culture. During the exponential phase of microbial development, new medium is supplied to the batch system in continuous culture, with a proportional withdrawal of the media containing the product. Constant culture results in growth that is almost balanced, with minimal variation in nutrients, metabolites, cell counts, or biomass. After cell removal (by vacuum drum filtration, separators, or microfiltration), extracellular enzymes are often recovered by ultrafiltration. If necessary, ion exchange or gel filtration are used for purification. The finished product may either be granulated to a non-dusty dry product or a concentrated liquid containing the essential preservatives, such salts or polyols. It is important to keep in mind that because enzymes are proteins, they may induce and have caused allergic responses in the past. Consequently, precautionary precautions must be taken throughout their manufacturing and use.

**Fermentation in the Solid State**

The utilization of many enzymes in various industrial processes is uneconomical due to the high cost of producing enzymes by submerged fermentation. Solid-state fermentation is a desirable solution to lower manufacturing costs. This low-cost fermentation method is best suited for the creation of bioprocesses utilizing agricultural leftovers. Higher fermentation productivity, higher end-concentration of products, higher product stability, lower catabolic repression, cultivation of microorganisms specialized for water-insoluble substrates or mixed cultivation of various fungi, and last but not least, lower demand on sterility due to low water activity, appear to be just a few of the biotechnological benefits of solid-state fermentation. even though it is now largely done on a lab scale. As more commercial enzymes are produced using fungal strains that are more suited for solid-state fermentation because it more closely matches their natural habitat, this process is growing in popularity. The native environment of wild-type bacteria is not replicated by submerged fermentation.

The main issues that have motivated the researchers to look for answers include scaling up, end-product purification, and biomass estimation. Solid-state fermentation scale-up has long been a bottleneck, but recently, with the development of biochemical engineering, a number of bioreactors have been developed that, to a certain extent, solve scale-up issues as well as those relating to on-line parameter monitoring, heat transfer, and mass transfer. Solid-state fermentation using natural supports results in more costly product recovery and purification operations, but their use implies lower production costs and often significantly greater activity levels. Therefore, before determining if the process is feasible for a particular goal, an economic review of the whole process should be conducted. The manufacture of valuable goods like enzymes is a particular use for this system. When compared to purified products, concentrated end-products with large titers are preferred for certain applications. For instance, concentrated crude cellulase is needed for the bioconversion of biomass, but in the leather sector, crude proteases are sufficient to remove the hair from the leather [7], [8].

Solid-state fermentation presents a significant problem in the separation of the biomass, which is crucial for kinetic research. There are a few indirect approaches that may be used, such the estimate of glu-cosamine, ergosterol, protein (kjeldahl), DNA, dry weight changes, and CO2 evolution, but each of them has its own flaws. Digital image processing has recently been developed as a technique for solid-state fermentation biomass measurement. KS400 software is used to process the pictures after they are taken using a digital camera and stereomicroscope. The measurement of oxygen intake and carbon dioxide evolution rate have recently been thought to be the most accurate ways to gauge how well a microorganism is growing. Tengerdy argued that solid-state fermentation was especially well suited for the

manufacture of lignocellulosic enzymes for a variety of agro-biotechnological applications. Cellulase production in submerged fermentation and solid-state fermentation was compared to demonstrate this. Cellulase yields in submerged fermenters were typically about 10 g/l, and a stirred tank bioreactor's average fermentation cost was around US$200/m3. Therefore, the submerged fermentation's manufacture of crude fermentation cost roughly $20/kg. The average production level in the solid-state fermenter was about 10 mg/g substrate, and the typical fermentation expense was just approximately US$25/mt. Cellulase generated through solid-state fermentation thus has a unit cost of roughly $0.2/kg.

**Downstream Operation**

More than half of the entire cost of enzyme manufacturing goes toward the purification and conditioning of enzymes for usage, often known as downstream processing of enzymes. The price of downstream processing is determined by the level of needed purity and, therefore, by the enzyme's intended application. Because of the purity needed, the downstream processing cost for a therapeutic enzyme will undoubtedly be greater than that for a technical enzyme, hence downstream processing has to be enhanced in order to lower production costs. the first stages in the purification of enzymes.

Following the phase of clarification, ultrafiltration is used to further purify the solution containing intracellular and extracellular enzymes. Knowing the molecular weight of the protein that has to be purified is necessary for this stage so that contaminants like ions and other proteins with lower molecular weight may be eliminated. The concentrated enzyme solution will still include other proteins, nucleic acids, and polysaccharides even after ultrafiltration. If the contaminants prevent the enzyme from acting as a catalyst in a certain process, it will also determine whether the impurities can be removed. Nucleic acid must be removed from recombinant enzymes to reduce the possibility of unintended gene transfer. Concentrated enzymes are better for chromatographic purification because they need less adsorbent to bind to the protein. In most cases, chromatography is used to purify enzymes. Different chromatographic adsorbents are used to separate enzymes according to their surface hydrophobicity, molecular size, and surface charge.

It used to take at least five separation processes, including chromatography, to purify an enzyme from a concentrated clarified homogenate. Each step may lose 10% of the enzyme, which resulted in poor enzyme recovery. Therefore, it was crucial to maximize enzyme recovery in order to decrease the cost of the enzyme and, in turn, the number of purification stages. Process engineering for chromatography has significantly advanced in recent years, with the creation of continuous chromatographic processes such simulated moving bed and continuous separation recently implemented in the downstream processing of proteins. As a result, it is now feasible to purify enzymes with a high rate of recovery and a small number of stages, which helps to lower the price of the enzyme [9], [10].

**Enzyme Development**

Even though they are very appealing for biological and chemical synthesis, enzymes cannot have the appropriate characteristics when used on a large scale. For instance, they can lose their capacity to function without pricey cofactors, their high activity in non-aqueous conditions, or their stability or tolerance to changes in operating settings. The ultimate objective of protein engineering research continues to be the accurate and rapid identification of the amino acid substitutions that produce desirable modifications in enzyme function. Site-directed, random, and directed mutagenesis may all be used to increase thermal stability. These methods are now widely used. The ability to overproduce enzymes in an appropriate host has proven to be quite challenging. Another option is to modify an enzyme that is

already on the market to make it a more effective industrial catalyst. Enzymes may be altered in the future to function more effectively in industrial processes, such as reducing the susceptibility of glucose isomerase to inhibition by the Ca2+ present in the starch saccharification reaction stream. Increasing the number of copies of the gene that codes for an enzyme may increase the quantity of that enzyme that an organism produces. This idea has been used to make Escherichia coli's penicillin G amidase more active. Another method for developing novel enzymes is site-directed mutagenesis. Only one or two amino acid residues out of the whole protein structure are gradually substituted in this method. Although the requisite tools and a large database of sequence structure correlations are available, it is still hard to precisely forecast the three-dimensional alterations brought on by such replacements. Assessing the long-term impacts, particularly the solvent interactions, on the new structure is the key challenge. Evidently, even very little sequence changes may result in significant conformational changes, which may have an impact on the enzymatic catalysis step that determines pace. However, it is realistic to assume that over the next several years, the relative likelihood of success will rise and the results of protein engineering will have a significant influence on enzyme technology, provided a sufficiently comprehensive data-base and acceptable tools.

**Use of Recombinant DNA**

Enzymes that may be employed in industrial process chemistry can be found in microorganisms that have been isolated from a variety of habitats. These microbes may be used to find novel biocatalysts using high-throughput screening (HTS) techniques. However, many microbes are difficult to grow in lab settings or their enzyme output is too low to be commercially viable. Cloning the genes encoding these enzymes and heterologously expressing them in frequently used industrial strains has become a regular practice using recombinant DNA technology. By genetically altering the microorganism, one may produce unique enzymes that are ideal for certain situations. With the use of recombinant DNA technology, enzymes may be produced at rates that are 100 times higher than those of native expression, resulting in high yields and cheap cost. As a consequence, a number of significant food-processing enzymes, including amylases and lipases, have come into existence with features suited for specific culinary uses. By eliminating native genes that encode extracellular proteases, some microbial strains have been genetically altered to produce more enzymes. Additionally, certain fungal producing strains have undergone modifications to lessen or completely abolish their capacity to produce hazardous secondary metabolites. This strategy prevents the production strain from receiving any extraneous or unknown DNA from the donor species.

**Engineering of Proteins**

Although the cost of producing enzymes is significantly reduced when recombinant DNA technology is used, there are still just a few uses for the enzymes that are created. For these enzymes, the majority of compounds of industrial relevance are not natural substrates. Even if the requisite enzyme activity is discovered, the yield is often poor. In addition, enzymes are often unstable in adverse reaction circumstances, such as pH levels that are higher or lower than the physiological pH 7, high temperatures, or the presence of organic solvents that are necessary to solubilize a variety of substrates. Site-specific and random mutageneses, which increase enzyme stability in a broader range of pH values and temperatures and resistance to a variety of organic solvents, are now easily accessible thanks to recent advancements in polymerase chain reaction (PCR) technology.

Recombinant expression makes it possible to produce large amounts of an enzyme, which makes it possible to employ X-ray crystallography to better understand an enzyme's tertiary structure and substrate-binding/recognition sites. This knowledge may help in the rational design of the enzyme by anticipating modifications to the amino acids that will affect the enzyme's catalytic rate, substrate specificity, and enantioselectivity in the synthesis of chiral compounds. Two PCR-mediated techniques random or saturated site-specific mutagenesis and gene shuffling are typically used to create mutants, and two distinct strategies a random technique called directed evolution and a protein engineering technique called rational design are currently available to engineer commercially available enzymes to be better industrial catalysts.

There are numerous specific methods for protein engineering, but they can be divided into two main categories: rational design and combinatorial methods. In protein engineering, a protein sequence is changed to achieve a desired result, such as a change in the substrate specificity or increased stability to temperature, organic solvents, and/or extremes of pH. The rational techniques, like site-directed mutagenesis, call for precise amino acid replacements, which necessitates a thorough understanding of the biocatalyst that is being enhanced, including its three-dimensional structure and the chemical mechanism of the reaction. The fundamental benefit of rational design is that relatively few protein variations are produced, necessitating little effort to screen for the enhanced features. Contrarily, combinatorial approaches offer the benefit of not needing as much protein expertise while producing a huge number of variations that must be tested. Additionally, it has been shown that non-obvious modifications in protein sequence often result in significant increases in their characteristics. Because these changes are exceedingly difficult to anticipate logically, they can only be discovered using combinatorial approaches.

**Applications of Enzymes at Scale**

In the fine chemical sector, isolated enzymes have several uses. The creation of chirally pure amino acids and uncommon sugars involves the employment of enzymes. A number of other compounds, including derivatives of penicillin and fructose, are also produced using them. Enzymes should be seen as a component of the rapidly expanding biocatalyst market, which also includes live cells that have undergone genetic engineering to become chemical factories. Major large-scale enzyme uses.

**Detergents**

Microbial enzymes were used on a big scale for the first time in detergents. In industrialized nations, the use of enzymes in detergent formulations is increasingly widespread; enzymes are present in around half of the detergents on the market. Proteins, carbohydrates, and lipids are all components of dirt. After a preliminary time of soaking, enzyme usage often enables lower temperatures to be used and shorter durations of agitation. In general, enzyme detergents are far more successful than non-enzyme detergents in removing protein from garments that have been soiled with things like blood, milk, sweat, grass, etc. The most crucial detergent enzymes for hydrolyzing protein-based stains are still proteinases. By hydrolyzing the ester linkages between the glycerol backbone and fatty acid, lipases break down lipids into more water-soluble compounds. Detergents that include amylases may get rid of stains made by starch.

**Food Sector**

The most extensively researched aspect of alpha-amylases in relation to better bread quality and longer shelf life. Amylases from fungi and bacteria are also used. The quantity that is

added has to be carefully monitored since too much might make the dough sticky. The drive to cut down on additional chemicals is one of the driving forces behind research into how enzymes affect the characteristics of bread and dough. Flour often includes trace quantities of cellulose, glucans, and hemicelluloses such arabinoxylan and arabinogalactan in addition to starch. There is evidence that using xylanases reduces water absorption, which lowers the quantity of additional water required while baking. The dough becomes sturdier as a result. Particularly, xylanases are utilized in Scandinavian dry crisps and whole meal rye bread. To enhance the qualities of the dough, proteinases may be added. Glucose oxidase has been used in lieu of chemical oxidants, and lipases have been employed to strengthen gluten.

## CONCLUSION

In today's industrial operations, enzymes impressive protein molecules that catalyze biological reactions have become essential instruments. They are effective and selective catalysts due to their capacity to speed up processes by building complexes with substrates in the transition state. An interdisciplinary subject called enzyme technology finds uses in many different industrial sectors and provides eco-friendly solutions. Novel uses of enzymes in many industrial processes are now possible because to recent developments in biotechnology, notably in genetics and protein engineering. Enzymes are essential for biological processes because they play a key role in defining the metabolic pathways inside cells. Enzymes have experienced major changes in manufacture, engineering, and use, from ancient purposes in the production of food and cheese to modern uses in diagnostics and DNA technologies. In several industrial fields, enzyme technology is at the forefront of innovation. The improvements in enzyme engineering, manufacturing, and use have transformed operations in a variety of industries. The progression from traditional applications to the present stage of precise engineering and customized uses demonstrates the noteworthy advancement in this discipline. Enzymes have evolved beyond their original roles in cells to play crucial roles in industrial processes, providing effective and sustainable solutions. The prospect for additional advances in enzyme technology is encouraging as biotechnology develops. Enzymes are positioned to play an increasingly more significant role in determining the direction of industrial processes with further study, enhanced manufacturing techniques, and a greater understanding of protein engineering.

## REFERENCES:

[1] K. NT, “Enzyme Technology - An Emerging Trend in Biotechnology.”, *Enzym. Eng.*, 2018, doi: 10.4172/2329-6674.1000163.

[2] B. Sharma, A. K. Dangi, en P. Shukla, “Contemporary enzyme based technologies for bioremediation: A review”, *Journal of Environmental Management*. 2018. doi: 10.1016/j.jenvman.2017.12.075.

[3] S. S. Nadar, P. Rao, en V. K. Rathod, “Enzyme assisted extraction of biomolecules as an approach to novel extraction technology: A review”, *Food Research International*. 2018. doi: 10.1016/j.foodres.2018.03.006.

[4] M. B. Osho, “Industrial enzyme technology: Potential applications”, in *Research Advancements in Pharmaceutical, Nutritional, and Industrial Enzymology*, 2018. doi: 10.4018/978-1-5225-5237-6.ch017.

[5] L. F. Stadlmair, T. Letzel, J. E. Drewes, en J. Grassmann, "Enzymes in removal of pharmaceuticals from wastewater: A critical review of challenges, applications and screening methods for their selection", *Chemosphere*. 2018. doi: 10.1016/j.chemosphere.2018.04.142.

[6] R. BCC, "Global Markets for Enzymes in Industrial Applications", *Focus Catal.*, 2018.

[7] H. A. Bunzel, X. Garrabou, M. Pott, en D. Hilvert, "Speeding up enzyme discovery and engineering with ultrahigh-throughput methods", *Current Opinion in Structural Biology*. 2018. doi: 10.1016/j.sbi.2017.12.010.

[8] R. Ravee, F. I. M. Salleh, en H. H. Goh, "Discovery of digestive enzymes in carnivorous plants with focus on proteases", *PeerJ*, 2018, doi: 10.7717/peerj.4914.

[9] M. Adli, "The CRISPR tool kit for genome editing and beyond", *Nature Communications*. 2018. doi: 10.1038/s41467-018-04252-2.

[10] J.-L. Wertz, M. Deleu, S. Coppée, en A. Richel, "Carbohydrate-Active Enzymes", in *Hemicelluloses and Lignin in Biorefineries*, 2018. doi: 10.1201/b22136-2.

# CHAPTER 10

# DIVERSE APPLICATIONS OF ENZYMES IN VARIOUS INDUSTRIES: FROM STARCH HYDROLYSIS TO BIOFUELS AND BEYOND

Dr. Vikas Kumar, Assistant Professor, Department of Agriculture & Environmental Sciences,
Shobhit University, Gangoh, Uttar Pradesh, India,
Email Id- vikas.panwar@shobhituniversity.ac.in

Dr. Alpana Joshi, Associate Professor, Department of SAES,
Shobhit Deemed University, Meerut, Uttar Pradesh, India,
Email Id-alpna.joshi@shobhituniversity.ac.in

**ABSTRACT:**

Due to their adaptability and effectiveness in accelerating certain biological processes, enzymes have become increasingly important as biocatalysts in a wide range of businesses. This essay examines the many uses of enzymes in fields including food and drink, textiles, biofuels, and other areas. The voyage begins with starch hydrolysis, where alpha-amylase and glucoamylase play crucial roles in turning starch to glucose, and continues to more contemporary uses including the creation of biofuel from lignocellulosic biomass. Examining how enzymes are used in many industries including dairy, beverages, textile, pulp and paper, leather, and personal care products we can see how they help with procedures like coagulation, hydrolysis, and modification. Also covered is the possibility for enzyme applications in DNA technology and how they might benefit long-term environmental sustainability. The area of industrial enzyme technology is expected to continue to expand and innovate, opening up promising opportunities for overcoming present and future issues in a variety of industries.

**KEYWORDS:**

Biocatalysts, DNA Technology, Enzymes, Lignocellulosic, Sustainability.

## INTRODUCTION

The first widespread usage of microbiol enzymes in the food sector was the introduction of enzymes that break down starch. The conversion of starch to glucose is mostly carried out by the enzymes glucoamylase and alpha-amylase. To increase the glucose output, extra debranching enzymes, such as pullulanase, are sometimes added. To make the disaccharide maltose, beta-amylase is commercially synthesized from barley grains. Enzymes have emerged as versatile biocatalysts with applications spanning across a multitude of industries, contributing to enhanced efficiency, sustainability, and innovation. These natural catalysts offer specificity and effectiveness in performing complex biochemical reactions that are often difficult to achieve using traditional chemical processes.

The exploration of enzyme applications in diverse industries showcases their transformative potential and underscores the dynamic evolution of enzyme technology. This paper delves into the remarkable array of industries that harness the power of enzymes, ranging from the traditional use of starch-degrading enzymes in food and beverages to cutting-edge applications in biofuel production and DNA technology. The versatility of enzymes in industries such as dairy, drinks, textiles, pulp and paper, leather, personal care products, and more, reveals the depth and breadth of their impact on modern production processes. Additionally, the potential for enzymes to contribute to sustainable practices and address environmental challenges is an area of burgeoning interest. As industries continue to evolve, the ongoing integration of enzyme technology promises to usher in new possibilities and innovations [1], [2].

There are several uses for beverages and dairy enzymes in the beverage sector. Chymosin is used to coagulate milk protein while manufacturing cheese. Beta-galactosidase, often known as lactase, is another enzyme utilized in the milk industry. It breaks down lactose into glucose and galactose. Milk products for lactose sensitive customers go through this procedure. The production of fruit juice also uses enzymes. Pectinase, xylanase, and cellulase are added to help the juice separate from the pulp. Juice clarification uses amylases and pectinases. Similar to this, enzymes are often employed in wine production to boost the yield and produce a better extraction of the essential ingredients.

The high molecular weight substances, like pectin, are hydrolyzed by enzymes. The first commercial success was achieved by adding beta-glucanase to feed diets based on barley. The beta-glucan found in barley contributes to the high viscosity of the chicken intestine. Overall, the use of enzymes in feed causes animals to acquire more weight while consuming the same quantity of barley, increasing the feed conversion ratio. In several experiments, xylanase was shown to improve the metabolizable energy by 7–10% when added to wheat-based broiler diet. Phytase, a phosphoesterase that releases phosphate from phytic acid, is another crucial feed enzyme. Phytic acid is often found in feed products made from plants. By reducing the amount of phosphorous in the feces, phytase supplementation reduces environmental pollution. It also reduces the need to supplement the diet with phosphorus. Phytase is now regarded as one of the most powerful feed enzymes, especially those derived from fungal sources. A feed-enzyme preparation often consists of a cocktail of several enzymes, including glucanases, xylanases, proteinases, and amylases.

**Textiles**

One of the areas of industrial enzymology that is expanding the fastest is the use of enzymes in the textile industry. Textile fibres are desized using amylases. The cellulases are yet another significant class of enzymes used in the textile industry. These (neutral or acidic) enzymes provide a fantastic replacement for stonewashing blue denim clothing because of their capacity to alter cellulosic fibres and so enhance the quality of textiles in a regulated manner. Eliminating the usage of stones offers various benefits, including easier handling, fewer environmental issues, and less wear and tear on washers and clothing. Enzymatic stonewashing creates the desirable appearance and softer finish while allowing up to 50% greater jean load. Since neutral cellulase has a wider pH range and less backstaining, it is the preferred enzyme for stonewashing. This second characteristic lessens the need for strict pH control of the wash and makes the finish more repeatable from wash to wash. With cotton or other natural fibres, fuzz production and pilling are frequent issues; cellulases are employed to break down the short fibre ends sticking out of the cloth, giving it a better finish. Recently, hydrogen peroxide has been investigated to replace chlorine-based chemicals as a bleaching agent for textiles, and excess hydrogen peroxide has been degraded using catalase. Another current method involves directly bleaching fabrics using oxidative enzymes. A recent contender in this area is laccase, a polyphenol oxidase from fungi. This enzyme, which contains copper, is oxidized by oxygen. It may oxidatively destroy a wide range of compounds, including colour pigments, when it is oxidized [3], [4].

Pulp & Paper Over the last 20 years, much research has been done to apply a variety of enzymes to the pulp and paper sector. Xylanases are used in pulp bleaching, where they hydrolyze leftover xylan to release lignin fragments. As a result, less bleaching agents with a chlorine basis are required. During recycling, cellulases are utilized to de-ink the cellulose fibres. Amylases are employed in the production of paper, particularly for the modification of starch, which increases the paper's tensile strength, stiffness, and erasability. Amylase enzymes are added in a regulated way to give the starch suspension the required viscosity.

When mechanical pulps of red pine are utilized as a raw material, the removal of pitch, a sticky substance made of lipids found mostly in softwoods, presents a unique difficulty. Lipases are capable of removing pitch. Proteolytic and lipolytic enzymes are used in the preparation of leather in the leather industry. The structure of animal skin as a raw material is related to the utilization of these enzymes. Unwanted components are removed using enzymes. The soaking step includes the addition of alkaline proteases. This shortens the processing time, removes and degrades protein, dirt, and lipids, and enhances water absorption by the dry skins. Pancreatic trypsin may also be utilized at this phase in certain circumstances. Proteases are used to dehair and dewool leather, which enhances the quality of the material (cleaner, stronger surface, softer leather, and fewer stains). To specifically remove oil, lipases are utilized in this step or the battering phase. The use of lipases in the leather industry is a relatively recent innovation [5], [6].

## DISCUSSION

The use of lignocellulosic biomass for the creation of biofuel is perhaps the most significant new use of enzymes being investigation right now. A plentiful renewable resource that is accessible to humanity is biomass. However, owing to the high cost of cellulases and their lack of specificity for different lignocellulosic substrates, their application is restricted due to the absence of a cost-effective enzyme conversion method. Enzymatic hydrolysis is a vital stage in the multistep process presently being used to produce bioetha- nol from biomass. Significant research has been done to identify effective cellulase systems and processing conditions for the production of biofuels, in addition to studies focused on biochemical and genetic advancements of the existing organisms used in the process. There are still issues with effective techniques, and ongoing research is being done in this area.

### Applications of Enzymes in Chemistry and the Pharmaceutical Industry

The vast number of chemicals that must be evaluated for biological activity in order to identify a single potential lead is a significant problem in the pharmaceutical industry. Combi- natorial biocatalysis has drawn a lot of interest in this context because it has the potential to both increase the complexity of the variety of already-existing chemical libraries and create new libraries from scratch. One example is the modification of the glycosylation pattern of bioactive substances using glycosyltransferases. This achievement has shown that bioconversion technology may be scaled up, even if only a small number of common compounds, such acrylamide, are now manufactured by enzyme technology (annual production scale: 40 000 tons). On a multi-ton scale, biocatalysis also produces a wide range of additional molecules, such as chiral compounds.

### Unique Enzymes

There are other specific uses for enzymes in addition to those involving high volumes. These include the manufacture of flavour, protein modification, personal care goods, DNA technology, and fine chemicals, as well as the use of enzymes in clinical analytical applications. These enzymes must be devoid of side-activities in contrast to bulk industrial enzymes, emphasizing the need of complex purification procedures. For immunoassays, alkaline phosphatase and peroxidases are utilized. Biosensors are a significant advancement in analytical chemistry.

### Personal care products with enzymes

Although the numbers utilized are minimal and this use of enzymes is very new, it is important to note as a potential development area. Cleaning contact lenses is one use. For

this, enzyme solutions including proteinase and lipase are used. In order to disinfect contact lenses, hydrogen peroxide is utilized. A catalase enzyme that contains heme may then be used to eliminate any remaining hydrogen peroxide. Some toothpastes include glucoseamylase and glucose oxidase because these enzymes release glucose from the starch-based oligomers created by alpha-amylase and transform glucose into the disinfectants gluconic acid and hydrogen peroxide. Enzyme solutions that break down proteins may be used to clean dentures. Enzymes like chitinase are also being researched for use in cosmetics for the skin and hair.

**Technology Using Enzymes in DNA**

The function of DNA-modifying enzymes is critical in DNA technology, which has revolutionized both conventional and contemporary biotechnology. They fall into two categories:

1. Restriction enzymes are proteins that can identify certain DNA sequences and break the chain at the sites of identification.
2. DNA-modifying enzymes: These create nucleic acids, break them down, assemble fragments of DNA, and remove sections of DNA.

Restriction enzymes cause cleavage after identifying a certain DNA code sequence. They are crucial to gene engineering. DNA polymerases use a model template that they duplicate to synthesize new DNA chains. The phosphodiester linkages between DNA sugars are hydrolyzed by nucleases. At the end of the DNA chain, phosphatases and kinases respectively add and remove phosphate groups. Phosphodiester linkages are created between neighbouring nucleotides by ligases to bind them together. These enzymes play important roles in DNA replication, the breakdown of foreign DNA, the repair of mutated DNA, and the recombination of various DNA molecules within the cell. The enzymes employed in gene technology are created similarly to conventional enzymes, but particular care must be taken during their purification.

Enzymes have been widely used to enhance the environment, safeguard our resources, and open up new possibilities. There is scarcely any place where enzymes are not present. Due to more efficient upstream and downstream processing, which results in cheaper and more effective enzymes, the worldwide commercial enzyme market has been gradually expanding. These are extensively used in the sectors covered in the chapter, although there is still room for development. This underlines the need of ongoing screening programs to find new enzymes with unique characteristics from foreign habitats. There is little doubt that enzymes will be extensively employed in the future, and this will be reflected in the quantity of enzymes that are now accessible on an industrial and scientific scale, the range of processes they can catalyze, and the environmental conditions in which they can function. In particular, new uses for cellulases in the manufacture of personal care products and improvements in the manufacturing of second-generation biofuels from biomass are to be anticipated. Cellulases are essential for converting biomass into sugars, which are then fermented to ethanol. Growing environmental concerns and price increases for energy are anticipated to give this application great significance [7], [8].

The field of industrial enzyme technology is still active and undergoing development as well as maturing. The previously identified enzymes and their functional significance are now better understood, and this raises the possibility that their catalytic activities have a wide range of innovative uses. The existing enzymes will be put to new applications, and novel enzymes that have been designed through enzyme engineering or that have been identified in their biological niches will be employed to catalyze hitherto unexplored processes. The age of

enzyme technology has barely begun. In the next years, difficult challenges in protein engineering and metabolic engineering are anticipated to be resolved by sophisticated high-throughput screening and selection methods, directed evolution tools, and molecular biology approaches [8], [9].

## CONCLUSION

The vast landscape of industries benefiting from enzyme applications highlights the significance of biocatalysis in shaping modern production processes. Enzymes have not only revolutionized traditional sectors like food and textiles but have also paved the way for novel applications, such as biofuel production and DNA technology. Their role in enhancing efficiency, reducing environmental impact, and improving product quality is undeniable. As industries strive for sustainability and resource optimization, enzymes are poised to play an increasingly pivotal role in addressing these challenges. The ongoing research and innovation in enzyme technology offer exciting prospects for further advancements, whether in the optimization of existing processes or the discovery of novel enzyme functionalities. The journey from starch hydrolysis to biofuels and beyond exemplifies the transformative potential of enzymes and their capacity to drive positive change across diverse industries.

## REFERENCES:

[1] J. Chapman, A. E. Ismail, en C. Z. Dinu, “Industrial applications of enzymes: Recent advances, techniques, and outlooks”, *Catalysts*. 2018. doi: 10.3390/catal8060238.

[2] A. M. Egorov, M. M. Ulyashova, en M. Y. Rubtsova, “Bacterial enzymes and antibiotic resistance”, *Acta Naturae*. 2018. doi: 10.32607/20758251-2018-10-4-33-48.

[3] M. Winkler, M. Geier, S. P. Hanlon, B. Nidetzky, en A. Glieder, “Human Enzymes for Organic Synthesis”, *Angewandte Chemie - International Edition*. 2018. doi: 10.1002/anie.201800678.

[4] Y. Hu, L. Dai, D. Liu, W. Du, en Y. Wang, “Progress & prospect of metal-organic frameworks (MOFs) for enzyme immobilization (enzyme/MOFs)”, *Renewable and Sustainable Energy Reviews*. 2018. doi: 10.1016/j.rser.2018.04.103.

[5] Y. Zhang, S. He, en B. K. Simpson, “Enzymes in food bioprocessing — novel food enzymes, applications, and related techniques”, *Current Opinion in Food Science*. 2018. doi: 10.1016/j.cofs.2017.12.007.

[6] M. Bilal, Y. Zhao, T. Rasheed, en H. M. N. Iqbal, “Magnetic nanoparticles as versatile carriers for enzymes immobilization: A review”, *International Journal of Biological Macromolecules*. 2018. doi: 10.1016/j.ijbiomac.2018.09.025.

[7] D. D. Boehr, R. N. D’Amico, en K. F. O’Rourke, “Engineered control of enzyme structural dynamics and function”, *Protein Science*. 2018. doi: 10.1002/pro.3379.

[8] H. Claus en K. Mojsov, “Enzymes for wine fermentation: Current and perspective applications”, *Fermentation*. 2018. doi: 10.3390/fermentation4030052.

[9] J. A. Harrigan, X. Jacq, N. M. Martin, en S. P. Jackson, “Deubiquitylating enzymes and drug discovery: Emerging opportunities”, *Nature Reviews Drug Discovery*. 2018. doi: 10.1038/nrd.2017.152.

# CHAPTER 11

# ADVANCEMENTS IN APPLIED BIOCATALYSIS: FROM ENZYME SELECTION TO NON-CONVENTIONAL BIOCONVERSION MEDIA

Amit Kumar, Assistant Professor, Department of Agriculture and Environmental Sciences,
Shobhit University, Gangoh, Uttar Pradesh, India,
Email Id- amit.kumar@shobhituniversity.ac.in

**ABSTRACT:**

From the choice of enzymes to the investigation of unconventional bioconversion medium, practical biocatalysis has seen major developments. In biocatalysis, high-selectivity chemical reactions are driven under controlled circumstances using biocatalysts like enzymes or entire cells. This article explores the many uses for applied biocatalysis as well as its difficulties. Considerations of activity, selectivity, and stability under operating settings go into choosing the best biocatalysts. The methods used for choosing a biocatalyst include genetic alterations, existing enzymes, and new biocatalyst screening. Depending on the intricacy of the reaction and mass transfer restrictions, isolated enzymes or entire cells are used. With a variety of techniques and supports available, immobilization of biocatalysts improves stability and simplicity of reuse. To deal with solubility and toxicity issues, non-traditional bioconversion media have been investigated. These media include organic solvents, ionic liquids, supercritical fluids, and more. Compatibility and mass transfer dynamics must be carefully considered when integrating biocatalysts with unconventional media. These developments highlight the potential of applied biocatalysis in several industrial fields and its widening boundaries.

**KEYWORDS:**

Biocatalysis, Bioconversion, Enzymes, Immobilization.

## INTRODUCTION

The idea behind applied biocatalysis is to employ a biocatalyst to encourage the chemical conversion of a given substrate into a product in a moderate, regulated environment using chemo-, regio-, and stereo-selective means. A cell that has the necessary enzyme(s) may serve as the biocatalyst, or it can be an isolated enzyme. The transformation is often referred to as biocatalysis or biotransformation depending on the characteristics of the biocatalyst. Unless otherwise specified for the context, the general word "bioconversion" will be used to refer to any of these conversions throughout the text. isolated enzymes and entire cells, in free or immobilized form, are now employed in the manufacturing and processing of a wide variety of chemicals and items. Thus, the production of consumer goods, fine chemicals, personal care items, and biopharmaceuticals, as well as the development of analytical and diagnostic applications, the biodegradation of harmful substances or waste products, the production of energy, and the restoration of damaged artwork all make use of biocatalysts. Despite its widespread use, it should be noted that creating, improving, and putting in place an efficient bioconversion system is difficult since many factors need to be taken into consideration. Investigated factors include the choice of the biocatalyst, its composition and nature, the traits of the bioconversion medium, and the preferred reactor configuration. These features are also connected to one another [1], [2].

The traditional approach for the development of a specific bioconversion system focuses on the properties of the biocatalyst because it will operate under strict operational conditions and

because its cost may be a significant portion of the overall process costs, although this last feature is frequently overestimated. Further undermining the significance of biocatalysts in process costs are recent improvements in biocatalyst synthesis, coupled with rising raw material prices. However, methods for quick development of biocatalysts with enhanced features such as activity, specificity, and stability, particularly under unconventional reaction conditions, affinity toward unusual substrates, as well as high throughput screening methods that allow the identification of new/improved biocatalysts and/or novel biocatalytic activities, have all contributed.

They have also cleared the door for a change in the conventional method and enable greater substrate concentrations, leading to increased production. To force the biocatalyst to function inside a biocatalytic system created around the reaction, taking into consideration the reaction's thermodynamics and the characteristics of the substrate and products. A mix of multiple technologies is needed to execute such a paradigm shift, which will cost money in the near term but should pay off in the medium and long run. The bioconversion system should be built to facilitate product recovery by in situ product recovery, either by transferring the product continuously to a second liquid or solid phase or by creating a second solid phase. If the biocatalytic phase is a component of a pathway that also involves chemical catalysis, further consideration is also necessary. In the synthesis of polymers, the combination of chemical and enzymatic catalysis is particularly appealing because the starting materials are frequently molecules with multiple similar functional organic groups that are easily distinguishable by the regio-selective enzyme but not by a chemical catalyst whose applications require protection and deprotection of all those groups aside from the one that is targeted for change [3], [4].

## DISCUSSION

Several criteria must be taken into account when choosing a good biocatalyst for a certain bioconversion. These include the capacity to function under the necessary operating circumstances (pH, temperature, medium composition, substrate, and product concentrations), as well as selectivity, activity, and stability. When selecting the biocatalyst for the planned bioconversion, there are many options to take into account, including using an existing biocatalyst, genetically altering an existing biocatalyst, or searching for new biocatalysts. The typical method for choosing an existing biocatalyst is to browse the literature. A database like BRENDA (http://www.brenda.uni-koeln.de), which provides quick access to information on existing enzymes such natural substrates and products, cofactors, pathways, and inhibitors, may be used to supplement this conventional method. The selecting process could be significantly accelerated as a result of this. The repository recently got some text-mining data.

It should be remembered that employing already available enzymes in unusual reaction settings may reveal untapped biocatalytic capabilities. Site-directed or random mutagenesis may also be used to genetically modify pre-existing biocatalysts to accomplish this. These alterations may also be performed to improve activity, stability, or selectivity. The third method of biocatalyst screening, which involves searching for new microbes with unique behaviours, takes into account nature's enormous biochemical variety. It should be noted that fewer than 10% of the microorganisms (i.e., bacteria) present in a particular environment can be cultivated on conventional medium, indicating that this strategy is far from being completely used. This often-arduous procedure has been greatly simplified by the development of technology that permits the screening of huge numbers of organisms using affordable, simple, quick, and selective detection techniques.

**Isolated enzymes or whole cells?**

For the catalysis of a single-step reaction, it is recommended to employ an isolated enzyme, provided that the isolation process is simple, affordable, and the produced enzyme is stable in a cell-free environment. According to estimates, the cost of the enzyme shouldn't be more than 5–10% of the whole product cost in order to compete with whole cell processes. There are several isolated enzymes that have been (partially) purified that have been used in bioconversion systems, including alcohol dehydrogenases, aldolases, amylases, amyloglucosidases, catalases, cellulases, galactosidases (including lactases), glucose isomerases, glucose oxidases, inulinases, glycosidases (including glycosy It could be difficult and costly to remove the enzyme from its natural environment, and the isolated enzyme might not be as stable or lose its catalytic function. When membrane-bound enzymes (such as the iron-containing oxygenases, such as cytochrome P450s and alkane hydroxylase) are implicated, loss of catalytic activity is often recorded.

Whole cell biocatalysts are often quicker and less expensive than isolated enzymes, and because the enzymes are shielded from the outside environment, they are probably more stable over time. On the other hand, a complete cell system has several enzymes in addition to the targeted enzyme, a characteristic that is likely to result in the generation of by-products. If the targeted enzyme can withstand the heat treatment, heating the cells may be used to remove undesired enzymatic activity. Utilizing lyophilized cells is one of the additional options for avoiding undesired enzyme activation. However, if those extra enzymes have no effect on product purity and yield, entire cells are preferred due to the aforementioned difficulties with cost and simplicity [5], [6].

However, whole cell bioconversions typically exhibit lower transformation rates than free enzymes, roughly by a factor of one or two orders of magnitude. This is because cell walls and membranes, which function as physical barriers and reduce substrate (and product) permeability, limit the amount of mass that can be transferred. These specific mass transfer restrictions might change the meaning of screening tests for whole cell biocatalyst identification, since some could be labelled non-active if the reaction of interest is not identified in a timely manner, even though the cell may contain active enzymes. It is possible to do cell permeabilization in order to get around these mass transfer restrictions. Without impacting the biocatalyst, many methods may be employed to change the cell wall or membrane's structure. Traditional strategies rely on physico-chemical techniques, including:

1. Heat-dried
2. Drying with acetone
3. Recurrent freezing and thawing cycles
4. Ultrasound
5. The addition of detergents (Pluronic F-68, Triton X-100, cetyltrimethylammonium bromide).
6. Incubation with organic solvents (toluene, diethyl ether, dimethyl sulfoxide, chloroform),

Cell permeabilization may be accomplished by media manipulation by the addition of substances that mess with the processes of cell wall or membrane production when biotransformation is carried out by developing cells. Examples include the employment of polycations such protamine, polymyxin B nonapeptide, and polyethyleneimine as well as glycine, isoniazid, D, L-norleucine, and m-fluorophenylalanine. These mass transfer limitation reduction techniques are widely used, although they were created via trial and error, involve many extra stages in the bioprocess, and may not have the appropriate

biocatalytic activity. Additionally, permeabilizing chemicals are likely to make downstream processing challenging. A alternative strategy relies on the insertion of mutations into the proteins responsible for the creation of cell walls or membranes in order to change cell permeability in a predictable way. The permeability barrier effect has also been reduced by molecular engineering by expressing an intracellular heterologous enzyme in the periplasmic space of a Gram-negative bacterium.

Whole cells are unquestionably the preferred alternative when multistep bioconversions are needed that include cascades of enzyme processes, such as in the creation of big and complex compounds, since they are too difficult to carry out in vitro. Examples of multistep bioconversions include the synthesis of carotenoid pigments, the generation of 2'-deoxyribonucleosides, the cleavage of sterol side chains to create steroid intermediates, and the manufacture of L-methionine from hydantoin. There aren't many cell-free linked enzymatic processes, and the use of such biocatalytic systems is limited to the union of two enzymes. The application of metabolic engineering and guided evolution may also boost the possibilities offered by whole cell-based biotransformation systems. The identification of bottlenecks in pathways is made possible by the quantitative investigation of metabolic regulation, which opens the door to genetic alterations intended to enhance natural pathways. In addition, it is possible to combine known routes to make new chemicals, opening up an almost limitless range of potential applications for applied biocatalysis.

**Biocatalyst immobilization**

The utilization of free biocatalysts suspended or dissolved in a liquid phase is fundamental to research on characterizing the characteristics of both biocatalysts and a specific bioconversion. Once that is established, immobilization of the biocatalyst is often sought for, although in other circumstances, such as the creation of detergents (washing powders), bread, and cheese, a free biocatalyst is required. It is simple to imagine certain process-level practical benefits from the confinement of the biocatalyst in the bioconversion system. The immobilized biocatalytic system's heterogeneity makes it easier to retrieve the biocatalyst and product, permits reusing the biocatalyst numerous times, allows for continuous operation, and supports a broad range of bioreactors. The biocatalyst is protected by a microenvironment during immobilization, and in the case of enzymes, it may even be able to replicate how they function naturally in cells, where they are often bound to cellular membranes. Thus, immobilization may maintain an enzyme's structural stability and catalytic activity.

A biocatalyst may need to be chemically altered (activated) in order to be immobilized onto the surface of a solid carrier; yet, the former frequently results in a significant loss of activity for the biocatalyst. As an alternative, a coupling agent, which can also serve as a spacer and mediate between the functional groups of the biocatalyst and carrier, may be utilized. This will lessen steric resistance. Recombinant DNA technology may be employed in a more sophisticated method to change the biocatalyst so that it can adsorb onto a certain carrier. These techniques, or combinations of them, are extensively used, and publications of new methodology or better approaches happen often. Since it produces flexible and durable immobilized biocatalysts as well as crosslinked enzyme aggre- gates, crosslinked enzyme crystals, and nanoscale biocatalysis, the application of sol-gel encapsulation in particular is gaining significant importance.

Only these biocatalysts can take advantage of the high surface area to volume ratios of nanoscale materials due to the nanometer size of enzyme molecules. These materials include silica, magnetite, gold, carbon nanotubes, and polymeric nanofiber nanoparticles. In order to facilitate the passage of hydrophobic substrates and products to/from a hydrophilic phase

where the enzyme is immobilized, the nanostructure may incorporate hydrophobic and hydrophilic domains. With this method, the rate of turnover for horseradish peroxydase-catalyzed reactions in heptane may be increased more than 200 times over with free enzyme [7]–[9].

The optimization of immobilized enzyme systems often involves conflicting difficulties, such as large surface area and enzyme loading, which frequently results in high mass transfer resistances inside the supports. The nanoscale method seems to provide an acceptable solution to these problems. However, there are significant limitations, chief among them the particle dispersion in the bioconversion media. Enzyme denaturation brought on by the action of chemicals employed in entrapment/encapsulation procedures; changes in the tertiary structure of enzymes following binding to a solid carrier or crosslinking. As contrasted to the free form Steric effects, changes in the temperature activity profile, as well as in thermal, operational, and storage stability. three-dimensional obstacles that restrict evaluation of the impacts of substrate partition. These happen when the carrier is charged or exhibits hydrophilic or hydrophobic properties that are different from those of the bulk media. results in various chemical concentrations on either side of the contact. The pH-activity profile has changed. If the chemicals involved are charged or have a hydrophilic or hydrophobic character different from the carrier, the same argument applies.

External and internal (diffusion) mass transfer barriers arise because substrate must move from the bulk solution to the immobilized biocatalyst's active site; the latter only occurs for porous supports. External mass transfer resistances may be reduced by high circulation rates. Changes in the specificity, kinetic constants, thermal, operational, and storage stability of the immobilized biocatalyst as compared to the free form recovery, limited bioreactor configurations, and health and environmental concerns related to the handling of nanoparticles all influence the overall reaction rate. This is because diffusion resistance occurs concurrently with the reaction.

Despite being very helpful, immobilization often modifies the characteristics of the biocatalyst. Since they affect how the process is designed, they need to be carefully evaluated. Despite the abundance of accessible techniques and supports, it is impossible to choose one technique and one support as the best effective for all biocatalysts and applications. The type and characteristics of the substrate, product, and biocatalyst must be taken into account while choosing the support and technique of immobilization. In the bioconversion system, entrapment is also not a suitable solution due to severe diffusion restrictions; hydrophobic substrates do not partition into hydrophilic supports, and low molecular weight enzymes readily leak out from gel-based supports.

Additionally, each approach has benefits and cons. Covalent attachment and crosslinking guarantee a strong and durable immobilization, with long-term stability, but they are expensive, and enzyme activity frequently decreases significantly upon immobilization. Adsorption is straightforward, inexpensive, and effective, but it is frequently easily reversible by changes in pH, ionic strength, or hydrodynamic conditions. Despite being fairly mild techniques that scarcely impact inherent biocatalytic, entrapment, microencapsulation, and membrane reactor confinement are often linked with significant mass transfer resistances, especially the former. Since the membrane retains the high molecular weight or insoluble substrates, such as starch, cellulose, inulin, or proteins, along with the biocatalyst, which is present in a soluble (enzyme) or suspended (cells) form, while allowing the low molecular weight products to migrate out, such mass transfer resistances can be turned into an advantage in membrane reactors for the conversion of high molecular weight or insoluble substrates. The optimal balance for maintaining biocatalytic activity and operational stability

must thus be found via a process of trial and error when choosing the most appropriate immobilization conditions for a certain biocatalyst and application [10], [11].

**The Medium for Bioconversion**

Bioconversion processes have been demonstrated to be feasible in the presence of organic solvents water miscible or immiscible, ionic liquids, supercritical fluids, gas phase, aqueous two-phase systems, and in liquid-solid resin assisted media. These methods are often referred to as "non-conventional biocatalysis." The primary drivers behind the requirement for bioconversion media other than aqueous include the sparing water solubility of most substrates and/or products in such media, as well as the potential toxic or inhibitory role of those compounds on the biocatalyst, which can be reduced if the biocatalyst and compounds are in different phases. In either scenario, the productivity may be significantly limited if the bioconversion is done in aqueous medium. According to Straathof, meaningful productivities need a second phase for molecules with an aqueous solubility between about 0.0003 and 1 M. Lowering the substrate concentration in the reaction medium improves selectivity since it has been shown that enantiomeric purity of products and substrate concentration correlate inversely in numerous bioconversion systems. In order to create a pool for molecules that are only slightly soluble in the phase where the biocatalyst is still present and/or to maintain their concentration in that phase below toxic/inhibitory levels, it is preferable to utilize an auxiliary second phase.

**Biological Solvents**

The oldest alternative to solely aqueous systems is by far the employment of organic solvents in a bioconversion medium, although this strategy was only firmly established in the early 1980s. The benefits and drawbacks of this strategy are well known. Bioconversion systems involving organic solvents can be either homogeneous or heterogeneous, depending on whether the solvents used are water miscible (e.g., acetonitrile, dimethyl sulfoxide, ethylene glycol, glycerol, methanol, propylene glycol) or water immiscible (diisopropyl ether, ethyl acetate, methyl-t-butyl ether, octane, n-octanol, toluene). The latter systems encourage process integration because they enable in-situ product recovery and provide a reservoir for hazardous or inhibiting substances.

Micro- and macro-heterogeneous systems are two further categories of heterogeneous systems. In macro-heterogeneous systems, there is a visible phase separation, as happens in two-liquid phase systems or systems that employ powdered or immobilized enzymes. In micro-heterogeneous systems, phase separation is only apparent on a microscopic scale, as in the case of reverse micelles. It is possible to attribute organic solvent toxicity, a significant issue with their use in bioconversion systems, to interactions with the non-polar groups of the enzyme and eventual disruption of hydrophobic interactions, as well as competition with the protein molecule for the crucial water needed by the latter for proper polypep- tide conformation. In the end, solvents may remove such a crucial water layer. When whole cells are involved, the solvent's harmful effects can be attributed to its buildup in the cytoplasmic membrane, which alters its composition and prevents the cell from performing vital tasks like dissipating pH and electrical potential and inhibiting membrane protein functions, ultimately leading to cell death.

A number of factors need to be taken into account when choosing a solvent because of the interactions between the solvent, substrate product, and biocatalyst. A good solvent must be inexpensive, non-biodegradable, non-toxic to people, exhibit strong affinity to substrates and/or products, be biocompatible with the biocatalyst, have a boiling point that is reasonably high (preferentially lower than water), and have low volatility. Additionally, it should be

considered that the organic solvent may have an impact on the biocatalyst's selectivity. The processes underlying biocatalyst/solvent interaction are too complicated for solvent biocompatibility to be predicted by a single physical parameter, which may be the cause of such a prediction model's shortcomings. In order to improve mass transfer and hence speed up the overall response rate, the bioconversion system must be designed with suitable hydrodynamic conditions and phase volume ratio values. The reaction medium must be avoided becoming emulsified since this reduces the amount of mass that may be transferred. Reactors with additional safety features, such as explosion-proof construction, may also be necessary.

**Ionizing Fluids**

There is a trend to develop suitable alternative solvents and technologies that may replace organic solvents held accountable for the production of hazardous wastes due to the ever-increasing pressure from governmental organizations, regulatory entities, NGOs, and public opinion to protect the environment. At room temperature, ionic liquids are salts that are in a liquid form. Unlike organic solvents, they have almost no vapour pressure, which opens the door to the creation of environmentally friendly and clean procedures. Ionic liquids are accessible in both water-miscible and water-immiscible forms, much as organic solvents. By changing the makeup of the anions and cations, it is possible to modify the physical characteristics of ionic liquids, such as density, hydrophobicity, melting point, and viscosity, to suit the needs of the bioconversion system. Ionic liquids are non-reactive and may be utilized in enantioselective and stereoselective processes. They also have good temperature and storage stability, the capacity to dissolve a broad range of compounds, from inorganic to organic and polymeric.

Some considerations need to be addressed while choosing an appropriate ionic liquid for use in a bioconversion system. The ionic liquid should be readily accessible and devoid of any contaminants that can obstruct the process. It should also be non-corrosive, non-toxic, and biocompatible. Additionally, relevant product isolation techniques such distillation, supercritical CO2, column chromatography, or extraction must to be used. The viability of using ionic liquids on a wide scale relies heavily on the effective recovery and reuse of the ionic liquid due to the fact that their cost may be two orders of magnitude more than that of typical organic solvents. The distribution coefficients for substrates and products between ionic liquids and buffer must be above 2.0, both for extraction efficiency and to lower their concentration in the aqueous phase, thereby reducing toxicity, in order for the ionic liquid to be used effectively.

**Aqueous Two-Phase Systems**

Two-phase aqueous systems have low interfacial tension between the two phases and are made up of solutions of two incompatible polymers, such polyethylene glycol and dextran, or a solution of a water-soluble polymer with another salt solution, like phosphate buffer or magnesium sulphate. These systems provide biocatalysts a comparatively mellow environment, making them especially well-suited for the extraction of hydrophilic compounds. The cost of many of the used polymers, given their purity levels, has hampered their large-scale implementation. The main issues in the design of two-phase aqueous bioconversion systems lie in the lack of suitable models for prediction of biocatalyst activity as well as biocatalyst and product partition. Aqueous two-phase systems may provide an intriguing option for bioconversion systems involving hydrophilic chemicals if less expensive, less pure polymers could be utilized without significantly reducing productivity.

Since the product is transferred to the resin as it is formed, resins with high surface areas added to the bioconversion media have been used to overcome limitations associated with product inhibition through in situ product recovery or to avoid liquid-liquid extraction from whole-cell bioconversion media. Additionally, resins may be utilized to supply substrates, however this method necessitates pre-saturating the resin with the substrate before incubating it in the bioconversion media. Additionally, resins may provide on-site substrate feeding and product recovery. Resin-based systems share a fundamental principle with two-liquid phase systems, but they avoid the negative effects on the biocatalyst that are often seen when organic solvents (or ionic liquids) are utilized. High resin loading, however, may cause irreparable harm to the biocatalyst. The affinity of the substrate, product, and biocatalyst towards the resin must be taken into consideration while choosing an appropriate solid phase. Low bioavailability of the substrate in the aqueous phase may result from excessive substrate binding to the resin. Another thing to prevent is the biocatalyst adhering to the solid phase.

## CONCLUSION

Advancements in applied biocatalysis have revolutionized the way we approach chemical transformations in various industries. The journey from enzyme selection to the use of non-conventional bioconversion media has unveiled new opportunities and challenges. The careful selection of biocatalysts, whether existing enzymes or engineered variants, sets the foundation for successful bioconversion processes. The choice between isolated enzymes and whole cells depends on factors like reaction complexity and mass transfer limitations. Immobilization techniques offer enhanced stability and process efficiency, although careful consideration is needed to maintain biocatalyst activity. The exploration of non-conventional bioconversion media addresses solubility issues and expands the scope of biocatalytic processes. Organic solvents, ionic liquids, and other media offer new avenues for reaction optimization, requiring a balance between biocatalyst compatibility and effective mass transfer. As applied biocatalysis continues to advance, interdisciplinary collaboration, novel technologies, and a deeper understanding of enzyme-substrate interactions will further propel the field's growth and impact across industries.

## REFERENCES:

[1] G. Burgé *et al.*, “Reactive extraction of bio-based 3-hydroxypropionic acid assisted by hollow-fiber membrane contactor using TOA and Aliquat 336 in n-decanol,” *J. Chem. Technol. Biotechnol.*, 2016, doi: 10.1002/jctb.4878.

[2] M. Moussa *et al.*, “Reactive extraction of 3-hydroxypropionic acid from model aqueous solutions and real bioconversion media. Comparison with its isomer 2-hydroxypropionic (lactic) acid,” *J. Chem. Technol. Biotechnol.*, 2016, doi: 10.1002/jctb.4813.

[3] H. Pramana, R. Esyanti, and A. Faizal, “The efficiency of growth medium bioconversion into banana (Musa acuminata, AA) plantlet biomass in temporary immersion system (TIS) RITA® bioreactor with different immersion periods,” *IMPACT Int. J. Res. Applied, Nat. Soc. Sci.*, 2016.

[4] D. Wang, X. Ju, G. Zhang, D. Wang, and G. Wei, “Copper sulfate improves pullulan production by bioconversion using whole cells of Aureobasidium pullulans as the catalyst,” *Carbohydr. Polym.*, 2016, doi: 10.1016/j.carbpol.2016.05.035.

[5] P. Chen *et al.*, "A microbial transformation using Bacillus subtilis B7-S to produce natural vanillin from ferulic acid," *Sci. Rep.*, 2016, doi: 10.1038/srep20400.

[6] M. Sidiq Muhayyat, A. Tawfiequrrahman Yuliansyah, and  dan Agus Prasetya, "Pengaruh Jenis Limbah dan Rasio Umpan pada Biokonversi Limbah Domestik Menggunakan Larva Black Soldier Fly(Hermetia illucens)," *J. Rekayasa Proses*, 2016.

[7] K. C. Surendra, R. Olivier, J. K. Tomberlin, R. Jha, and S. K. Khanal, "Bioconversion of organic wastes into biodiesel and animal feed via insect farming," *Renew. Energy*, 2016, doi: 10.1016/j.renene.2016.03.022.

[8] M. S. Muhayyat, A. T. Yuliansyah, and A. Prasetya, "Pengaruh Jenis Limbah dan Rasio Umpan pada Biokonversi Limbah Domestik Menggunakan Larva Black Soldier Fly (Hermetia illucens)," *J. Rekayasa Proses*, 2016.

[9] A. Das, P. Ghosh, T. Paul, U. Ghosh, B. R. Pati, and K. C. Mondal, "Production of bioethanol as useful biofuel through the bioconversion of water hyacinth (Eichhornia crassipes)," *3 Biotech*, 2016, doi: 10.1007/s13205-016-0385-y.

[10] Y. Wu and H.-J. Shin, "Cellulase from the fruiting bodies and mycelia of edible mushrooms: A review," *J. Mushroom*, 2016, doi: 10.14480/jm.2016.14.4.127.

[11] H. Li, G. Zhang, and Y. Dang, "Adaptive laboratory evolution of Klebsiella pneumoniae for improving 2,3-butanediol production," *Bioengineered*, 2016, doi: 10.1080/21655979.2016.1199304.

# CHAPTER 12

# ADVANCEMENTS IN BIOCONVERSION SYSTEMS: FROM SOLID-GAS INTERACTIONS TO RATIONAL DESIGN

Amit Kumar, Assistant Professor, Department of Agriculture and Environmental Sciences,
Shobhit University, Gangoh, Uttar Pradesh, India,
Email Id- amit.kumar@shobhituniversity.ac.in

**ABSTRACT:**

A thorough analysis of the ever-changing field of bioconversion processes, with an emphasis on cutting-edge methods, tactics, and factors to take into account when designing and enhancing bioconversion systems. The benefits of solid-gas interactions over liquid-based systems are examined in this article, with an emphasis on better mass transfer, increased substrate solubility, and less environmental effect. It explores the use of supercritical fluids (scfs) as environmentally friendly substitutes, outlining the advantages, difficulties, and most recent advancements. The research also looks at different bioreactor layouts, highlighting their functions in enabling effective bio-transformations. Additionally, it is explained how computational methods, molecular modelling, and chemometrics may be used to rationally design bioconversion processes, demonstrating how they can speed up testing and prediction. The review's insights on bioconversion systems' potential futures highlight the necessity for multidisciplinary cooperation and innovation.

**KEYWORDS:**

Bio-transformations, Bioconversion Systems, Solid Gas, Supercritical Fluids.

## INTRODUCTION

Solid-gas systems have several benefits over liquid-based systems, including improved mass transfer due to high diffusion coefficients and low viscosity of gases, enhanced solubility of substrates and products, eventual elimination of solvent use, minimization of microbial contamination due to relatively high temperatures (e.g., 45 to 85 °C), low risk of by-product formation, simpler immobilization procedures, and eased immobilization. Since the thermodynamic activities of the various species may be fixed individually, these systems can also provide significant information on the interactions between biocatalysts and their surroundings and the consequent influence on catalytic activity and stability. The method for generating a gas phase, the absolute working pressure, and the thermodynamic activity of water are important aspects of the system's design [1], [2].

### The Supercritical Fluids

The rising environmental worries about the quantity of waste produced by the chemical industry, the majority of which are organic solvents and their by-products, may be linked to interest in the usage of supercritical fluids (SCFs). Because of the high diffusivity of substrates and products, low viscosity of the bioconversion medium, and internal mass transfer limitations, which are frequently a bottleneck in heterogeneous bioconversions, SCFs also have advantages in terms of mass transfer. Because it is non-toxic, non-mutagenic, non-flammable, and thermodynamically stable, the SFC most often employed in bioconversions, sc-CO2, offers clear advantages in terms of health and safety. Additionally, it is recyclable and ecologically beneficial. However, when hydrophobic chemicals are present, their non-polar character often favours the use of sc-CO2. The introduction of surfactants in recent

years has enabled the solubilization of both hydrophilic and hydrophobic compounds, potentially expanding the spectrum of uses for sc-$CO_2$ in bio-transformations.

**Bioreactors**

In basic chemical reactors that operate in batch, continuous, or fed-batch modes, bioconversions are often carried out. When the substrate is poisonous or inhibitive above a certain concentration and/or is sparingly soluble in the aqueous phase, the latter mode is an appropriate substitution for the employment of an auxiliary second phase. Due to the possibility of substrate restriction, careful observation is necessary. However, batch reactors are not always employed when free biocatalysts are accessible. If immobilized biocatalysts are utilized in this mode of operation and if reuse is intended, the biocatalyst must be separated and recovered, which may result in a loss of mass and activity.

**Mixture Reactors**

The immobilization support particles are often susceptible to shear stress, despite the fact that stirred tanks are frequently utilized to provide a nearly perfect mixing pattern and prevent concentration (and in particular pH) and temperature gradients. This implies that stirred tank reactors should only utilize long-lasting immobilized biocatalyst preparations. The so-called basket reactor is an alternative, in which the immobilized biocatalyst particles are kept in a basket that functions as the impeller blades or the baffles of the tank reactor. A plug flow pattern is a more often used strategy. If a single pass results in a poor conversion yield, a plug flow reactor type—which may be a packed or fluidized bed reactor—operates in complete recycling mode. Given that the reactor may be thought of as a differential reactor, this characteristic is also very helpful for the collection of kinetic data. Additionally, by running at high flow rates, external mass transfer resistances may be readily decreased [3], [4].

## DISCUSSION

Reactants and media components may be introduced continuously or in pulses in a fed-batch reactor. To prevent medium overflow, special attention must be paid to how feeding affects the reaction volume, specifically how hydrodynamic conditions and starting headspace. The process' modelling and control are more intricate than those of the other operating modes, and there isn't a lot of research specifically focused on enzymatic bioreactors in this area.

**Permanent Reactors**

When compared to alternative modes of operation, the continuous operation of immobilized biocatalysts offers a few benefits, including ease of automated control, simplicity of operation, and product quality control. The continuous feed stirred tank reactor (CSTR) and the plug flow reactor (PFR) are the two categories into which continuous reactors may be separated. Since total mixing is accomplished in the ideal CSTR and the conditions within the CSTR are identical to those in the output stream, low substrate and high product concentrations result from conversion that is independent of the location in the vessel. The conversion yield in the ideal PFR is vessel length-dependent. However, since there are no mixing mechanisms in the PFR, the conditions within the reactor are uneven, often with gradients in temperature, velocity, and concentration that are perpendicular to the flow direction [5], [6].

Consider kinetic and operational characteristics while deciding between these two kinds. Therefore, the PFR is chosen over the CSTR for Michaelis-Menten kinetics because it uses less biocatalyst to get the same conversion yield. Given the differences between the PFR and the CSTR, it is recommended to employ the former for substrate-inhibited systems and the

latter for product-inhibited systems. The use of a PFR is not recommended if pH control is necessary. The size of the immobilized biocatalyst needs to be carefully considered since small particles might cause a large pressure decrease and clogging. Low pressure drop allows for the use of fluidized bed reactors (FBR), which have a mixing pattern intermediate to both the CSTR and the ideal PFR. Also more efficiently handled in an FBR or CSTR are insoluble substrates and very viscous fluids. It is not easy to choose an appropriate reactor; one must have a complete understanding of the needs of a particular bioconversion system. Development and characterization of a bioconversion process rationalization and acceleration. Systems for bioconversion are highly complicated and reliant on a variety of factors. To accelerate the speed of process growth, it is thus necessary to design rational planning techniques to construct a rational experimental planning, along with quick and dependable processes that enable the evaluation of the relevant aspects and characterization of the system. By using advancements in computational sciences and in tiny systems and components, focused efforts and technical advances are helping to make this ambition a reality.

**Computing Techniques**

The development of tools in computational sciences enables the creation of recommendations for sensible experimental design, resulting in time and resource savings. When combined, the two computational disciplines of molecular modelling and chemometrics significantly advance the creation of predictive models. Virtual models that provide a better understanding of enzyme-substrate interactions may be created using molecular modelling. These mostly depend on the computation of the reaction's free energy, which was discovered via the modelling of the transition state. Molecular mechanics calculations are often used for this, however they cannot provide exact predictions. On the other hand, these computations don't need a lot of computer power and provide results quite rapidly. The computing requirements and complexity of quantum mechanics approaches make them unsuitable for usage. Even this may be too computationally intensive since it handles the active site and substrate at the quantum mechanics level while the rest of the system is treated at the molecular mechanic’s level.

Enantioselectivity of enzymes is predicted using molecular modelling approaches, which are also often used to characterize enzyme-substrate interactions. Chemometrics uses a variety of mathematical techniques, including multivariate statistical analysis and experimental design, to allow the connection between measurements made on a chemical system or process and the state of the system. By lowering its dimensionality, the former facilitates the understanding of data from complicated systems with many variables, while the latter offers a useful tool for simultaneously studying numerous variables and determining the best experimental circumstances. In order to construct empirical equations or parameters for predictive models, combining the two approaches is extremely helpful. When comparing penicillin G amidases from various sources, this combination technique proved effective in identifying the amino acid residues crucial for selectivity [7], [8].

**Methods of Microscale Processing**

This method enables the parallelization, automation, and cost reduction of experimental trials by using small bioreactors with volumes under 100 ml in conjunction with analytical techniques and equipment capable of handling a large number of samples in a short amount of time. Such small-scale bioreactors include stirred miniature bioreactors and membrane reactors in addition to shaken containers with various capacities and configurations, such as shake flasks, test tubes, and microtiter plates. The potential of these devices has been further

increased by technological advancements that have made it possible to monitor and regulate pH and dissolved oxygen tension online (at least in certain situations, some of which also contain air-flow rate control).

Current uses of miniature bioreactors include strain enhancement, growth/bioconversion medium creation, and early-stage recombinant or wild-type organism evaluation. It is also important to watch out that the operating circumstances don't obscure the outcome. For instance, the results of the series of tests are likely to be illusory if oxygen is accidentally used as the limiting substrate when examining the impact of media composition on catalytic activity. If tiny bioreactors are utilized in the latter phases of process development, reproducibility and scalability become of paramount relevance. In these situations, it is important to determine if the "rule of thumb" scaling techniques employed in industry to get from bench-top to production scale are appropriate. These techniques rely on a number of variables, such as the kLa (oxygen volumetric mass-transfer coefficient), power consumption per unit volume, agitator tip speed, constant dissolved oxygen tension, or mixing duration. Despite the fact that kLa and power consumption per unit volume are frequently used as benchmarks and that consequently significant progress has been made in the development of empirical correlation for the prediction of such parameters, the diversity of parameters demonstrates that there is no single criterion and that not all miniature systems are eligible to meet all the criteria for scaling.

An overview of applied biocatalysis with a focus on the problems that must be solved when designing a particular bioconversion system and the pertinent factors that must be taken into account when choosing the best option to be used during the various stages of such a process. There are certain general rules that aid in the overall design of a bio-conversion system; however, it is noted that given the inherent needs, each system requires careful consideration. A change in the design paradigm of bioconversion systems from utilizing biocatalysts with attributes orientated to the reaction limitations to adapting the former to the needs of the latter has been made possible by recent technical advancements that have increased the potential of designer bio-catalysts. The usage of alternate, productivity-boosting medium is growing as a result of biocatalysts' capacity to function in media other than aqueous [9], [10]. The development and use of "green" bioconversion technologies that use non-toxic, organic solvent-free media supercritical fluids, ionic solvents, gas phase are encouraged by growing environmental concerns.

To forecast the behaviour in such medium, much effort is needed to develop predictive models. The efficiency of bioconversion systems in comparison to chemical-based methods is also growing as a result of the use of miniaturized systems that can quickly and efficiently assess and analyze a large number of factors, which significantly reduces the time and resources needed for the development stages of bio-based processes. A reasonable foundation for the engineering of biocatalysts is provided by the combination of advances in computational sciences and molecular modelling, which further reduces the costs and time necessary to construct the models. The development of quicker and more accurate screening tools, the promotion of the integration of complementary fields of knowledge (engineering, biology, chemistry, mathematics, and computational sciences), and the establishment of current trends all highlight current trends for a more rational basis in the design and development of bioconversion systems.

For the manufacture of important molecules, bioconversion technologies have arisen as flexible and environmentally friendly alternatives to conventional chemical procedures. Researchers are investigating novel approaches to improve the performance of bioconversion systems by using solid-gas interactions and rational design principles as the need for greener

and more effective chemical transformations increases. In-depth analysis of current developments in the area is provided in this study, with special emphasis on the value of solid-gas systems, the use of supercritical fluids (SCFs), the function of bioreactor designs, and the use of computational methods in reshaping the bioconversion landscape.

**Solid-Gas Interactions**

Solid-gas interactions have attracted interest since they might completely alter how bioconversion processes are carried out. Solid-gas systems provide a number of benefits over liquid-based systems, including increased mass transfer rates brought on by high gas diffusion coefficients and low viscosity. These elements help to increase substrate solubility and lessen diffusional constraints, which raise reaction speeds and overall effectiveness. Solvent removal is another benefit of solid-gas systems, lowering environmental impact and operating expenses. Additionally, the comparatively high temperatures in solid-gas systems aid in reducing microbiological contamination, and downstream processing is made simple by the minimal danger of by-product production. The practicality of solid-gas systems in diverse biocatalytic applications is further improved by the simplicity and convenience of immobilization methods.

Supercritical fluids (SCFs) have become adaptable mediums for bioconversion processes, in particular supercritical carbon dioxide (sc-CO2). Interest in SCFs as environmentally friendly substitutes has increased as a result of growing environmental concerns about organic solvents. Due to their high diffusivity, SCFs have exceptional mass transfer qualities that make it possible to move substrates and goods quickly. Particularly Sc-CO2 has a number of benefits, including non-toxicity, inflammability, and thermodynamic stability. These features make sc-CO2 a good option for bioconversions, improving both sustainability and safety. The spectrum of substrates that may be solubilized in SCFs has increased with the addition of surfactants, enabling the conversion of hydrophilic and hydrophobic molecules. Additional alternatives for bioconversion are provided by different SCFs such sc-ethane, sc-propane, and sc-butane, albeit these come with problems for enzyme stability, pressure, and water activity.

**Bioreactor Configurations**

The effectiveness and scalability of bioconversion processes are substantially influenced by the choice of bioreactor design. Reactor types such as batch, continuous, fed-batch, and permanent each have their own benefits and difficulties. The reuse of immobilized biocatalysts may present difficulties in batch reactors, which are best suited for reactions involving hazardous or sparingly soluble substrates. Controlled conversion rates are possible with stirred tank reactors and plug flow reactors because they balance variables including mixing, concentration gradients, and pressure drop. These reactor types should be chosen based on their kinetic properties, substrate or product inhibition, pH control, and other process-specific factors. Additionally, the development of tiny bioreactors and microscale processing methods has sped up the optimization and scaling up of bioconversion processes by enabling parallelization, automation, and cost reduction in experimental trials.

Computational approaches, molecular modelling, and chemometrics have all been integrated to revolutionize the design and optimization of bioconversion systems. This is known as rational design. Enantioselectivity and catalytic activity may be predicted with the use of molecular modelling, which sheds light on the interactions between enzyme and substrate. Understanding reaction processes and transition states is made easier by combining techniques from quantum mechanics and molecular mechanics. Chemometrics makes it possible to correlate system measurements with performance using data, which helps

experimental planning. Combining computational methods enables scientists to create prediction models, speeding up the investigation of reaction circumstances and substrates.

## CONCLUSION

Due to the need for efficient and sustainable chemical transformations, the subject of bioconversion has made significant strides recently. Exploration of unconventional media has created new opportunities for biocatalysis by providing improved mass transfer, solubility, and selectivity. Examples of these non-conventional media include solid-gas interactions and supercritical fluids (SCFs). Solid-gas systems have become popular replacements for conventional liquid-based systems because they provide advantages such streamlined immobilization processes, less by-product production, and decreased solvent consumption. Due to its environmental friendliness, high diffusivity, and capacity to solubilize both hydrophilic and hydrophobic substrates, the use of SCFs, especially supercritical carbon dioxide (sc-CO2), has gained pace. These innovations are reshaping the bioconversion landscape and accelerating the shift to cleaner, more effective methods. From Solid-Gas Interactions to Rational Design" highlights how bioconversion systems have undergone significant change. There are now creative solutions to problems in biocatalysis thanks to research into solid-gas interactions and the use of supercritical fluids. The numerous bioreactor designs provide possibilities for improving distinct bioconversion situations, enabling customized approaches for particular enzymatic processes. Researchers are better equipped to develop and optimize bioconversion systems by combining computational methods, molecular modelling, and chemometrics. The development of bioconversion processes will continue to be shaped by multidisciplinary cooperation, cutting-edge technology, and a sharp emphasis on sustainability, pushing the area towards better efficiency, selectivity, and eco-friendliness.

## REFERENCES:

[1] Y. K. Lin *et al.*, “Production of γ-cyclodextrin by Bacillus cereus cyclodextrin glycosyltransferase using extractive bioconversion in polymer-salt aqueous two-phase system,” *J. Biosci. Bioeng.*, 2016, doi: 10.1016/j.jbiosc.2015.11.001.

[2] M. Moussa *et al.*, “Reactive extraction of 3-hydroxypropionic acid from model aqueous solutions and real bioconversion media. Comparison with its isomer 2-hydroxypropionic (lactic) acid,” *J. Chem. Technol. Biotechnol.*, 2016, doi: 10.1002/jctb.4813.

[3] C. Ke *et al.*, “Whole-cell conversion of l-glutamic acid into gamma-aminobutyric acid by metabolically engineered Escherichia coli,” *Springerplus*, 2016, doi: 10.1186/s40064-016-2217-2.

[4] B. Ahmed, K. Mabrouk, K. Cherif, and B. Boudjemaa, “Bioethanol production from date palm fruit waste fermentation using solar energy,” *African J. Biotechnol.*, 2016, doi: 10.5897/ajb2016.15368.

[5] D. Antunes Viegas, M. Rodrigues, J. Francisco, A. Falcão, G. Alves, and A. O. Santos, “Development and application of an ex vivo fosphenytoin nasal bioconversion/permeability evaluation method,” *Eur. J. Pharm. Sci.*, 2016, doi: 10.1016/j.ejps.2016.04.018.

[6] H. Jia *et al.*, "Intelligent Microbial Heat-Regulating Engine (IMHeRE) for Improved Thermo-Robustness and Efficiency of Bioconversion," *ACS Synth. Biol.*, 2016, doi: 10.1021/acssynbio.5b00158.

[7] B. M. Quinn, E. A. Apolinario, A. Gross, and K. R. Sowers, "Characterization of a microbial consortium that converts mariculture fish waste to biomethane," *Aquaculture*, 2016, doi: 10.1016/j.aquaculture.2015.12.002.

[8] P. Hu *et al.*, "Integrated bioprocess for conversion of gaseous substrates to liquids," *Proc. Natl. Acad. Sci. U. S. A.*, 2016, doi: 10.1073/pnas.1516867113.

[9] Y. Fu *et al.*, "How to establish a bioregenerative life support system for long-term crewed missions to the moon or mars," *Astrobiology*, 2016, doi: 10.1089/ast.2016.1477.

[10] S. Mao, L. Yu, S. Ji, X. Liu, and F. Lu, "Evaluation of deep eutectic solvents as co-solvent for steroids 1-en-dehydrogenation biotransformation by Arthrobacter simplex," *J. Chem. Technol. Biotechnol.*, 2016, doi: 10.1002/jctb.4691.